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Abstract 
 
The prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium 
tuberculosis has been increasing to alarming levels globally. This has been exacerbated by 
tuberculosis (TB) co-infection with HIV where the epidemic is endemic. South Africa as a developing 
country is hit hard by TB and efforts to develop TB drugs that are compatible with anti-retroviral 
medication and also effective against MDR/XDR, could help shorten the treatment duration of the 
current TB treatment regimens. This thesis presents the identification and characterisation of a novel 
furanone based compound (F1082) and its derivatives as leads for anti-TB drug development. 
Furanones are generally known for an array of biological activities ranging from antibacterial, 
antifungal and antitumor. 
F1082 has an aromatic benzene structure and was identified from screening synthetic compounds 
against M. tuberculosis. It is potent against M. tuberculosis at minimum inhibitory concentration 
(MIC) of 8 µg/ml. It is selective for mycobacteria since it did not inhibit the growth of Gram-positive 
and Gram-negative bacteria at concentrations five times the MIC for M. tuberculosis. F1082 is 
generally bacteriostatic around MIC concentrations in its effects against M. tuberculosis however; it 
may be bactericidal at higher concentrations. It is as effective against MDR, XDR and clinical isolates 
of M. tuberculosis at the same concentration as the M. tuberculosis H37Rv reference strain. This 
suggests that F1082 may have a different mechanism of action compared to current TB drugs. It has 
been shown to have no antagonistic effect with the first-line anti-TB drugs and it has been shown to 
synergize with rifampicin by reducing the MIC of rifampicin. A drawback of F1082 is that it is 
cytotoxic to human cell lines, but this is presently being addressed through the synthesis of analogues 
that have shown improved activity and less cytotoxicity. The synthesis of more than 40 analogues has 
led to identification of 4 compounds that have more than five times higher activity and more than 100 
times less cytotoxicity against human cell-lines.  
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Microarray analyses have identified possible metabolic pathway/s in M. tuberculosis that is/are 
affected by F1082. One subset of genes which showed the most prominent alteration encodes the 
siderophores, which are involved with iron homeostasis in the M. tuberculosis bacillus. Of these 
genes, 7 were of interest (mbtB, mbtC, mbtD, mbtE, mbtF, mbtH and bfrB) as they all fall in the same 
cluster and are involved in iron acquisition. Due to the involvement of iron we also show that F1082 
generates oxidative stress that is metal (iron) dependent. From the results we conclude that F1082 is a 
promising antituberculosis lead compound with unique target properties and also specificity against 
mycobacteria.  
 
Opsomming 
Die voorkoms van veelvuldige middelweerstandige M.tuberculosis (MDR) en uiters 
middelweerstandige M.tuberculosis (XDR) is besig om toe te neem teen ‘n kommerwekkende tempo 
wêreldwyd. Hierdie situasie word vererger met die ko-infektering van M.tuberculosis en HIV. Suid-
Afrika, as ontwikkelende land, word sleg benadeel met tuberkulose siekte. Antituberkulose middels 
wat kan saamwerk met bestaande antiretrovirale middels en ook effektief is teen MDR en XDR 
stamme, kan alles meewerk om die behandelingstyd van tuberkulose te verkort. In hierdie tesis 
identifiseer en karakteriseer ons ‘n furanoon-gebaseerde verbinding (F1082) en derivate daarvan as 
voorloper-middels vir anti-tuberkulose middelontwikkeling. Furanone is algemeen bekend vir ‘n 
verskeidenheid van biologiese aktiwiteite insluitende antibakteriële-, antifungale- en antitumor 
aktiwiteite. 
F1082 bevat ‘n aromatiese benseenstruktuur en is oorspronklik geïdentifiseer gedurende die 
skandering van sintetiese middels teen M.tuberculosis. Dit het ‘n sterk werking teen M.tuberculosis 
met ‘n minimum inhibitoriese konsentrasie (MIC) van 8ug/ml. Dit is baie selektief vir mikobakterieë 
aangesien dit nie gram-positiewe of gram-negatiewe bakterieë teen 5 maal die MIC, soos vir 
M.tuberculosis, geïnhibeer het nie. F1082 is bevind om, by laer konsentrasies, bakteriostaties te wees 
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in sy aktiwiteit teen M.tuberculosis maar by hoër konsentrasies word ‘n meer bakteriosidiese effek 
waargeneem. F1082 is effektief teen MDR, XDR en kliniese isolate van M.tuberculosis en teen 
dieselfde konsentrasie soos vir die M. tuberculosis H37Rv verwysingstam waargeneem is. Dit 
impliseer dat F1082 dalk ‘n alternatiewe meganisme van werking het in vergelyking met die van die 
huidige TB teenmiddels. F1082 toon geen antagonistiese werking in kombinasie met die voorste anti-
TB middels nie, maar toon wel sinergistiese werking in kombinasie met rifampisien. F1082 toon nog 
sitotoksiese aktiwiteit teenoor menslike sellyne, maar die sintese van derivate van F1082 toon tot 
dusvêr groter anti-TB aktiwiteit en verminderde sitotoksisiteit. Die sintese van meer as 40 homoloë 
het gelei tot die identifisering van vier verbindings met vyf keer hoër anti-TB aktiwiteit en honderd 
keer verminderde sitotoksisiteit teen menslike sellyne as F1082 self.  
“Microarray” ontledings het ‘n aantal metabolise paaie geïdentifiseer waar F1082 ‘n effek kan 
uitoefen. Een stel gene wat die mees uitstaande effek toon kodeer vir siderofore wat betrokke is by 
yster homeostase in M.tuberculosis. Van hierdie gene was daar sewe van belang omdat hulle in 
dieselfde groep voorkom en almal betrokke is by ysteropname (mbtB, mbtC, mbtD, mbtE, mbtF, 
mbtH, bfrB). Weens die rol wat F1082 in ysterhomeostase speel, toon ons ook dat F1082 
intrasellulêre oksidatiewe stres bevorder wat yster afhanklik is. Al ons resultate dui daarop dat F1082 
‘n belowende ant-TB voorloper verbinding is met spesifisiteit teen M.tb en unieke teikeneienskappe in 
M. tuberculosis. 
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1.1 Historical tuberculosis 
 
Tuberculosis (TB) is a fascinating disease, and even today still poses a challenge to the medical 
fraternity. TB is an old disease identified in the past as Phthisis, Consumption, Pott’s disease, The 
Great Plague, King’s Evil or Lupus vulgaris. (Mathema et al., 2006; Daniel, 2006). Tuber is a Latin 
name referring to all forms of degenerative protuberances or tubercles and tuberculosis was the term 
for diseases causing such tubercles (Shikano et al., 2009).   Although tuberculosis was probably 
described for the first time in Indian texts, pulmonary TB was known since the time of Hippocrates as 
phthisis, which is derived from the Greek for “wasting away”. Scrofula, a less common manifestation 
of TB that affects the lymph nodes, especially of the neck and most common in children, was 
documented during the European Middle-Ages and it was believed that cure would come from the 
power of the divine touch of the king. Pott’s disease or Gibbous deformity, causing skeletal 
abnormalities, has been identified in skeletal remains from ancient Egyptian and Aztec times. 
In Western and Northern America, TB reached its peak during the18th and 19th centuries, during the 
age of Industrialisation (Holmberg, 1990). At that time there was a mass movement of people into 
cities, where people lived and worked in harsh, unhygienic conditions which favoured the spread of 
infectious diseases. The Industrial Revolution is known for its over-crowded factories, where people 
worked in polluted air workplaces, were poorly paid and worked and lived in cramped spaces also 
with poor or no aeration. People were undernourished and had little or no access to health care. As 
these conditions favoured TB, it gained a stronghold in the population and maintained its position as a 
major cause of death. 
It is now accepted that tuberculosis existed in the Americas before European contact (Arriaza et al., 
1995; Gómez i Prat and de Souza, 2003) although it has not yet been determined which species or 
genotype of M. tuberculosis was responsible. It is hypothesized that the disease reached the Americas 
via animals (Rothschild et al., 2001) or early nomads (Daniel, 2006) who crossed the Bering land 
bridge at least 10 000 years ago. The suggestion that more virulent strains of tubercle bacilli 
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originated in Europe and spread to the Americas during the colonial expansions from the fifteenth 
century onwards (Clark et al., 1987) has not yet been verified nor disproved. 
1.2 Tuberculosis (TB): the disease 
 
It is often stated that around 2 billion people, about one third of the world’s population, are infected 
with tubercle bacilli. During 2007, 1.77 million people died from the disease according to the World 
Health Organisation (: http://www.who.int/tb). It is also reported that about 10% of infected people 
become ill over a life time with active tuberculosis (in absence of immunosuppression) which 
includes those with less effective immune systems such as the very young and old, or those who 
suffer from malnutrition. This high level of latent TB infection indicates a long-term co-existence of 
the human host and the bacterial pathogen (Hirsh et al., 2004).  
Tuberculosis in mammals is caused by a group of closely related bacterial species termed the 
Mycobacterium tuberculosis complex family. This family includes M. tuberculosis, M. africanum, M. 
canetti, M. bovis, M. caprae, and M. pinnipedii (Smith et al., 2006). Other mycobacteria are wide-
spread in the environment but members of the M. tuberculosis complex are obligate pathogens 
(Grange, 1996). Many of the mycobacteria, including M. tuberculosis, are very slow growing with an 
in vitro doubling time of approximately 24 hours (Grange, 1996) . The pathogenic species are able to 
survive and grow within macrophages (phagosome), which enables them to evade the host immune 
system (Malik et al., 2001). An active cell-mediated response is required to contain and kill the 
tubercle bacilli (Ernst, 1998).   
Today, the principal causative agent of human tuberculosis is M. tuberculosis. M. bovis has a wide 
host range, although is the main cause of tuberculosis in bovidae. Unpasteurised milk and milk 
products are regarded as the main route of transmission of zoonotic TB caused by M. bovis in 
countries where there are no effective eradication programmes (O’Reilly and Daborn, 1995). In the 
past, and today in the absence of effective eradication programmes, it is estimated that M. bovis is 
responsible for about 6% of human deaths from tuberculosis (O’Reilly and Daborn, 1995). Other 
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members of the M. tuberculosis complex also cause human infections, such as M. canetii, M. 
africanum, although these tend to appear in specific geographic regions (Gagneux et al., 2006).  
Tuberculosis infection may involve almost any organ in the body, but the most common clinical 
presentation is pulmonary tuberculosis, in which transmission is via infectious aerosols released from 
the lungs of an infected person (Chandir et al., 2010). In the alveolus of the lung, inhaled tubercle 
bacilli are ingested by the macrophages and are normally contained by the host immune response 
(Frieden et al., 2003). This can lead to granuloma formation and eventually to a calcified lesion 
(Dannenberg et al., 1994). Spread of the bacteria within a year of initial infection results in primary 
disease. However, it is thought by many that the organism may remain dormant but viable for 
decades. If the immune response is subsequently compromised, the bacteria may escape into the lungs 
causing re-activated pulmonary tuberculosis (Marais et al., 2009). In a minority of cases, the bacteria 
spread to other host tissues via the lymphatic system and blood, thereby becoming disseminated 
throughout the body, resulting in miliary or extra-pulmonary tuberculosis (EPTB) (Golden and 
Vikram, 2005). In immunocompetent adults it is estimated that primary EPTB disease occurs in 15-
20% of all cases (Donoghue, 2009). 
Infection of the lymph nodes results in swollen glands and is the most common clinical presentation 
of EPTB (Golden and Vikram, 2005). Cervical lymphadenitis and skin lesions were previously known 
as scrofula or lupus vulgaris. Pleural effusions, genito-urinary tract tuberculosis, meningitis, skeletal, 
ocular and abdominal tuberculosis are additional clinical presentations of the disease, especially in 
communities where no effective chemotherapy is available (Thwaites et al., 2008). Gastro-intestinal 
tuberculosis can result from swallowing infected sputum or by ingestion of infected animal products, 
resulting in the potential for transmission of infection via faeces and urine (Donoghue, 2009).  
Despite half a century of anti-TB chemotherapy, it is often said that one third of the world’s 
population asymptomatically still harbour a dormant or latent form of M. tuberculosis with a risk of 
disease reactivation (Figure 1.1). Reactivation of latent TB, even after decades of subclinical 
persistence, is a high risk factor for disease development particularly in immunocompromised 
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individuals such as those harbouring the human immunodeficiency virus (HIV), or on anti-tumour 
necrosis factor therapy or with diabetes (Barry et al., 2009). 
 
                      
Figure 1.1 Stages of M. tuberculosis infection (“Koul et al., 2011”)   
Mycobacterium  tuberculosis aerosol transmission and progression to infectious TB or non-infectious 
(latent) disease is shown (Figure 1.1). A sizeable pool of latently infected people may reactivate into 
active TB, years after their first exposure to the bacterium. In cases of drug-susceptible (DS)-TB with 
treatment compliance (denoted by asterisk), 95% of patients recover upon treatment, whereas 5% 
relapse. If untreated (denoted by double asterisks), high mortality results (Figure 1.1). 
1.3 TB epidemiology 
 
1.3.1 Incidence 
 
There were an estimated 9.4 million incident cases (range, 8.9 million – 9.9 million) of TB globally 
(equivalent to 137 cases per 100 000 population) in 2009, as illustrated (Figure 1.2). The absolute 
number of cases continues to increase slightly from year to year, as slow reductions in incidence rates 
continue to be adjusted by increases in population. Estimates of the number of cases as published by 
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the WHO, (2010) indicate that women (defined as females aged ≥ 15 years old) account for an 
estimated 3.3 million cases (range, 3.1 million to 3.5 million), equivalent to 35% of all cases. 
Estimates of the number of cases need to be improved with more and improved reporting and more 
analysis of notification data disaggregated by age and sex. Most of the estimated number of cases in 
2009 occurred in Asia (55%) and Africa (30%); smaller proportions of cases occurred in the Eastern 
Mediterranean region (7%), the European region (4%) and the region of the Americas (3%). The 22 
high-burden countries (HBCs) that have received particular attention at global level since 2000 
account for 81% of all estimated cases worldwide (Figure 1.2). The five countries with the largest 
number of incident cases in 2009 were India (1.6 – 2.4 million), China (1.1 – 1.5 million), South 
Africa (0.4 – 0.59 million), Nigeria (0.37 – 0.55 million) and Indonesia (0.35 – 0.52 million). India 
alone accounts for an estimated one fifth (21%) of all TB cases worldwide, and China and India 
combined account for 35% (WHO, 2010). Of the 9.4 million incident cases in 2009, an estimated 1.0 -
1.2 million (11-13% were HIV positive, with the best estimate of 1.1 million (12%) (Figure 1.2). 
These numbers are slightly lower than those reported in previous years, reflecting better estimates as 
well as reduction in HIV prevalence in the general population. Of these HIV-positive TB cases, 
approximately 80% were in the African region. 
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Figure 1.2 Estimated TB incidence rates, by country, 2009 (from WHO report 2010) 
 
 
Figure 1.3 Estimated HIV prevalence in new TB cases, 2009 (from WHO report 2010) 
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1.3.2 Prevalence 
 
In Wolrd Heath Organisation (WHO), 2010, there were 14 million TB (prevalent) cases estimated 
(range, 12 million to 16 million) for 2009, equivalent to 200 cases per 100 000 population (Figure 
1.3). Prevalence is a robust indicator of the burden of the disease caused by TB when it is directly 
measured in a nationwide survey. When survey data are not available it is difficult to estimate its 
absolute level and trend. In those countries where surveys are done and repeated at periodic intervals, 
estimates of the prevalence of TB and trends in rates of TB prevalence will improve (WHO 2010). 
1.3.3 Mortality 
 
In 2009, an estimated 1.3 million deaths (range, 1.2 million to 1.5 million) occurred among HIV-
negative cases of TB, including 0.38 million deaths (range, 0.3 – 0.5 million) amongst women WHO, 
2010). This is equivalent to 20 deaths per 100 000 population (WHO, 2010). In addition there were an 
estimated 0.4 million deaths (range, 0.32 million – 0.45 million) among incident TB cases that were 
HIV-positive; these deaths are classified as HIV deaths in the 10th revision of the International 
Classification of Diseases (ICD-10). The number of TB deaths per 100 000 population among HIV-
negative people plus the estimated number of TB deaths among HIV-positive people equates to a best 
estimate of 26 deaths per 100 000 population (WHO, 2010). 
1.3.4 MDR-TB, XDR-TB and TDR-TB 
 
The World Health Organisation (WHO) released statistics estimating the spread of multi-drug 
resistant tuberculosis (MDR-TB) defined as M. tuberculosis strains resistant to rifampicin and 
isoniazid and extensively resistant tuberculosis (XDR-TB) defined as MDR-TB that is also resistant to 
at least three of the six classes of second line agents. According to the WHO world report released in 
2010 (Who, 2010), there were 440 000 estimated cases of multi-drug resistant TB (MDR-TB) in 2008 
(range, 390 000 – 510 000). The 27 countries (15 in the European Region) that account for 86% of all 
such cases have been termed the 27 high MDR-TB burden countries. The four countries that had the 
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largest number of estimated cases of MDR-TB in 2008 were China (100 000; range, 79 000 – 
120 000), India (99 000; range 79 000 – 120 000), the Russian Federation (38 000; range, 30 000 – 
45 000) and South Africa (13 000; range, 10 000 – 16 000). By July 2010, 58 countries and territories 
had reported at least one case of extensively drug resistant TB (XDR-TB) (WHO, 2010). 
Another important discovery raising concern is the identification of a form of incurable tuberculosis 
which was reported by a physician in India (Udwadia et al., 2012). Although reports call this latest 
form a “new entity” researchers suggest that it is instead another development in a long-standing 
problem. The discovery make India the third country in which a completely drug resistant form of the 
disease has emerged, following cases documented in Italy in 2007 (Migliori et al., 2007) and Iran in 
2009 (Velayati et al., 2009). However, data on the disease, dubbed totally drug-resistant tuberculosis 
(TDR-TB), are sparse, and official accounts may not provide an adequate indication of its prevalence. 
The term such as “total drug resistant” have not been clearly defined for tuberculosis. While the 
concept of “total drug resistance” is easily understood in general terms, in pratice, in vitro drug 
susceptibility testing (DST) is technicallt challenging and limitations on the use of results remain: 
conventional DST for drugs that define MDR and XDR-TB has been thoroughly studied and 
consensus reached on appropriate methods, critical drug concentrations that define resistance, and 
reliability and reproducibility of testing (WHO, 2008a). Data on the reproducibility and reliability of 
DST for the remaining second-line drugs (SLD) are either more limited or have not been established, 
or the methodology for testing does not exist. Most importantly, correlation of DST results with 
clinical response to treatment has not yet been adequately established. Thus, a strain of TB with in 
vitro DST results showing resistance could in fact, in patient, be susceptible to these drugs. The 
prognostic relevance of in vitro resistance to drugs without an internationally accepted and 
standardised drug susceptibility test therefore remain unclear and current WHO recommendations 
advise against the use of these results to guid treatment (WHO, 2008b). 
Lastly new drugs are under development, and their effectiveness against these “total drug resistant” 
strains has not yet been reported. For these reasons, the term “total drug resistant” tuberculosis is not 
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yet recognised by the WHO. For now these cases are defined as extensively drug resistant 
tuberculosis (XDR-TB), according to WHO definitions. 
1.4 Immune response to M. tuberculosis 
 
Immediately after infection, alveolar macrophages and dendritic cells, which phagocytose M. 
tuberculosis, migrate through the lymphatic system towards the regional lymph node, forming the 
Ghon complex (Lin et al., 2009). Simultaneously, phagocytic cells can penetrate the pulmonary 
parenchyma, initiating an inflammatory focus to which other macrophages will be attracted (Flynn et 
al., 2011). In this case, the accumulation of inflammatory cells around the microorganism initiates the 
formation of granulomas, coordinated by T-lymphocytes. The T-cells become indispensable to the 
formation of stable granulomas, contacting mononuclear phagocytes and influencing their 
differentiation and activation status (Winau et al., 2006, Fallahi-Sichani et al., 2011). M. tuberculosis 
may be contained in this granuloma, and there is a belief that they may persist for decades, in latent 
form, without triggering activation of the disease (Barry et al., 2009). 
Immunosuppression, either due to the poor health status of the individual (e.g. malnutrition, diabetes), 
HIV infection, or use of immunosuppressants, is thought to be a frequent cause of the multiplication 
of the bacilli enclosed in the granuloma and of the reactivation of TB (endogenous reaction), as 
compared to reinfection (exogenous) with M. tuberculosis (Kaufmann, 2005). Macrophages in the 
tissue constitute one of the first lines of defences against mycobacteria. After being phagocytosed, the 
bacilli remain within the phagosome. If there is phagosome-lysosome fusion, antigens can be 
processed and subsequently presented to T-helper (Th) lymphocytes (CD4+), through the major 
histocompatibility complex class II (MHC II) molecules (also known as antigen presenting cells), 
which are found in macrophages, dendritic cells, and the B lymphocytes. It is known that the T-helper 
type 1 (Th 1) CD4+ cells play a central role in the immune response to mycobacteria (Gallegos et al., 
2008). However, cytotoxic T cells (CD8+), which recognize antigens from the cytoplasm (tumour or 
viral), also participate in the immune response to M. tuberculosis (Palma et al., 2010). The CD8+ T 
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cells can recognize peptide fragments bound to MHC class I cells, which are expressed in practically 
all differentiated or mature cells of the organism. In the case of mycobacteria, it has been 
demonstrated that apoptotic vesicles from infected cells containing antigens of the bacillus associated 
with MHC class 1 can specifically stimulate CD8+ T cells (Winau et al., 2006). Alternatively, in a 
phenomenon known as cross-presentation, antigens of intracellular pathogens can be presented via 
MHC class I cells, owing to the capacity of the phagosomes to fuse with the endoplasmic reticulum, 
and to the protein recruitment from the endoplasmic reticulum to the phagosome. Consequently, 
phagocytosed antigens can access the cytoplasm, suffer degradation by the proteases, known as 
proteasomes, return to the phagosome through transporters associated with antigen processing 
(TAPs), and bind to MHC class I molecules located in the phagosome, leading to the subsequent 
expression on the cell surface and to the recognition by CD8+ cells(Margulies, 2009).  
A complex cascade of events taking place in response to mycobacterial infection and human host 
immune response is depicted (Figure 1.4). Cytokines, molecules produced and secreted by different 
immunocompetent cells after some stimulus, are central component in the defence against 
mycobacteria. During immune response, the cytokines produced participate in the regulatory 
processes, as well as effector function (Cooper et al., 2011).  
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Figure1.4 Mechanism involved in the activation of macrophages and T lymphocytes by mycobacteria 
(from Teixeira et al., 2007). 
Atypical lymphocytes (CD4- and CD8-) have receptors containing gamma/delta polypeptide chains 
and recognize phosphoric components of M. tuberculosis (Tanaka et al., 1995), regardless of MHC 
class I or II, whereas the T lymphocyte receptor restricted only to CD1 can be stimulated by 
glycolipids derived from the cell wall of the mycobacteria (Cohen et al., 2009). Therefore the immune 
system can recognize and effectively respond to a broad spectrum of antigenic determinants of 
different biochemical characteristics. In this recognition, there is a hierarchy among the T cell 
subpopulations that contribute to the immune response to mycobacteria, and the CD4+ and CD8+ T 
lymphocytes are the most important in this hierarchy (Gallegos et al., 2008). 
There is an enormously complex immune response to M. tuberculosis infection, and macrophages 
play an important role in this host response.  These cells play two vital roles as the primary effector 
cells in killing and the habitat in which the mycobacteria reside. For the mycobacteria to survive and 
to develop a productive disease, they must develop strategies to evade the host immune system. Here, 
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we discuss some of the important strategies adopted by pathogenic mycobacteria to persist within 
macrophages as these areas may be exploited as targets for drug development. 
An early microbicidal activity that any intracellular microbe will encounter within the macrophage is 
an oxidative burst (Russell, 2011). This is a nonspecific immune mechanism triggered by many 
microbes that results in the production of highly reactive chemical species known as reactive nitrogen 
intermediates (RNIs) and reactive oxygen intermediates (ROIs) (Ehrt and Schnappinger, 2009). 
Intermediate reaction products of O2 en-route to water include superoxide (O2), hydrogen peroxide 
(H2O2) and hydroxyl radicals (OH·), and reactive products of these with halides and amines. With 
regard to RNIs the products correspond to molecular species in different oxidation states ranging from 
nitric oxide to nitrate (Nathan, 2008). From various studies it has been shown that the generation of 
the ROIs and RNIs is required for mycobacterial killing. However, it is unlikely that effective killing 
would be achieved without delivery of bacteria to acidic compartments (late endosome/lysosomes), as 
suggested by the studies of different laboratories (Flannagan et al., 2009). These findings and the 
lessons learned from mycobacterial immunology can direct one to potential weaknesses in the 
mycobacteria and can provide targets for development of new drugs from chemical compounds from 
synthetic libraries or natural products.   
1.5 Tuberculosis (TB) disease prevention 
 
1.5.1 BCG vaccination 
 
The first BCG vaccination was carried out in 1921 (Grange et al., 1983). This vaccine, known as 
Bacille Calmette-Guerin (BCG), an avirulent M. bovis strain, was attenuated from the clinical isolates 
for over a decade by serial passages on glycerol saturated potato slices (Calmette, 1931). Due to the 
high demand, the original BCG was distributed globally, even before the establishment of an 
appropriate culture protocol (Aaby et al., 2000). Numerous BCG strains, with a variety of antigenic 
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and immunological differences, exist today in various parts of the world. BCG is currently used as a 
TB vaccine worldwide, and BCG vaccination is mandatory in many areas (Delogu and Fadda, 2009). 
There have been significant advances in our understanding of the biology and the pathogenesis of 
tuberculosis. Unfortunately this increase in knowledge has not yet resulted in the development of a 
satisfactory vaccine; one that will overcome the problems associated with the current vaccine, BCG. 
Bacille Calmette-Guerin is an attenuated strain of Mycobacterium bovis and, although sometimes 
efficacious in laboratory models of disease (Smith, 1985), gives rise to variable protective efficacy in 
human populations (Andersen and Doherty, 2005). The increasing incidence of TB co-infection 
associated with HIV infection and the emergence of multidrug-resistant strains of M. tuberculosis has 
emphasized the importance of prevention through effective vaccination, possibly using a safe, non-
viable subunit vaccine. Clearly a subunit vaccine would be preferable to overcome the difficulties 
associated with the use of a live vaccination such as BCG and to harness the relevant facets of the 
protective immune response to mycobacteria.  
1.5.2 Problems associated with BCG 
 
The efficacy of BCG in field trials has varied tremendously and in some geographical regions the 
vaccine has not shown any efficacy at all (Brandt et al., 2002). It is noteworthy that in the regions 
where BCG had the lowest efficacy such as South India (ten Dam, 1984) there is high level infection 
with mycobacteria from the soil or water sources (Herbert et al., 1994). More than 20 different species 
of mycobacteria were found in these studies and it would appear that many of these species share 
antigens with BCG. Several investigators have suggested that such prior exposure to environmental 
mycobacteria may provide varying levels of resistance against tuberculosis (Palmer and Long, 1966; 
Brandt et al., 2002). If so, one might expect low prevalence of disease, which is not necessarily the 
case (there is no control and this is speculation). However, sensitization provided by such exposure 
may have an adverse effect on the outcome of vaccination due to antagonistic interactions (Stanford et 
al., 1981). This issue remains to be resolved but, in general, the data collectively demonstrate the 
problem with the current BCG vaccine at least in tropical regions. Evidence in animal studies suggests 
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that immunity can be provided by mycobacterial species in the environment, but those isolated from 
South India provide only 50% of that afforded by BCG (Palmer and Long, 1966). Furthermore, the 
sensitization by environmental mycobacteria is acquired gradually and therefore does not provide 
sufficient immunity in early life. In individuals sensitized by environmental mycobacteria, subunit 
vaccination with M. tuberculosis antigens may be the optimal way to boost immunity provided by 
natural exposure.  
A more recent development that has had a significant impact on the use of BCG is that of 
immunodeficiency due to the human immune deficiency virus (HIV). HIV imposes an obvious safety 
problem and limits the use of live BCG vaccine due to the risk of BCG-related pathology, as has been 
reported to occur up to 30 years after vaccination (Reynes et al., 1989) and may be common in HIV 
positive children (Hesseling et al., 2003). Furthermore, it is known that tuberculosis drives the 
progression of HIV infection to AIDS (Leroy et al., 1997; Goletti et al., 1996). Employing a vaccine 
based on live mycobacteria in a population already harbouring the HIV virus must therefore be 
considered carefully.  
The antigenic similarity between BCG and M. tuberculosis is probably a major factor responsible for 
the efficacy of BCG (Fifis et al., 1991). However, this similarity creates problems for screening 
populations for tuberculosis with tuberculin PPD which contains multiple antigens shared between the 
vaccine and the pathogen (Farhat et al., 2006). As a result, BCG is not used in a number of countries 
that rely on tuberculin for diagnosis of tuberculosis. The ideal future vaccine would allow screening 
for tuberculosis to proceed without the potential pitfall of false positives within a vaccinated 
population.   
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1.6 Tuberculosis (TB) treatment 
 
1.6.1 Evolution of antituberculosis drugs 
 
 Since the discovery of Mycobacterium tuberculosis by Robert Koch in 1882, a chronological 
development of antituberculosis drugs in relation to decades is shown (Figure 1.5). Antituberculosis 
drug development was catalysed in the 1940s when streptomycin was discovered and thought to 
provide the “magic cure” for tuberculosis (Fox et al., 1999). This enthusiasm was soon curbed when it 
became apparent that the final outcome of the “cures” with this single agent soon approached that of 
untreated patients. A decade later, isoniazid was discovered and when used in conjunction with 
streptomycin, rapid and durable cures were obtained (Fox et al., 1999). A combination of 
streptomycin with isoniazid and para-aminosalicylic acid resulted in the first combination therapy 
regimen which was given over 24 months (Schmitz and Kleine-Allekotte, 1960). Para-aminosalicylic 
acid was replaced in the mid-1960s by ethambutol, which was tolerated and reduced treatment 
duration to 18 months (Schmitz and Kleine-Allekotte, 1960). The introduction of rifampicin to 
combination therapy in the late 1960s offered a cure in more than 95% of patients and further reduced 
the treatment duration to 9 to 12 months (WHO 2009). Pyrazinamide was added in the 1980s and 
facilitated the modern-day short-course treatment. 
 
Figure 1.5 Time-line in TB and antituberculous drug development (from Lalloo and Ambaram, 2010). 
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1.6.2 Current TB treatment 
 
Today many TB antibiotics are available which can, based on their activity, be classified into 3 
groups: those with bactericidal activity, those with sterilizing activity, and those that prevent drug 
resistance. Bactericidal activity is the capacity of a drug to reduce the number of actively dividing 
bacilli in the initial therapy stage. Although rifampicin and streptomycin have some bactericidal 
activity, the most potent anti-TB drug is isoniazid (Hershfield, 1999). Sterilizing activity as in the case 
of rifampicin and pyrazinamide is the ability of the drug to eliminate the putative subpopulation of 
dormant bacteria from which clinical relapse can occur (Davies, 2010). Drug resistance is prevented 
by drugs that eliminate all bacterial populations and do not allow the emergence of resistant 
organisms. Most effective treatment regimens consist of at least two bactericidal ant-TB drugs 
(isoniazid and rifampicin) to kill actively growing M. tuberculosis populations, followed by a 
continuation phase for elimination of intermittent dividing and dormant bacteria (Frieden et al., 2003). 
A major challenge still remains: elimination of latent TB, which is a results from exposure M. 
tuberculosis that are alive in the body but remain inactive.The current treatment is ineffective in 
eliminating latent TB. 
The therapy combination and duration is broadly classified into three categories. Category 1 consists 
of an initial phase of two months with daily (5/7) doses of INH, RIF, PZA and EMB. This is followed 
by a continuation phase of four months with daily (5/7) dose of INH and RIF, for newly smear-
positive and seriously ill smear negative patients or seriously ill patients with extrapulmonary 
manifestations (Holland et al., 2009). Category 2 is recommended for previously treated smear-
positive patients who come for re-treatment due to relapse, failure or default. The regimen consists of 
an initial phase of two months with daily (5/7) doses of INH, RIF, PZA, EMB and SM followed by a 
continuation phase of one month with daily (5/7) doses of INH, RIF, EMB with or without PZA. 
Category 3 is recommended for treatment of new smear-positive patients and those with 
extrapulmonary manifestations, but not seriously ill. The combination consists of an initial phase of 
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two months with thrice weekly doses of INH, RIF and PZA followed by a continuation phase of four 
months with thrice weekly doses of INH and RIF (Myers, 2005). 
In an attempt to reduce the global burden of TB, the World Health Organisation (WHO) formulated 
the Millennium Development Goals (MDGs). The target of the MDGs is to halve TB prevalence and 
death rates by 2015 compared to that of 1990, and furthermore to completely eliminate TB by 2050. 
To achieve this, the WHO developed the Directly Observed Treatment, short-course (DOTS) strategy 
in the mid-90s, which was recommended internationally and consequently expanded worldwide 
(Hopewell et al., 2006). DOTS is a 6 months therapy regimen consisting of an initial 2 months 
treatment phase with four first-line drugs (isoniazid, rifampicin, pyrazinamide and ethambutol), 
followed by a 4 month treatment phase with only isoniazid and rifampicin. The addition of DOTS, 
where patients consume each dose of anti-TB drugs under supervision, to the treatment strategy is 
strongly recommended. This approach maximizes the probability of therapy completion, hence 
limiting the emergence of drug-resistance (Blumberg et al., 2003). Approximately 90% of the drug 
susceptible TB cases are cured when this regimen is fully adhered to (WHO, 2010). For MDR cases 
WHO recommends DOTS-plus, which includes adding second-line drugs to the conventional DOTS 
program (WHO, 2010). 
1.6.3 Classification of TB drugs 
 
Currently available TB drugs are classified by the World Health Organisation as first-line, second-
line, and third-line drugs based on accessibility, efficacy and drug sensitivity (Lalloo and Ambaram, 
2010). Table 1.1 is a practical classification of anti-TB drugs. Second-line drugs may be more toxic, 
less effective, and not routinely available in developing countries and are reserved for drug-resistant 
TB. Third-line drugs are generally still under development, or of unproven or diminished efficacy, 
more toxic, and/or very expensive (Falzon et al., 2011). Many are used for XDR-TB, for which 
treatment options are seriously limited. Drugs such as imipenem, metronidazole, co-amoxiclav, 
clofazimine, and perchlorperazine are used under exceptional circumstances despite lack of evidence 
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in many cases for their efficacy (Chambers et al., 2005). Global recognition of XDR-TB has 
prompted intensive clinical research into these and newer drugs for TB treatment. 
Table 1.1 Classification of antituberculosis drugs 
First-line Second-line Third-line 
Rifampicin Aminoglycosides Rifabutin 
Isoniazid Amikacin Macrolides 
Ethambutol Neomycin Clarithromycin 
Pyrazinamide Polypeptides Linezolid 
 Capreomycin Thiacetazone 
 Viomycin Thioridazine 
 Emviomycin Arginine 
 Flouroquinolones VitaminD 
 Ofloxacin Perchlorperazine 
 Levofloxacin  
 Ciprofloxacin  
 Moxifloxacin  
 Thioamides  
 Ethionamide  
 Prothionamide  
 Para-aminosalicylic acid   
 
1.6.4 Challenges with the current treatment and the quest for new tuberculosis 
drugs. 
At present, MDR-TB is treated by a combination of multiple drugs with therapies lasting up to 18-24 
months; only four of these drugs were directly developed to treat TB (Gandhi et al., 2010). 
Suboptimal therapy leads to almost 30% of MDR-TB patients experiencing treatment failure (Mitnick 
et al., 2003). The treatment options for XDR-TB are even more limited, since XDR bacilli are 
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resistant not only to isoniazid and rifampicin, but also to flouroquinolones and injectables such as 
aminoglycosides. In addition, there are serious side effects with most XDR-TB and MDR-TB drugs, 
including nephrotoxicity, ototoxicity with aminoglycosides, hepatoxicity with ethionamide and 
dysglycemia with gatifloxacin (Ma et al., 2010). Thus the current situation necessitates the immediate 
identification of new scaffolds that can address emerging resistance and also requires the conduct of 
appropriate clinical trials, since historically, very few clinical studies have been performed to evaluate 
the efficacy of drugs in MDR-TB or XDR-TB patient cohorts. Improving diagnostics with wider 
coverage of drug susceptibility testing will also help address the high mortality of MDR/XDR-TB and 
curb the emergence of resistance. 
TB accounts for about one in four of the deaths that occur among HIV-positive people (WHO 2010). 
Of the 9.4 million TB cases in 2009, 11-13% was HIV-positive, with approximately 80% of these co-
infections confined to the African region (WHO 2010). The frequent co-infection of TB in HIV 
patients further complicates the selection of an appropriate treatment regimen because (1) increased 
pill burden diminishes compliance (2) drug-drug interactions lead to sub-therapeutic concentrations of 
antiretrovirals; and (3) overlapping toxic side effects increase safety concerns. The interaction 
between HIV drugs and TB antibiotics can occur because of rifampicin-induced increased expression 
of the hepatic cytochrome P450 oxidase system (CYP) (Niemi et al., 2003). This CYP induction 
results in increased metabolism and decreased therapeutic concentrations of many co-medications, 
such as HIV protease inhibitors (L’homme et al., 2009). Even in the presence of CYP 450 inhibitors 
such as ritonavir, normal trough levels of various classes of protease inhibitors cannot be rescued and 
consequently, standard protease inhibitor regimens, whether boosted or not, cannot be given with 
rifampicin. The only treatments for HIV-infected TB patients with minimal drug-drug interactions are 
non-nucleoside-reverse-transcriptase inhibitor (NNRTI) containing regimens. However, there are 
fewer options for patients with NNRT-resistant mutations and therefore new chemistry approaches are 
being used to identify new rifamycins, such as rifabutin, with reduced CYP-induction properties (Ma 
et al., 2010).  
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However the presence of ritonavir in the protease cocktail increases the serum concentration of 
rifabutin, thereby increasing its accompanying toxicity (Dye and Williams, 2010). In order to search 
for newer rifamycin analogues with minimal interaction with HIV and other co-medications, the 
upfront screening of newer molecules in a CYP profiling (pregnane-X receptor) assay can be 
performed (Goodwin et al., 1999). This receptor drives transcription of CYP genes and can identify 
chemical analogues with minimal interactions with drug metabolizing enzymes such as CYP450. 
Furthermore, availability of co-crystal structures of rifampicin with bacterial RNA polymerase 
(Campbell et al., 2001) might help to design molecules with better drug resistance profiles. In HIV 
patients harbouring MDR- or XDR-TB strains, drug-drug interaction studies of second-line antibiotics 
are not well established, (for example ethionamide, cycloserine, kanamycin, amikacin, capreomycin 
and para-amini salicylate) (Burman et al., 1999). Thus, there is a clear need for new studies to 
investigate the interaction of antiretrovirals with second-line TB drugs and with those currently in 
clinical development. 
Confounding these issues is the association of TB with other chronic diseases such as diabetes, which 
is known to increase the risk of developing active TB three fold (Dye and Williams, 2010). The 
biological rationale for the slower response of diabetics to anti-TB drugs and for their increased risk 
of developing MDR-TB is poorly understood, although it is well known that cell-mediated immunity 
is suppressed in diabetes, which could explain higher TB rates. Attainment of bacterial culture 
negativity, relapse rates and mortality are significantly higher in diabetic TB patients (Touré et al., 
2007). We therefore need to identify new TB molecules that are strongly bactericidal and have 
minimal drug-drug interactions with oral anti-diabetic drugs (Dooley and Chaisson, 2009). Diabetics 
also tend to have a high body mass index (BMI) and are often obese, which may in part lead to lower 
TB drug concentrations (Ruslami et al., 2010). Where there is a poor response to TB treatment in 
diabetic patients, therapeutic drug monitoring may be useful in TB management. 
After decades of a standstill in TB drug development, the drug pipeline has begun to show promise 
over the last 10 years. The main criteria established by the TB Alliance are to select drug candidates 
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for further development and are: shortening of the current treatment, activity against MDR-TB, and 
lack of interactions with antiretroviral drugs. During the last few years, increasing awareness of the 
lack of Research and Development (R&D) for neglected diseases has led  some pharmaceutical 
companies to establish an institute undertaking R&D activities on a ‘non-profit-no-loss’ basis. Other 
companies have engaged in tuberculosis R&D on a for-profit basis and with some success (Moran, 
2005). 
Major advances have been also made in tuberculosis basic research. Modern molecular and genetic 
analytical tools have become available for M. tuberculosis (such as targeted mutagenesis, array-based 
analysis of mutant libraries, techniques for conditional gene silencing and global gene expression 
profiling) and this has led to impressive improvement in the knowledge and understanding of the 
basic biology and physiology of M. tuberculosis (Wassenaar et al., 2009). 
Despite these positive changes, there are still problems that need to be tackled. A critical question 
today is whether they are sufficient to bring improved treatment to patients in the next few years. The 
next important question is whether there are an adequate number of promising compounds in the TB 
pipeline for a broadly effective new treatment combination to be developed. Although different 
attrition rates might apply, the number of candidate compounds is still small compared to the drug 
pipelines for diseases of major concern to wealthy countries, such as cancer or cardiovascular 
diseases. 
1.7 TB Drug discovery and development process 
 
Mycobacterium tuberculosis is a difficult pathogen to combact and the drugs used are more tan 40 
year old. Although cure rates are as high as 95% have been reported, they are not typical observed in 
stting where health facilities are afar in developing countries. If cure rates of 85% are achievable, it is 
reasonable to ask why TB still kills 1.7-1.8 million people every year (WHO, 2010). The most 
straighward answer to the question is that these drugs are not ideal for treating TB. However the most 
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answer is undoubtedly complex and is related not only to the current treatment but also rooted to 
socioeconomical issues. The most noteworthy accepted treatment for TB that is long lasting and 
involves multiple-drug combination is challenged by the fact that the current treatment is not 
efficacious and M. tuberculosis ability to develop resistance to any single agent. There is an urgent 
need todevelop new or improved drug for the treatment of TB. Drug discovery development for 
treatment of TBis slow and the time spent to identify lead compounds has been delays by much 
attrition applied in this process. Therefore drug discovery in TB treatment is an area of focus and 
requires collective effort. 
Drug discovery and development is the mission of pharmaceutical research companies to the path 
from understatnding a disease to bringing a safe and effective new treatment to patients. Scientist 
work to piece together the basic causes of a disease at level of genes, proteins and cells. Out of this 
understanding emerge “targets” which potential new drugs might be able to affect. Researchers work 
to validate these targets, discover the right molecule (potential drug) to interact with the target chosen, 
test the new compound in the lab and clinics for safety and efficacy and gain approval and get the new 
drug into the hands of doctors and patients. The task of discovering and developing safe and effective 
drugs is even more promising as our knowledge of disease increases. As scientist work to harness his 
knowledge, it is becoming an increasingly challenging. 
It takes about 10 to 15 years to develop one new medicine from the time it is discovered to when it is 
available for treatmenting patients (Figure 1.6). The average cost to research and develop each 
successful drug is estimated to be US $800 million to $1 billion. This number includes the costs of 
thousands of failures. For every 5, 000 to 10, 00 compounds that enter the research and development 
(R & D) pipeline, ultimately only one receives approval. These numbers defy imagination, but a 
depper understanding of the R & D process can explain why so many compounds don’t make it and 
why it takes such a large, lengthy effort to get one medicine to patients. Success requires immense 
resources (the best scientific minds, highly sophisticated technology and complex project 
management. It also takes persistence and sometimes, luck. Ultimately, though the process of drug 
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discovery brings hope and relief to millions of patients. In the following discussion we unravel the 
process of TB drug discovery and how we have engaged ourselves in coming with a promising 
molecule to TB drug development pipeline.  
 
Figure 1.6 Tthe attrition rate of compounds as they travel through the drug development process over 
time (Adopted from PhRMA, 2008). 
The complex nature of drug discovery and development requires a great knowledge of understanding 
The special challenges with M. tuberculosis biology 
TB drug research is mostly challenged by broad strectrum anti-bacterial drug research; identifying and 
developing a novel antibiotic is extremely difficult. The need for new antibiotics and the low success 
rate of finding such antibiotics ( only two new antibiotics series have been brought to market in the 
last 40 years) and have been published (Fischbach and Walsh, 2009). Besides the fact that 
pharmaceutical companies have redirected their resources in drug discovery but still fall short of 
effective target-based “hits” (Payne et al., 2007). Furthermore aside from specific challenges, there 
are several barriers in TB area including: no well-established pharmarcokinetic (PK)-
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pharmacodynamic (PD) paradigms; lack of validation and human-like pathology of animal model 
currently available for drug discovery; lack of adequate clinical laboratories for clinical trials; and the 
lack of adequate research funds. 
1.7.1 Current TB drug under development 
 
The major drugs currently under development are listed in Table 1with their mode of action (MOA). 
There are several reports on the advancement of these compounds under development (Palomino et 
al., 2009; Barry and Blanchard, 2010), and herein we provide a summary.  
TMC207, a lead compound in diarylquinoline series and was originally discovered by Janssen 
Pharmaceutical (Koul et al., 2007). This compound is undergoing Phase II clinical development for 
both multi-drug resistant (MDR) and drug-sensitive (DS)-tuberculosis (TB) indications. Its MOA is 
by inhibiting the M. tuberculosis ATP synthesis by interacting with the subunit c of ATP synthase 
(Koul et al., 2007).TMC was identified from estimated 7, 000 compounds screened on a whole-cell 
based assay against surrogate strain Mycobacterium smegmatis. Its MOA was established by 
analyzing the whole genome sequence of laboratory generated drug-resistant M. tuberculosis mutants. 
It is active against dormant M. tuberculosis organisms. Although a large number of TMC207 have 
been synthesized by Tibotec and TB Alliance for further development, one challenge might be to 
overcome the lipophilic nature of the compound. This might affect the PK, drug formulation and 
potentially may have other consequences. 
PA-824, is a derivative of CGI-17341 whose anti-TB activity was already reported (Ashtekar et al., 
1993). It is currently in Phase II clinical exploration against DS-TB patients. Its bacterial activity has 
been shown to be similar to that demonstrated by standard first-line drug regime (Diacon et al., 2010). 
The MOA of the compound has been shown to in M. tuberculosis PA-824-resistant mutants to 
involve reduction of the nitro-imidazole moiety by an F420-dependant enzyme (RV3547, deazaflavin-
dependent nitroreductase) (Manjunatha et al., 2006).The generation of the des-nitro intermediates and 
cell killing has been the suggested bactericidal mechanism under anaerobic conditions. The exact 
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MOA under aerobic conditions is still a limitation, however, inhibition of mycolic acid 
biosynthesishas been suggested (Manjunatha et al., 2009). A diverse range of PA-824-derivatives 
have been synthesized (Kmentova et al., 2010) and some of them are in preclinical candidate stage of 
development. 
OPC-67683, is also an analogue of CGI-17431, discovered and under development by Otsuka 
Pharmaceutical Company (Sasaki et al., 2006). It has a similar mode of action to Pa-824 (Matsumoto 
et al., 2006). OPC-67683 is reported to 4-16 times more potent than PA-824 in vitro and has no cross-
resistance with TB first-line drugs. It is currently in Phase II clinical trials for MDR-TB patients. 
Moxifloxacin and gatifloxacin, both are the most advanced compounds under development for TB 
drugs. They are in Phase III clinical trials. They are quinolones and both have 8-methoxyquinolone 
they were initially developed as broad-spectrum antibiotics and now being repurposed as anti-TB 
drugs. Fluoroquinolones in bacteria target gyrase and topoisomerase IV but in M. tuberculosis it is 
assumed they target solely gyrase since there is no evidence of topoisomerase IV (Diacon et al., 
2011). Moxifloxacin and gatifloxacing are more potent in vitro than other quinolones such as 
ciprofloxacin and ofloxacin which are used as second-line drugs. They are both in Phase III clinical 
trials in DS-TB patients replacing either ethambutol or isoniazid in standard first-line treatment 
(Aristoff et al., 2010). 
Rifampin and rifapentin, in recent years, efforts to use high dose of refampin (rifampicin) is under 
investigation whether it might contribute to treatment shortening (Diacon et al., 2007). Earlier trials of 
high-dose rifampin were reviewed and it was concluded that higher than standard rifampin dosing 
results in improved culture conversion rate (Steingart et al., 2011). Rifampetin is a newer analogue of 
the rifamycin class. It is more potent against M. tuberculosis and has a longer shelf-life in human 
compared with rifampin (Temple and Nahata, 1999). Rifapentine is currently evaluated in Phase II 
clinical trials. Rifamycin class of compounds inhibits M. tuberculosis RNA polymerase and resistance 
occurs by mutation in RNA polymerase (Aristoff et al., 2010). A challenge about this class of 
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compounds is that they induce cytochrome P456, this could affect the plasma levels of co-
administered drugs. 
Oxazolidinones, linezolid which represent the oxazolidinone class of antibiotics is one of the newly 
introduced antibiotics into the market and daptomycin representing lipopetide class of antibiotics. 
They are potent against Gram positive bacteria including methicilin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant Enterococci. It has also been shown that linozolid is active against 
M. tuberculosis by in vitro and in animal models (Alcalá et al., 2003). In M. tuberculosis it targets the 
ribosome and is active against MDR-TB clinical isolates. Linezolid has been used for MDR-TB and 
XDR-TB and additional Phase II clinical trials are ongoing (Fortún et al., 2005). Two oxazolidinones 
are also in clinical trial development include PNU-100480 from Pfizer and AZD5847 from 
AstraZeneca. It well known that linezolid adverse side effect results to hematological adverse effects 
(Gerson et al., 2002) and may not bet used fro treatment longer than 14 days. Therefore second-
generation oxazolidinone agents will be the key to their development. 
SQ109, is an anlogue of ethambutol that was prepared through recombinatorial chemistry 
(Protopopova et al., 2005). SQ109 is implicated in affecting cell wall biosynthesis and also active 
against ethambutol-resistant strains, however its precise MOA is not well known. It has been shown to 
have synergistic effect in combination with rifampin, isniazid, or TMC207 (Nikonenko et al., 2007). 
The challenge with this molecule is low bioavailability, however Phase I sduties have been completed 
and recruitment for Phase II studies. 
Meropenem and clavulanic acid, β-lactam antibiotics have been used for the first against M. 
tuberculosis. Deletion of the major β-lactamase of M. tuberculosis, BlaC, resulted in activity with of 
β-lactam antibiotics against M. tuberculosis (Flores et al., 2005). A combination of clavulanic acid, a 
β-lactamase inhibitor and meropenem, a carbapenem antibiotic was shown to be active and potent in 
vitro in XDR-TB strains under aerobic and anaerobic conditions (Hugonnet et al., 2009). By in vitro 
studies it has been shown that combination of any of the carbapenems (imipenem, meropenem and 
ertapenem) with clavulanic acid reduce the minimal inhibitory concentration (MIC) of carbapenem 
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from 8-16 to 1-4 µg/ml. In vivo studies of combination of imipenem or meropene with clavulanic acid 
improve survival of mice with less reduction of colony forming units when compared to isoniazid 
after 28 days of treatment. 
Benzothiazones, a promising new class of antimycobateria is represented by BZT043 with an MIC 
against M. tuberculosis of 0.004 µg/ml (Igarashi et al., 2003). In vivo studies indicate that this 
compound reduces bacterial load by 1 to 2 logs in the lung and spleen of mice, respectively. By 
sequencing, resistant mutant strains, it appears that it targets the enzyme decaprenylphosphoryl-β-D-
ribose 2’-epimerase (DprE1), which is involved in the biosynthesis of cell-wall component, 
arabinogalactan. The proposed MOA involves the reduction of the nitro group to a nitrosoresidue, that 
reacts with the cysteine group of DprE1 (Trefzer et al., 2010) 
Caprezamycins, are closely related natural products of complex structure (Igarashi et al., 2003).They 
are active against DS and DR strains of M. tuberculosis with an MIC of 3.13 µg/ml. They are similar 
to other known lipo-uridine antibiotics, it is believed their MOA to be the inhibition of lipid 
biosynthesis, with specificity the inhibition of phospho-MurNAc-pentapetidetranslocase (MraY, 
translocase I) (Bugg et al., 2006). There is not enough data on PK properties and hence the compoud 
can only be given by injection and can only be used for DR-TB patients. Caprazmycins are still in 
preclinical development stage. 
DC-159a, is an 8-methoxy-fluoroquinolone and was originally developed as a broad spectrum 
antibiotic, but was recently repurposed for TB treatment. It’s been shown to be more potent than 
moxifloxacin and gatifloxacin by in vivo studies against DS M. tuberculosis strains and retained 
activity against 11 strains of quinolone-resistant M. tuberculosis strains (Disratthakit and Doi, 2010). 
It also shown to be active in both replicating and non-replicating phases (Ahmad et al., 2011). 
Although many compounds show promise in vitro, not all compounds or molecules showing 
antimycobacterial activity either in vitro or in animal models end up evaluated in human clinical 
trials. Table 1.2 show some compounds that are currently undergoing clinical trials, opening the 
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possibility of eventually replacing one or more of the current first-line anti-TB drugs (Chen et al., 
2006; Jia et al., 2005; Spigelman, 2007). 
Table 1.2 Main TB drugs undergoing clinical evaluation 
Drug type Drug name Phase Mechanism of action Sponsor Reference 
Diamine SQ-109 I Cell wall biosyntheisis 
but its exact MOA not 
established 
Sequella Reddy et al., 
2010 
Pyrrole LL-3858 O I Multiple Lupin Kant, 2009 
Nitromidazooxazine PA-824 I Multiple Global TB 
Alliance 
Manjunatha et 
al., 2009 
Flouroquinolone Gatifloxacin III DNA synthesis 
inhibition (inhibition of 
the gyrase) 
EU/TDR Rustomjee et 
al., 2008 
Flouroquinolone Moxifloxacin III DNA synthesis 
inhibition (inhibition of 
the gyrase) 
Bayer/Global 
TB Alliance 
(GATB) 
(Rustomjee et 
al., 2008 
Diarylquinolone TMC207 II ATP synthesis 
inhibition (subunit of 
ATP synthase 
Tibotec/J&J Koul et al., 
2007 
 
 
1.7.2 Identification of new chemical scaffolds 
The poor efficiency of identifying new TB drugs by screening pharmaceutical library collections has 
been linked to the limited chemical diversity within these collections (Payne et al., 2007). 
Additionally, most TB drugs and antibacterials in general do not follow Lipinski’s ‘rule of 5’, which 
defines the optimal drug-like features; whereas pharmaceutical compound collections are biased 
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towards these properties (Projan, 2003). In spite of these challenges, the current TB clinical pipeline 
(Figure 1.7) is slowly expanding, although it is arguably inadequate for the development of a 
completely novel regimen. The key question remains how to search for new TB drugs and where to 
look for them? 
 
Figure 1.7 A representation of the current clinical pipeline for TB (“Koul et al., 2011") 
1.7.3 Novelty in screening 
Attempts to advance identification of new TB drugs targets have also been driven by the availability 
of the genome sequence of M. tuberculosis (Cole et al., 1998a), but unfortunately this approach has 
yet to lead to the identification of new advanced drug candidates. Genome-derived, target-based 
approaches have had little success in the antibacterial therapeutic area in general (Payne et al., 2007). 
The essentiality of a target for replication may be a prerequisite but it does not ensure its druggability, 
since for many essential targets we are unable to identify specific inhibitors with drug-like properties. 
For example, several high-throughput screening campaigns to identify inhibitors of isocitrate lyases 
(Cole et al., 1998a), which are key glyoxylate-shunt-pathway enzymes (Smith et al., 2003) found to 
be essential for mycobacterial intracellular growth and their long-term persistence in mice, were 
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discontinued owing to lack of druggability of these targets (Working group on New TB drugs, 2010). 
Secondly, we have often failed to understand how to convert good bacterial enzyme inhibitors into 
compounds that can easily penetrate the highly impermeable bacterial cell wall. Without proper 
understanding of these entry mechanisms of antibiotics across bacterial cell walls, any medicinal 
chemistry approach to engineer (via chemical modifications) a ‘permeability property’ into enzymatic 
inhibitor has proven to be quite challenging. 
Over time, it has emerged that shifting the screening strategy from single-enzyme target to phenotypic 
screens at a whole bacterial cell level is a much more successful strategy (Payne et al., 2007). Such a 
strategy recognises a potential holistic interaction of a drug target(s) with one or more components in 
a bacterial cell and defines its essentiality in a more relevant physiological space. One of the 
drawbacks of the whole-cell-screening approach is that upfront knowledge regarding the mechanism 
of action remains largely unknown, thereby preventing any input from structural biology into 
medicinal chemistry efforts around the drug design. Another challenge of the whole-cell-screening is 
to determine the right in vitro growth conditions that are relevant for in vivo infections, as certain 
metabolic targets behave differently depending on the composition of the growth medium (Pethe et 
al., 2010). Whole-cell-screening can deliver many ‘hits’, but several of these may work via non-
specific mechanisms (such as detergent effects) and have cytotoxic effects. As such, the key in whole-
cell-screening campaign is to identify the quality of ‘hits’ by certain counter screening assays (for 
example cytotoxicity across several cell lines, monitoring non-specific membrane leakage, analysing 
red-blood haemolysis), so as to account for good selectivity and specificity. 
The recent success with the whole-cell-screening approach is particularly exemplified by the 
identification of new TB drug candidates such as diarylquinolones (TMC207), which target ATP 
synthesis, and benzothiazinones (BTZ043), which targets cell wall arabinan synthesis (Andries et al., 
2005; Koul et al., 2007; Makarov et al., 2009). An interesting feature of both these molecules is that 
they target the membrane-associated proteins that may be more easily accessible to drugs from the 
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periplasmic space (that is the target binding sites are exposed to the periplasm) and this to some extent 
may overcome certain issues of mycobacterial membrane permeability(Andries et al., 2005).  
 
1.7.4 Nature as a source of medicinal compounds 
 
Over thousands of years, natural products have been used in attempts to treat and prevent human 
diseases. Natural product “medicines” originated from various source materials including terrestrial 
plants, terrestrial microorganisms, marine organisms, terrestrial vertebrates and invertebrates 
(Newman et al., 2000). The importance of natural products in modern medicine has been discussed in 
recent reviews and reports (Newman et al., 2000; Koehn and Carter, 2005; Paterson and Anderson, 
2005). The value of natural products in this regard can be assessed using 3 criteria: (1) the rate of 
introduction of new chemical entities of wide structural diversity, including those serving as templates 
for semisynthetic and total synthetic modification, (2) the number of diseases treated or prevented by 
these substances, and (3) their frequency of use in the treatment of disease. 
An analysis of the origins of the drugs developed between 1981 and 2002 showed that natural 
products or natural product-derived drugs comprised 28% of all new chemical entities (NCEs) 
launched onto the market (Newman et al., 2003). In addition, 24% of these NCEs were synthetic or 
natural mimic compounds, based on the study of pharmacophores related to natural product (Newman 
et al., 2000). This combined percentage (52% of all NCEs) suggests that natural products are 
important sources of new drugs and are also good lead compounds suitable for further modification 
during drug development. The large proportion of natural products in drug discovery has stemmed 
from the diverse structures and the intricate carbon skeletons of natural products. Since secondary 
metabolites from natural sources have been elaborated within the living systems, they are often 
perceived as showing more “drug-likeness and biological friendliness than totally synthetic 
molecules” (Koehn and Carter, 2005), making them good candidates for further drug development 
(Balunas and Kinghorn, 2005; Jones et al., 2006; Drahl et al., 2005). 
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Scrutiny of medical indication by source of compounds demonstrated that natural products and related 
drugs are used to treat 87% of all categorized human diseases (Scott et al., 2004; Keating and Figgitt, 
2003), including antibacterial, anticancer, anticoagulants, antiparasitic, and immune suppressant 
agents among others (Newman et al., 2003). There was no introduction of any natural product or 
related drug for 7 drug categories (anaesthetics, antianginal, antihistamine, anxiolytic, chelator and 
antidote, diuretic, and hypnotic) from 1982 to 2002 (Newman et al., 2003). In the case of antibacterial 
agents, natural products have made significant contributions as either direct treatments or templates 
for synthetic modification. Of the 90 drugs of that type that became commercially available in the 
United States or were approved worldwide from 1982 to 2002, 79% can be traced to a natural product 
origin (Newman et al., 2003).  
The number of natural product drug discovery programs has steadily declined since the 1980s, 
primarily because pharmaceutical companies have shifted to using synthetic libraries that are more 
amenable to high-throughput screening and simplified synthesis. Despite this, between 1981 and 
2002, approximately 50% of all new chemical entities approved by U.S. Food & Drug Administration 
(FDA) were natural products, natural products derivatives, or synthetic mimetic related to natural 
(Koehn and Carter, 2005). They were prescribed predominantly as anti-allergy/pulmonary/respiratory 
agents, analgesics, cardiovascular drugs and for infectious diseases. Another study found that natural 
products or related substances accounted for 40%, 24%, and 26%, respectively, of the top 35 
worldwide ethical drug sales from 2000, 2001, and 2002 (Butler, 2004). Current drug discovery from 
terrestrial plants depend mainly on bioactivity-guided isolation methods, which, for example, have led 
to discoveries of the important anticancer agents, paclitaxel from Taxus brevifolia and camptothecin 
from Camptotheca acuminate (Kinghorn, 1994). Other NCEs discovered or modified from terrestrial 
plants include: (1) Apomorphine hydrochloride, which is a potent dopamine receptor agonist used to 
treat Parkinson’s disease (Deleu et al., 2004); (2) Tiotropium bromide used for the treatment of 
bronchospasm in the United States (Koumis and Samuel, 2005); (3) Nitisinone: this drug has been 
used for the treatment of hereditary tyrosinaemia type 1(HT-1) (Mitchell et al., 2001); (4) 
Galantamine hydrobromide is used as a selective acetylcholinesterase inhibitor for Alzheimer’s 
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disease treatment (van Agtmael et al., 1999); (5) Arteether use as an antimalarial agent (van Agtmael 
et al., 1999).  
1.7.5 South African approach to the use of indigenous plant for drug 
development 
 
The idea for the development of African indigenous plants or plant compounds as medicines led to the 
formation of a consortium funded by the Government of South Africa and thus the National Drug 
Development Platform (NDDP) was established (http://www.sahealthinfo.org/noveldrug/partnership). 
The NDDP brings together a multi-disciplinary research and development team in a consortium which 
has the combined technical skills, research facilities and strategic capability required to develop novel 
drugs from medicinal plants. The platform further provides for the establishment of new agro-
processing businesses in rural communities for supply of plant material required for new drugs. The 
primary goal of NDDP was to evaluate the use of medicinal plants used by traditional healers and to 
develop drugs for neglected disease such as tuberculosis, malaria and diabetes at low cost for the 
benefit of the poor and needy people (Douwes et al., 2008). 
Due to continuing indications that the global pharmaceutical industry is suffering from declining 
productivity (fewer) new medicines are introduced despite increased spending on research ( Script 
reports, 2001: Natural Product Pharmaceuticals: A diverse approach to drug discovery). Yet there is 
an increasing need for innovation in selecting therapeutic agents and finding lead compounds. The 
vast majority of current drug discovery carried out by pharmaceutical industry relies on molecular 
approaches, involving defined molecular targets. Molecular approaches in turn are dominated by high 
throughput screening. Pharmaceutical companies with the best and most diverse chemical collections 
will ultimately dominate the industry (Strohl, 2000). Broadly speaking, chemical diverse collections 
can only come from two sources of large numbers of compounds: combinatorial chemistry and natural 
products (Taniguchi and Kubo, 1993). Although combinatorial chemistry can provide large numbers 
of compounds for high throughput screening such compounds tend to have limited structural 
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diversity. By contrast, natural products provide a wealth of small molecules with drug-like properties 
and with incredible structural diversity (Balick, 1990) 
The rationale of the scientific approach is based on the use of indigenous natural products and by 
indigenous people. To achieve the goals of the project is making use of collaboration with South 
African scientist as consortium in a coordinated plan. The consortium incorporates microbiology, 
chemistry, pharmacology, botany and traditional medicinal practices. As a member of the consortium 
my role as a microbiologist was to perfom biological assays in order to guide chrmist in synthesis of 
compounds and working with other divisions to provide a TB drug candate compound.   
                        
Mycobacterium tuberculosis                                                    Vernonia staehelinoides (blouteebossie) 
Figure 1.8 Pictures of opposing effects: how a persistent problem of TB disease (M. tuberculosis) can 
be solved by natural occurring plant (blouteebossie) product from which furanone (F1082) was 
original identified.  
As part of a national programme to identify and develop novel antibiotics (antimalarial and 
antituberculosis) agents from indigenous medicinal plants, bioassay-guided fractionation of the 
dichloromethane extract of the leaves of Vernonia staehelinoides (Figure 1.8) led to the isolation of 
two structurally-related hirsutinolides, displaying in vitro antiplasmodial activity. The compounds 
lacked selectivity (cytotoxicity vs. bioactivity) but the results led to the identification of mucochloric 
and mucobromic acids as privileged 2(5H)-furanone substructures (Pillay et al., 2007). Halogenated 
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furanones were first discovered to inhibit bacterial colonization of the red algae Delisea pulcra 
(Manefield et al., 2002) and have also been shown to act as biofilm inhibitor for several bacterial 
species in laboratory experiments (Hentzer et al., 2002; Rice et al., 2005; Lönn-Stensrud et al., 2007). 
‘Biofilms are defined as matrix-enclosed bacterial populations adherent to each other/or to surfaces or 
interfaces’ (Costerton et al., 1995). Furanones have been suggested to interfere with the quorum 
sensing system in Gram-negative bacteria (de Nys et al., 2006). The furanone ring system is a widely 
recognised component of natural products exhibiting a wide range of interesting biological activities 
such as antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, vasodilation and anti-
convulsant (Alam et al., 2010; Hashem et al., 2007). These furanones are the subject of study in this 
thesis for anti-M. tuberculosis activity.  
The synthesis of the three most active compounds is depicted (Figure 1.9). Mucobromic and 
mucochloric acids were transformed to the respective ethyl carbonates, exemplified by F952, by 
treatment with ethyl chloroformate in the presence of diisopropylethylamine at low temperature 
(Zhang et al., 2002; Gondela and Walczak, 2011). The carbonates were obtained in average yield of 
50%. Two sequential nucleophilic substitution reaction of the carbonate and β-halo (bromine) group 
by selected phenols and 4-aminoquinoline diamine, respectively, delivered the target compounds in 
moderate to high (un-optimized) yields (Scheme 1). 
O
O
XX
HO
Mucobromic acid (X= Br)
Mucochloric acid (X = Cl)
O
O
XX
O
O
EtOCl
O
EtO
OHR
O
O
XX
OR
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NCl
HN
NH2
F1052 (X = Br; R = H)
F1082 (X = Br; R = Ph)
i
ii
iii
 
Figure 1.9 Reagents and conditions: (i) 1.05 equiv. of ethyl chloroformate, CH2Cl2,  -10oC, 1.5 h, 49-
50%; (ii) 1.1 equiv phenol, 0.3-1.0 equiv CsF, CH2Cl2, 25oC, 72-80%; (iii) 1.5-2.0 equiv amine, N-
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methylpyrrolidine, 55-78%. Derivatives of the F1082 were synthesized based on the chemical 
structure of the compound by the Jenny-Lee Pandayan at CSRI, Pretoria as illustrated in Appendix AI. 
This thesis investigates the possible mechanism of action of a furanone based compound (F1082) and 
future development through synthesis of derivatives 
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Scientific rational 
 
The special feature of this project is that the compounds original from indigenous plants and is done 
by researchers in the developing word. The exploration of indigenous plants for medical value to 
solve complex problem of tuberculosis is a country’s worth. 
Hypothesis 
 
If F1082 inhibits the growth of M. tuberculosis, we therefore hypothesize that there is a mechanistic 
manner by which F1082 articulates its inhibitory activity. 
1.10 Aim of the study 
 
To evaluate a furanone based compound (F1082) and derivatives as potential candidates for 
antituberculosis drug development and to elucidate the mechanism by which F1082 exerts its 
antimycobacterial activity. 
1.10.1 Objectives 
 
I.	Activity	testing	
 
 To determine the minimal inhibitory concentration (MIC) of F1082 against M. tuberculosis. 
 To generate and carry out activity testing of F1082 and analogues against M. tuberculosis 
H37Rv, pan-susceptible, MDR and XDR clinical isolates of M. tuberculosis. 
 Evaluate whether F1082 is bactericidal or bacteriostatic in its effect. 
 To evaluate F1082 in combination with existing anti-TB drugs. 
 To evaluate F1082 cytotoxicity in human cell-line. 
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II.	Cellular	targets	of	F1082	
 
 Identification of M. tuberculosis genes and metabolic pathway/s affected by F1082 activity 
using microarray technique. 
 Confirmation of the microarray data by qPCR. 
III.	Detection	of	mutation	targets	
 
 Generate deletion mutants of target genes identified with microarray. 
 Determine the survival ability of the deletion phenotypes under F1082 treatment. 
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Figure 1.10 Schematic representation of the project outline with possibilities for further studies or 
development.  
The blue coloured segments indicate areas which have not been fully determine during the time by 
which this report was written. It must be indicated that although mutants were attempted to be created 
but due to inhibitory activity of the compound not able to kill bacteria no mutants were generated and 
hence sequencing was not performed. The need for resistant mutant to the compound is a grey areas 
that when discovered could provide greater understanding of the underlying mechanism of action of 
this compound. 
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CHAPTER TWO 
 
F1082 activity testing against M. tuberculosis by 
in vitro culture assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 42 
 
2.1 Introduction 
 
With the findings observed from this chapter, one may expect to be able to deduce whether there is 
any cross resistance of F1082 to the current TB-drugs. In clinically practice drugs that have the same 
mechanism of action are difficult to develop as there is a tendency that resistance to one drug may 
confer resistance to the other (Blaschitz et al., 2011). Clinical experience is that inadequate exposure 
to anti-TB drugs may result in the emergence of resistant mycobacteria (Zhao and Drlica, 2008). 
However the mechanism by which drug resistance is induced is not always known. The term 
‘phenotypic drug-resistance’ is used to indicate drug-tolerant mycobacteria that exhibit reduced 
susceptibility to anti-TB drugs without known genetic mutations. Phenotypic drug resistance might, 
for instance, due to increased efflux pump activity, porin loss, permeability decrease or drug-
modifying enzymes, resulting in reduced intracellular drug concentrations (Gumbo et al., 2007). 
‘Genotypic drug-resistance’ indicates resistance associated with known mutation in the genome of M. 
tuberculosis and relates to known levels of resistance.  Therefore drugs or compounds that have or 
show different mechanisms of action are more preferred for development. The techniques and assays 
utilised for this work involve the use of the BACTEC 460 system [which is being discontinued by the 
manufacturer (Becton and Dickison) in 2012]. 
A major obstacle in TB eradication is the ability of TB bacilli to transition to a non-replicating (latent) 
state in which metabolism is reduced to extremely low basal levels. This status is currently defined as 
dormancy or non-replicating persistence (NRP). Besides latent bacteria, a part of the bacterial 
population in patience with active tuberculosis also persists in a non-replicating state, and there is an 
obvious need for the eradication of this population. The maturing granuloma exposes the pathogen to 
harsh microenviroment characterised by limited nutrients, low oxygen and low pH, which does not 
support rapid growth but rather induces a state of dormancy in bacteria (Voskuil et al., 2003). There is 
evidence of both macrophage physiology and the nature of TB granuloma which suggest that hypoxia 
is the major factor for inducing NRP state of the tubercle bacilli. There is evidence that some very 
specific adaptation to oxygen depletion occur to make it possible for hypoxic NRP state to exist. 
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Current available anti-TB drugs are not particularly effective against a subpopulation of “persistent” 
bacilli (Wayne, 1994), however in nowadays there are compounds that are specific for NRP include 
(OPC67683, Kanamycin/amikacin, metronidazole, TMC207). It is therefore imperative to find drugs 
that can target this population. In this study, the Wayne model of persisters was also used to evaluate 
the F1082 activity against non-replicating persisters. 
All compounds have the capacity to be toxic depending upon dosage (Rozman and Doull, 2001). This 
realisation allowed for a significant advance in the field of early medicine. This observation also 
makes toxicity testing necessary and critical in practice to identify and define safety thresholds for all 
new chemotherapeutics. The advent of in vitro cytotoxicity testing has greatly streamlined this 
process and is now considered to be a necessary or important activity. In vitro cytotoxicity testing has 
become an integral aspect of drug discovery because it is a convenient, cost effective, and predictive 
means of characterising the toxic potential of new chemical entities. In this study, we used a viability 
assay (MTT) described later for toxicity testing.  
In this chapter, the aim is to: 1) determine the MIC of F1082 against M. tuberculosis H37Rv; 2) 
compare the activity of F1082 against clinical isolates [including multi-drug resistant (MDR)] clinical 
isolates of M. tuberculosis; 3) to evaluate the activity of F1082 with anti-TB drugs against non-
replicating persisters (NRP), generated by Wayne model; 4) to determine F1082 activity in 
combination with current anti-TB drugs and 5) to assess the cytotoxicity of F1082 in THP1 cell line. 
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2.2 Materials and Methods 
 
2.2.1 Minimal inhibitory concentration (MIC) determination of F1082 and 
derivatives 
 
Susceptibility of an M. tuberculosis reference strain, H37Rv and clinical isolates was done using the 
BACTEC 460 TB-system (Becton Dickinson, USA) as proposed by (Siddiqi et al., 1981). The 
methodology is easy to perform, rapid, robust and suitable for screening the number of compounds 
that were checked in this work. 
2.2.1.1 Bacterial strains and growth conditions 
 
M. tuberculosis H37Rv (ATCC 27294) was obtained from the American Type Culture Collection 
(Rockville, Md). Clinical isolates of M. tuberculosis were obtained from our in-house Divisional 
strain collection (Ang et al., 2008). All isolates were confirmed to be genotypically unrelated 
according to IS6110 genotyping. Isolates were identified as drug resistant by mutational analysis and 
genotyping testing (Ang et al., 2008). Stock cultures in 15% glycerol were prepared from log phase 
culture at an optical density (OD600nm) of 0.6 (2 x 108 CFU/ml) see section 2.3.2 (Figure 2.5). Cultures 
for experimental treatment were initiated by diluting a frozen stock inoculum 1:200 into fresh 
Middlebrook 7H9 supplemented with 10% oleic acid-albumin-dextrose- catalase, v/v (OADC; Difco  
Laboratories, Detroid); 0.05% Tween 80, v/v ( Sigma, St. Louis, Mo) in a vented, screw cap, tissue 
culture flask and cultured to log phase (OD600  0.6) at 37°C. The growth conditions for the non-
replicating persisters (NRP) are detailed in section 2.2.3 of this chapter. 
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Table 2.1 M. tuberculosis strains/isolates used for susceptibility and combinational testing 
Strain Description Mutant Functional use 
H37Rv M. tuberculosis laboratory 
strain (ATCC 27294) 
 Base-line 
susceptibility test 
R1129 M. tuberculosis clinical isolate 
resistant to INH 
katG 315 ACA (Ser 
315 Thr) 
Combinational 
effect 
R5182 M. tuberculosis clinical isolate 
resistant to RIF 
 
rpoB 531(TTG Ser 
531 Leu)]  
Combinational 
effect 
 
2.2.1.2 Antibiotics 
 
F1082 (Figure 2.1) and derivatives (Appendix A) thereof were provided by Dr Chris Parkinson, CSIR, 
Pretoria, South Africa. Isoniazid, rifampicin and ethambutol were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Stock solutions of isoniazid and ethambutol were prepared in distilled and 
deionised water at 10 mg/ml, sterilized by filtration (0.22 µm filter) and stored frozen at -80˚C. Stock 
solutions of rifampicin, at 10 mg/ml were prepared in 100% DMSO and stored at -80˚C. Stock 
solution of F1082 was prepared in dimethyl sulfoxide (100% DMSO) at 15mg/ml and stored at -80˚C. 
 
Figure 2.1 The chemical and crystal structure of F1082 
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2.2.1. 3 Minimum inhibitor concentration determination by BACTEC 460 System 
 
The growth of mycobacteria can be determined within one week by the extent of oxidation of [14C] 
palmitic acid (in a liquid Middlebrook 12B medium) to 14CO2 which is measured in the BACTEC 460 
instrument (Collins and Franzblau, 1997). Owing to the quantitative nature of the data, the relative 
activity of various samples can be compared by testing at only 1 or more concentrations and 
determining a percent inhibition of 14CO2 production relative to drug-free undiluted controls (Cantrell 
et al 1998). Alternatively, multiple concentrations can be tested and the MIC calculated (Cantrell et 
al., 2004).  
The BACTEC 460 system (Becton Dickinson) was used to determine the MIC for each individual 
compound and to study the combined effects of compounds (drugs) on M. tuberculosis survival in 
vitro (Siddiqi et al 1981). M. tuberculosis H37Rv or RIFR or INHR M. tuberculosis isolates were 
grown on 12B. The growth of the bacilli, expressed as the growth index (GI), was monitored daily by 
measuring the release of 14CO2 after the bacteria consumed 14C-labelled palmitic acid in the medium. 
Drug free controls, including the undiluted and the 1:100 diluted bacterial inocula, were included in 
each experiment to monitor bacterial growth. When the GI value of the 1:100 inoculum vial reached 
∆GI of 30 or greater the results were interpreted. Delta (∆) GI is defined as the difference in GI values 
between the latest and the previous reading. The MIC of a given drug was defined as the lowest 
concentration at which the GI of the drug vial was less or equal to the GI of the 1:100 control. The 
BACTEC drug susceptibility testing was completed within 5-8 days. 
2.2.2 Growth kinetics of M. tuberculosis (exposed to F1082) 
 
To monitor the optimal bacterial growth kinetics: log phase cultures of H37Rv were diluted 1:6 in 
OADC supplemented 7H9 growth medium and OD600 measured daily for 15 days. For colony forming 
unit (CFU) determination, tenfold serial diluted suspensions were plated on 7H11 agar daily. The 
bacterial growth by CFU and the OD600 was compared to determine optimal culture conditions for our 
experimental design. 
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For growth kinetics by CFU enumeration, M. tuberculosis H37Rvcultures at 1.3 x 106 CFU/ml were 
exposed to antimycobacterial agents. The concentration range for F1082 was 2 to 128 µg/ml and for 
INH 0.2-5 µg/ml, using two fold increasing concentrations. M. tuberculosis H37Rv cultures exposed 
to compounds (and solvents as controls) were incubated for 21 days at 37°C and CFUs were counted 
at day 1, 2, 5, 10 and 21 as described (Bakker-Woudenberg et al., 2005). A bacteriostatic effect is 
defined as the lowest concentration that inhibited visible growth at day 21. Bactericidal effect is 
defined as killing capacity of the agent expressed as the lowest concentration that resulted in ≥ 99% 
killing at day 1, 2, 5, 10 or 21.  
To determine the bactericidal or bacteriostatic effect of the drug/compound at different concentrations 
after 1, 2, 5, 10, and 21 days of exposure, the bacterial suspensions were centrifuged at 10 000 rpm on 
a bench top centrifuge for 4 minutes at room temperature, washed in 7H9 broth supplemented with 
OADC and centrifuged again. Samples were tenfold serially diluted and plated onto 7H11 agar 
supplemented with OADC. After 15 to 21 days of incubation at 37°C, CFU numbers were counted 
and the values were used to plot a dose response curve for each concentration (Figure 2.6 and Figure 
2.7). 
2.2.3 Non-replicating persisters (NRP) 
Popular working models suggest that unfavourable micro-environmental conditions inside the human 
lesion, such as oxygen and nutrient, are external triggers that terminate growth of subpopulations of 
tubercle bacilli and render them phynotypical resistant drug. Most antibiotics are more effective 
against replicating than nonreplicating bacteria (Hobby and Lenert, 195; Levin and Rozen, 2006). 
However, a major problem in TB treatment is to eradicate a persistent or nonreplicating subpopulation 
of bacteria (McCune et al., 1966; Muñoz-Elías et al., 2005). Indeed in vitro models using oxygen 
depletion in nutrient nutrient-rich medium (Wayne model) or nutrient starvation in oxygen-rich 
medium (Loebel model) have demonstrated the survival of M. tuberculosis for extended periods in a 
non-replicating and drug-tolerant state (Betts et al., 2002). Therefore since F1082 is a novel 
compound we want to evaluate its activity on NRP as this provides fundal information for any new 
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drug under development. For non-replicating persistence, M. tuberculosis H37Rv was used for all 
conditions. A volume of 20 ml single seeding of bacteria from stock cultures was grown in Dubos 
Tween-Albumin (DTA) broth, prepared according to the manufacturer’s instruction from Dubos broth 
base (Difco, Detroit, Mich), to an optical density of 580 nm (OD580) of 0.4. This corresponds to a cell 
density of about 2.5 x 108 CFU/ml. The stock was dispensed in small aliquots of 1 ml in 2 ml screw 
cap tubes and stored at -70°C. When a working culture was needed, a seed culture was thawed and 
100 µl was inoculated into 10 ml of DTA and incubated at 37° C with agitation until it reached an 
OD580 of 0.4 (2.5 x 108 CFU/ml) with shaking at 250 rpm. 
The 10 ml working culture was incubated at 37°C with shaking at 250 rpm. This shaking should 
produce a small vortex at the top surface of the medium, maximizing aeration. The screw caps were 
slightly loosened (about 1/8 to 1/4 turn) and held in place with a small strip of tape. Growth rate was 
monitored on a daily basis until it reached an OD580 of 0.4 and this culture was used as seed culture 
for non-replicating persistence experiments. In a number of experiments, Wayne and Hays (1996) 
have noted that the NRP stage 1 lasted until the A580 reached values between 0.4 and 0.45 before 
shifting into NRP 2 plateau. 
2.2.3.1 Limitation of Aeration for Shift down to NRP Stages 
For liquid cultures we used 20 x 125 mm screw-cap test tubes, with a total capacity of 25.5 ml. An 8 
mm long Teflon-coated magnetic stirring bar was placed in each of the tubes containing 17 ml DTA 
medium, leaving an air head space of 8.5 ml, corresponding to ratios of headspace air volume to 
liquid volume of 0.5. These proportions are hereafter referred to as headspace ratio (HSR). Each tube 
was inoculated with 170 µl of working culture from 2.2.3 (OD580 = 0.4) to yield a calculated initial 
optical absorbance (OD580) of 0.004. The tubes were closed tightly with a tightly fitting rubber 
vaccine cap. The rubber caps were used since reagents were to be injected into the tubes during the 
course of the experiment. Since the experiment was planned to last more than 21 days, the caps were 
sealed with Parafilm. The tubes were placed in plastic racks on the Biostire 4 magnetic stirrer 
(Wheaton, Millville, N.J.) at 120 rpm in a 37°C incubator. The OD580 was determined daily, taking 
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care not to agitate the tubes while transferring them to the spectrophotometer. Growth curves using 
the optical measurements were plotted on a logarithmic scale to permit clear definition of the two 
deflection points, i.e., from aerobic growth into microaerophilic NRP stage 1, and then into anaerobic 
NRP stage 2 (Wayne and Hayes, 1996) see (Figure 2.2). Aerobic growth occurs for approximately 60 
hours. After which the mycobacteria shift to the microaerophilic NRP-1 stage until oxygen is 
completely depleted. When the culture is about 160 hours old the mycobacteria shift down to 
anaerobic NRP-2 stage. 
 
Figure 2.2 In vitro model of hypoxically induced nonreplicating persister of M. tuberculosis. Arrows 
indicate the start of NRP-1 (microaerophilic) and NRP-2 (anaerobic) and the sampling points for 
markers assessment of each stage. (A) aerobic growth (B) hypoxic culture and NRP growth (from 
Mitchison, 2004).  
 
2.2.3.2 Initiation of Shift up and Synchronized Replication from the NRP State 
 
To permit bacilli in the NRP state to resume replication, it is necessary to reintroduce oxygen into the 
system. On recovery from the hypoxic condition, bacilli exhibit synchronized replication (Wayne and 
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Hayes, 1996). M. tuberculosis H37Rv under NRP state with drugs concentrations was allowed to 
replicate by allowing air in sealed tubes and was grown for 18 days (Figure 2.8).  
2.2.3.3 Determination of the Colony Forming Units (CFUs) 
 
Colony counting was performed as described above (section 2.2.2) with the following changes. In 
preparation for counting of colonies on agar, dilutions of liquid culture were made in DTA medium. 
Dubos oleic-albumin (DOA) agar was prepared from Dubos oleic agar base (Difco) supplemented 
with Dubos oleic albumin complex to final concentrations of 50 µg/ml of oleic acid and 5 mg/ml 
albumin and then dispensed in 3 ml amounts into each of the 12 wells of sterile Falcon no. 3043 tissue 
culture plates (Becton Dickinson, Lincohn Park, NJ). These agar plates were inoculated (in triplicate) 
with 20 µl of selected dilutions of test culture and the plates were incubated at 37°C. Colonies were 
counted twice weekly: the closed plates were inverted and colonies were counted under a dissecting 
microscope at a magnification of x10, using transmitted light. The readings were discontinued after 
the counts were stable for a week or all showed diminishing counts due to spreading and fusion of 
colonies.  
2.2.3.4 Non-replicating persisters (NRPs) assay 
 
The Wayne model (Wayne and Hayes, 1996), based on the well-established principle of culturing 
hypoxic persister cells under gradual oxygen depletion was used to evaluate whether F1082 affects 
the metabolic recovery of non-replicating persisters (NRPs) and its ability to kill hypoxic NRP cells. 
F1082 was tested in duplicate in low oxygen Wayne model system as described by (Lenaerts et al., 
2005a). Briefly, mid log cultures of M. tuberculosis H37Rv were diluted 100-fold in Dubos medium 
and grown at 37°C with low stirring for 24 days in tubes sealed with silicone rubber septa. After 24 
days (anaerobic conditions) drugs [F1082, isoniazid (INH), and rifampicin (RIF)] were injected 
through the septa of the 24-day-old cultures at final concentrations of 8 and 64 µg/ml for F1082 and 
10 and 50 µg/ml for INH and RIF and incubation continued for another 4 days. These concentrations 
have been previously used to evaluate several anti-TB drugs in this model and were adopted here for 
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direct comparison (Lenaerts et al., 2005b). Oxygen consumption was monitored in cultures containing 
methylene blue at 1.5 µg/ml. Reduction and decolourization of this dye served as a visual indication 
of oxygen depletion. Regrowth of bacteria from NRP state was achieved by re-aeration (exposure to 
oxygen) of the sample tubes. Fresh air was reintroduced into hypoxic cultures by loosening the caps 
for exit from dormancy. This exposure to air allowed dormant bacilli to regrow (2.2.3.2). Regrowth 
was monitored by measuring OD580 and the values were used to plot a re-growth curve for each drug 
concentration (Figure 2.8).  
2.2.4 Chequerboard synergy assay 
 
Any new candidate anti-TB drug should be tested in combination with other antibiotics to assess any 
antagonistic, additive or synergistic effects. How F1082, a new compound with unique attributes, 
interacts with existing first line anti-TB agents is important to understand, as this could allow the 
design  of efficacious therapeutic drug combinations and minimize undesired side effects in a new 
combination therapy. Using the chequerboard titration in which a series of dilutions of two antibiotics 
are studied for the effects on bacterial growth inhibition at all possible concentrations, both alone and 
in combination, the nature of the interaction between the two antibiotics can be determined 
algebraically (Holfer et al., 1987). The effects of drugs in combination were evaluated based on GI 
values using the technique that was described previously (Hoffner et al., 1987). To assess the effect of 
each drug and in combination, BACTEC 460 system (described in section 2.2.1.3) was used 
2.2.4.3 Data analysis 
 
The interaction between two antibiotics in combination can be described as synergistic, additive, no 
effect or antagonistic. Synergy is defined as x/y < 1/z, where x is the GI of the test vial with the 
combination of drugs, y is the lowest GI of the single drugs of the combination and z is the number of 
drugs combined. In order to translate the experimental data into the classification of drug-drug 
interactions, the quotient x/y (where x is the data obtained when two antibiotics are in combination 
and y is the data with the lower value of the two agents when tested separately at the same 
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concentration) can be used. If the x/y value is equal to 1, it is interpreted that one of the drugs in the 
combination is inactive. If x/y is less than 0.5 for a two drug combination, it implies that the two drugs 
when used together are more effective than when they are used separately, suggesting synergistic 
effects. If x/y values fall between 0.5 and 0.75, an additive effect may exist between the two drugs, 
suggesting a weak enhancement between them. If x/y values are greater than 2, it suggests 
antagonistic interaction between the two drugs. If the window between x/y is greater than 1 and less 
than 2 this may be interpreted as the transition area from no effect to antagonistic. By applying the 
simple algorithm as described by (Hoffner et al., 1987), we can evaluate the potential outcome of the 
two drugs in combination.  
2.2.5 Cytotoxicity 
 
THP-1 cells are human monocyte cells which originated from the peripheral blood of a male with 
acute monocytic leukemia (Tsuchiya et al., 1980). These monocytic cell lines can be differentiated in 
vitro to macrophage-like cells for toxicity experiments and a model that resembles TB infection in 
human macrophages (Sly et al., 2001). 
2.2.5.1 Growth of THP-1 cells 
 
A 1:10 dilution from frozen stock of THP-1 human macrophage cell line (ATCC TIB-202) was 
cultured in RPMI 1640 (Gibco-BRL) supplemented with 10% heat-inactivated foetal bovine serum 
(FBS) with penicillin-streptomycin (100 U/ml), complete medium (CM). The cells were then 
transferred into a 50 ml tissue culture flask (Nunc, Easy Flask 200 Filt. Nunclon #092974), and 
examined under the light microscope. The cells were further diluted by additional complete medium 
to achieve approximately 50% cell confluence and the cells were incubated at 37˚C in 5% CO2. The 
cells were inspected daily and when ˃ 90% confluence was achieved they were further diluted. 
Depending on the final amount of the cells required it would be 1:1 or a 1:10 dilution, the dilution 
ratio refers to the dilution of the cells in the new media for growth and colony expansion. 
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The cells were transferred to a 50 ml tube and centrifuged for 5 minutes at 1200 rpm in a bench-top 
centrifuge (Eppendorf 5810 R, Hamburg, Germany). About 10 to 15% of residual complete medium 
was used for subsequent growth of the cells as it contains secreted hormones and growth factors 
which stimulate cell proliferation and keep the cells at optimum growth rate. The rest of the complete 
medium was discarded and freshly made complete medium was added to the cells for the final volume 
required before diluting into tissue culture flasks.  
2.2.5.2 Preparation of THP1 cells for storage 
 
An 80% confluent culture of cells was pelleted by low speed centrifugation, (1000 rpm) in a bench-
top centrifuge (Eppendorf 5810 R, Hamburg, Germany) for 5 minutes, resuspended in FBS and 
cooled on ice for 5 minutes. A 20% v/v DMSO dilution was made in unsupplemented RPMI and 
cooled on ice for 5 minutes. The cells were frozen at a final concentration of 10% DMSO by 
combining the cell mixture and 20% DMSO solution in an equal volume. Aliquots of 1ml in 2ml 
Eppendorf tubes were wrapped in paper towel to allow cells to cool slowly in the -80°C freezer (to 
store cells for up to a month) or liquid nitrogen tank (for long term storage) 
2.2.5.3 Preparation of THP1 cells from frozen stock 
 
Frozen THP1 cell stocks were thawed at 37˚C as quickly as possible and diluted in approximately 10 
ml complete RPMI medium, to dilute the DMSO in which the cells were frozen. The cells were 
pelleted by low speed centrifugation (1000 rpm for 5 minutes) in a bench-top centrifuge (Eppendorf 
5810 R, Hamburg, Germany), and then resuspended in 10 ml complete RMPI medium and aliquoted 
into cell culture flasks to be incubated as described in section (2.6.1). 
2.2.5.4 Differentiation of the THP-1 cells 
 
The human monocyte cell line THP-1 was maintained in RPMI 1640 medium (Gibco-BRL) 
supplemented with 10% fetal bovine serum (FBS; Gibco-BRL) and 1 mM sodium pyruvate (Sigma). 
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In order to transform the cells into macrophages, the cells were subcultured four times without sodium 
pyruvate and then seeded into 6-well microplates (Costar Corning) at a concentration of 2 x 106 cells 
per well in complete RPMI 1640 supplemented with phorbol-12-myristate-13-acetate (PMA; 
Calbiochem Bioscience) at a concentration of 6.25 ng/ml. Cell cultures were washed twice with RPMI 
1640 every 48 hours for no longer than 4 days. Before starting the experiment, the number of cells 
was counted by haemocytometer. 
2.2.5.5 Colorimetric MTT (tetrazolium) assay 
 
The yellow dye 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) is reduced by 
mitochondrial dehydrogenase in living cells to produce insoluble purple MTT formazan crystals 
(Garn et al., 1994) which, after solubilisation, can be measured spectrophotometrically. This property 
has been used to assess the viability of cells. For the assay we used 5 x 105 cells/ml counted by 
haemocytometer. We used the 96-well plate for cytotoxicity testing as shown in Figure 2.3. Briefly, 
100 µl of cell suspension was added to rows A-G, subsequently another 100 µl of CM was added to 
rows A-G and 200 µl of CM to row H (serves as blank). The cells were incubated for 24 hours and 
were examined under the microscope to check that the cells settled. F1082 dilutions were done in CM 
to concentrations of (200; 20; 2; 0.2; 0.02; 0.002) µg/ml. The medium was then removed from all the 
wells, leaving a thin film of CM covering the cells. Row G serves as a positive control (no drug) and 
row H as blank (no cells), 200 µl of CM were added to row G and H. An aliquot of 100 µl of drug in 
triplicate was added, starting from row E, subsequently adding 100 µl of CM to wells containing 
F1082 concentrations, thus the final concentration range (0.001 to 100) µg/m. The plate was covered 
with a sterile lid and incubated for 48 hours at 37°C. To develop the plate, 25 µl of sterile MTT was 
added to each well and the plate was incubated for a further 4 hrs. The plate was shaken at 200 rpm in 
a microplate shaker (ORBIT P4, Bio Express) for 10 minutes. The medium was carefully aspirated 
from each well, 100 µl of DMSO was added to each well and the plate was shaken for 5 minutes on a 
microplate shaker to dissolve the formazan crystals. The absorbance at 540 nm was read immediately 
thereafter on an automatic microplate reader (Model 450. Bio-Rad Laboratories, Ltd., WatFord, 
Stellenbosch University  http://scholar.sun.ac.za
 55 
 
England). Inhibitory concentration (IC50) data were obtained from a dose-response curve plotted using 
Graphpad prism 5. Inhibitory concentration 50 (IC50 Human) was defined as the concentration of the 
compound required to reduce a 50% decrease of cell growth compared to control cultures. A 
selectivity index (SI), corresponding to the ratio between anti-tuberculosis and cytotoxic activities, 
was calculated according to the following formula: 
SIM. tuberculosis = IC50 Human/IC50 M. tuberculosis  
 
 
 
Figure 2.3 Ninety-six well micro plate to indicate the use of the plate for multiple purposes, showing the column 
and row positions (adapted from Martin et al., 2007) 
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2.3 Results and Discussion 
 
2.3.1 Determination of the minimal inhibitory concentration of F1082 against 
H37Rv and clinical isolates of M. tuberculosis. 
M. tuberculosis was grown in the BACTEC 460 system in the presence of various concentrations of 
F1082 (ranging from 2 to 8 µg/ml) and the GI was monitored on a daily basis (Figure 2.4). Three 
controls were used i.e.  (1) Neat (bacterial growth with no antibiotics), (2) 1:100 diluted bacterial 
culture (representing 99% bacterial inhibition) and (3) rifampicin at 2 µg/ml (RIF) representing a 
negative control. All concentrations of F1082 showed some degree of growth inhibition of M. 
tuberculosis when compared or the same to the neat; however the concentration of F1082 that was 
comparable to the 1:100 control was 8 µg/ml and was therefore considered as the MIC of the 
compound (MIC was defined as the lowest concentration of the compound that gave 99% growth 
inhibition). 
 
 
 
 
 
 
 
 
Figure 2.4 Inhibition of M. tuberculosis H37Rv growth with various concentrations of F1082  
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The activity of derivatives of F1082 (n = 42) were tested against M .tuberculosis in the BACTEC 460 
system. All the derivatives were tested at a baseline screen of 45 µM, which was three times the MIC 
of F1082 (8 µg/ml = 14.52 µM calculated from molecular weight of F1082). The basis for screening 
at that concentration was to select compounds that showed activity and not simply toxicity. 
Compounds that showed activity were used to determine an MIC and cytotoxicity data in the same 
way as for F1082. Promising compounds include JP 206, JP 210, JP 216, and JP 223 (Table 2.2) as 
they showed improved activity with less cytotoxicity when compared to F1082. These compounds 
warrant testing in MDR-MTB isolates and  in animal models furthermore their mechanisms of action 
remains to be determined. The list of all compounds tested with their activity and cytotoxicity data is 
shown in Appendix AII.   
Table 2.2 Activity of F1082 and derivatives against H37Rv, pan-susceptible, and MDR clinical 
isolates of M. tuberculosis and cytotoxicity data.  
ND-represent ‘not done’ as some of these compounds were under synthesis and we did not have 
enough at the time this work was reported.   
MIC (µM) Cytotoxicity 
(IC50,µM) 
 H37Rv INH, 
EMB RIF 
resistant 
INH 
mono-
resistant 
RIF mono-
resistant 
22 pan-
susceptible 
clinical 
isolates 
Chinese ovary 
Hamster cells 
F1082 14.52  14.52 14.52 14.52 14.52 ˂ 10 
JP206 2.8 ND ND ND ND 68 
JP210 11.25 ND ND ND ND ˃100 
JP216 5.6 ND ND ND ND 82 
JP223 5.6 ND ND ND ND 83 
 
The activity of F1082 against clinical isolates of M. tuberculosis including MDR was also tested in 
order to evaluate whether there is any comparable resistance or cross-resistance in line with the 
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current TB front-line drugs. All clinical isolates were tested using F1082 at a concentration of 8 
µg/ml. All clinical isolates showed susceptibility (more than 90 % inhibition) to F1082 equivalent to 
that of M. tuberculosis H37Rv (Table 2.3). These results suggest that F1082 has a different 
mechanism of action to the current anti-TB drugs and that there is unlikely to be any cross-resistance 
with the current TB front-line drugs. This is encouraging, because a new mechanism of action of a 
novel compound could provide new scaffolds or targets to which anti-TB drugs could be developed. 
However, the challenge is to determine the specific target or pathway which it inhibits.  
Table 2.3 Susceptibility testing of M. tuberculosis clinical isolates with F1082 (8 µg/ml) 
Drug susceptibility Number M. tuberculosis 
isolates 
Percentage inhibition (%) 
INH and RIF susceptible 20 >90 
INH, RIF and EMB susceptible 1 >90 
INH mono-resistant 2 >90 
RIF mono-resistant 1 >90 
INH and RIF resistant 1 >90 
INH, RIF and EMB resistant 1 >90 
 
2.3.2 Growth kinetics of M. tuberculosis H37Rv  
 
In order to design experiments and use bacteria that are in the same growth phase under similar 
conditions, we had to establish the relationship between optical density (OD600nm) and viable cell 
counts (by colony forming units, CFU). This enabled us to design experiments that are comparable 
and reproducible. A direct and proportional relationship between the CFU and the OD600nm was 
observed in log phase. However, in the stationary phase, the CFU continues to increase, levels off and 
then declines, whereas the OD600 levels off before the CFU (Figure 2.5).   For our experiments we 
chose to use bacteria that are at log phase (OD600 of 0.2-0.3 2 x 106 CFU/ml). At this phase, the 
bacteria are actively growing and are affected by compounds that target actively growing bacteria. 
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Figure 2.5 A correlation between the optical density (OD600) and the colony forming units (CFU/ml) 
of M. tuberculosis H37Rv in the absence of drug. 
 
For the time-kill assay, we monitored concentration-dependent and time dependent effects of anti-TB 
drugs. Isoniazid (INH) was used as a control at concentrations ranging from 0.2 to 5 µg/ml and F1082 
at concentrations ranging from 2 to 128 µg/ml over a period of 21 days. The M. tuberculosis H37Rv 
growth curves were plotted for INH (Figure 2.6) and F1082 (Figure 2.7). Exposure of log phase M. 
tuberculosis to INH resulted in a concentration and time dependent effect (Figure 2.6). A four-fold log 
reduction of bacteria was observed after 48 hours at 5 µg/ml (INH) showing a bactericidal effect of 
the drug. Substantial killing by INH was not observed when M. tuberculosis was in the late log phase 
of growth after 120 hrs. The rise in the CFU/ml in isoniazid treated group after 120 hours of drug 
exposure may be explained by the selection of isoniazid-resistant mutant given the relatively high 
starting concentration of > 106 organism which was chosen intentional for subsequent microarray 
experiments. This bacterial population exceeds the spontaneous isoniazid resistant mutation rate of M. 
tuberculosis in vitro (Karakousis et al., 2008). This is consistent with the literature that INH does not 
affect non-replicating M. tuberculosis (Bryk et al., 2008).   
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Figure 2.6 Time dependent dose response curve of M. tuberculosis H37Rv with INH 
 
When M. tuberculosis was grown in the presence of various concentrations of F1082, we observed a 
different scenario. There was no sharp reduction of bacterial load, but a transient reduction of CFUs 
of approximately two-fold between 4 and 24 hours, which was concentration dependent (Figure 2.7). 
After 24 hours, bacteria resumed growth at all concentrations of F1082. However we observed a 
subsequent growth suppression of bacteria by two-fold after 48 hours in a concentration dependent 
manner. This effect may indicate that F1082 may have more than one target by which it exerts its 
effect. Since we observe a transient reduction of two log units of viable bacteria at first, we concluded 
that F1082 has a bacteriostatic effect (Kaur et al., 2009). This suggests that F1082 inhibits the growth 
of M. tuberculosis rather than is bactericidal. However, high concentrations (128 µg/ml) as shown in 
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Figure 2.7 appear to exhibit further bacterial load reduction, suggestive of bactericidal effect at this 
concentration. 
 
 
Figure 2.7 Time dependent dose response curve of M. tuberculosis H37Rv with F1082 
  
2.3.3 Non-replicating persisters (NRPs) 
 
M. tuberculosis was grown under oxygen limitation to establish non-replicating persisters as described 
by the Wayne-type model (Lenaerts et al., 2005a) and was subsequently exposed to different 
compounds. The M. tuberculosis H37Rv cultures were revived from 28 days of oxygen limitation, 
exposed to oxygen by loosening the tightened sealed tube caps, shaken at 250 rpm and the OD580 
measured daily for 18 days. A growth response curve was plotted as shown in Figure 2.8 
The control cultures, including the DMSO control, grew with a long lag phase (about 5 days) as the 
cultures were adapting and changing from a non-replicating to a replicating state under sufficient 
oxygen (Figure  2.8). RIF exerted its bactericidal activity (at concentration of 10 and 50 µg/ml) by 
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killing the NRP and no re-growth was observed as was also observed by Hurdle et al., (2008). Since 
INH lacks the killing effect on non-replicating bacteria, re-growth of M. tuberculosis was observed 
even at 50 µg/ml of INH (Figure 2.8). F1082 also failed to kill non-replicating bacteria, since re-
growth was observed even at a concentration of 64 µg/ml, which is 8 x MIC. This is not uncommon 
with bacteriostatic compounds as they inhibit growth rather than killing bacteria (Kohanski et al., 
2007). These results were further confirmed with CFU counting and were consistent with RIF killing 
99.6% of the bacterial population at 10 µg/ml, INH killing 22% at 50 µg/ml and F1082 10% of the 
bacteria at 64 µg/ml.  
 
Figure 2.8 A re-growth dose response curve of M. tuberculosis H37Rv after 28 days of oxygen 
limitation.  
2.3.4 Testing for Synergy 
 
In this study, we investigated the interaction of F1082 in combination with other anti-TB drugs in 
vitro. The activity of F1082 in combination with rifampicin (RIF), isoniazid (INH) and ethambutol 
(EMB) was evaluated (in duplicate) against M. tuberculosis H37Rv and clinical RIF mono-resistant 
clinical isolate by a chequerboard titration method in the BACTEC 460 system, to assess whether 
F1082 may enhance the efficacy of existing TB drugs in a synergistic manner. Synergistic effect is 
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defined as when the activity of two drugs in combination is greater to the sum of their independent 
activity when studied together; additive effect as the activity of two drugs in combination is equal to 
the sum (or a partial sum) of their independent activity when studied separately; and antagonistic 
effect as the activity of the two drugs in combination is less to the sum (or partial sum) of their 
independent activity when studied separately. 
The MIC of a drug is defined as the lowest concentration that inhibits the growth of 99% of bacterial 
inocula, thus it is clear that synergistic, additive or antagonistic effects of combination drugs must be 
evaluated at individual drug concentrations that are less than the level of the MIC for effects to be 
observed. The concentration of each individual drug used, as well as the quotient values for 
combination of F1082 with isoniazid, ethambutol and rifampicin at drug concentrations below the 
MIC values (Table 2.4). The concentration of each of the drugs used in combination was expressed as 
a fraction of the MIC value. This table includes only the combinations at which synergy or additive 
effects were observed. F1082 at 0.5 x MIC showed synergy with rifampicin (0.2 µg/ml), an additive 
effect for both isoniazid (0.04 µg/ml) and ethambutol (0.4 µg/ml), when MIC fractions (Table 2.3) 
were used. No antagonistic effect was observed with any of the two-drug combinations tested in this 
study.  
Table 2.4 Synergy quotients for F1082 tested in two-drug combinations with isoniazid (INH), 
rifampicin (RIF) or ethambutol (EMB) against M. tuberculosis H37Rv. 
 
 MICs: INH, 0.05 µg/ml; RIF, 0.4 µg/ml; EMB, 1.6 µg/ml; F1082, 8 µg/ml. *0.04 µg/ml; **0.2 
µg/ml;***0.4 µg/ml.                                                                                                                                                            
a  Synergy was defined as x/y < 1/z, where x is the growth index (GI) of the test vial with combination 
Synergy quotients (x/y) in drug combinations (drug + 0.5 x MIC F1082) 
Drug INH* RIF** EMB***  
Dose 0.8 x MIC 0.5 x MIC 0.25 x MIC  
Interaction 0.65b 0.11a 0.75b  
     
Stellenbosch University  http://scholar.sun.ac.za
 64 
 
of drugs, y is the lowest GI of the single drugs of the combination and z is the number of drugs 
combined. For a two-drug combination, a quotient of < 0.5 was indicative of synergistic effect, a 
quotient of 1 indicated no interaction, a quotient of > 2 would show an antagonistic effect and a 
quotient of < 0.75 but > 0.5 indicated an additive effect. 
 bAdditive effect. < 0.75 but > 0.5 
2.3.4.1 Interaction of F1082 with rifampicin in M. tuberculosis H37Rv (RIF MIC of 
0.4 µg/ml). 
 
When F1082 was used with rifampicin, we observed marked synergy between the two drugs as 
indicated by the average quotient values (Table 2.5) in M. tuberculosis H37Rv. F1082 at 0.5 x MIC 
showed synergy with rifampicin at concentrations as low as 0.25 x MIC. Additive effect was observed 
when 0.25 x MIC F1082 was combined with 0.5 x MIC rifampicin. Interestingly, the combination 
with both drug combinations below 0.5 MIC (0.25 MIC F1082 + 0.25 x MIC rifampicin) showed no 
interaction so therefore there is no undesired antagonistic effect for these drugs at concentrations 
tested in this study..  
Table 2.5 Synergy quotients for F1082 tested in combination with rifampicin (RIF) against M. 
tuberculosis H37Rv 
MIC fraction F1082a MIC fraction RIFb Quotients (mean x/y ± 
SD)c 
Interaction 
interpretation 
 
0.5 
0.5 0.11 ± 0.098 synergy 
0.25 0.39 ± 0.268 synergy 
 
0.25 
0.5 0.63 ± 0.388 additive 
0.25 1.04 ± 0.086 No interaction 
 
aMIC of F1082 = 8 µg/ml 
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bThe average MIC of RIF from two experiments (0.4 µg/ml). The MIC fractions used in the table 
represent the concentrations used in combinations in respect to the MIC of that particular experiment.                         
cData obtained from two separate experiments. Please refer to the Table 2.3   footnotes for x/y 
quotient definition. 
2.3.4.2 F1082 and rifampicin interaction in M. tuberculosis rifampicin mono-resistant 
(RIFR) strain (RIF MIC > 100 µg/ml). 
 
To examine whether the synergistic interaction between F1082 and rifampicin also facilitated 
inhibition of growth of drug-resistant M. tuberculosis strains, we evaluated drug interaction with RIFR 
M. tuberculosis clinical isolates. The rifampicin MIC for RIFR M. tuberculosis was more than 100 
µg/ml, much higher than the average MIC for drug susceptible M. tuberculosis H37Rv (0.4 µg/ml). 
The RIFR phenotype did not affect the MIC of F1082 for this strain: MIC was 8 µg/ml, the same value 
as that determined for rifampicin-susceptible (RIFS) M. tuberculosis H37Rv. The RIFR results [Figure 
2.9 (a)] show that bacteria grew with minimum growth inhibition of 36 % in the presence of 100 
µg/ml of rifampicin compared to DMSO control. Adding 0.25 x MIC (2 µg/ml) of F1082 to this 
culture inhibited (47 %) growth. The scaling down of RIF concentration to 0.25 x MIC (2 µg/ml) 
F1082 gave 98 % inhibition even at 6.25 µg/ml [Figure 2.9 (a)]. The x/y quotients for rifampicin at 
100, 50 and 25 µg/ml were (0.95, 0.74 and 0.68), respectively, indicating no effect and additive effect. 
Synergistic effects were observed at 12.5 and 6.25 µg/ml rifampicin (x/y = 0.12 and 0.21, 
respectively) between F1082 and rifampicin (Table 2.5). 
Table 2.6 F1082 tested in combination with rifampicin (RIF) againat RIF monoresistant isolate 
RIF-monoresistant isolate RIF (µg/ml) 
F1082 (2 µg/ml) 100 50 25 12.5 6.25 
Interaction 0.95 0.74 0.68 .012 0.21 
Iterpretation No effect additive additive synergy synergy 
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However, 0.5 x MIC of ethambutol did not show any additive or synergistic activity with rifampicin 
on strain RIFR [Figure 2.9 (b)]. This could be interpreted that EMB invariable with RIF, however no 
antagonistic activity was observed at the concentrations tested. In both cases (RIFS and RIFR 
combination with F1082), the concentrations to MIC ratio at which the synergy between F1082 and 
rifampicin was observed, was similar to those obtained for the RIFR strain, implying that the 
synergistic interaction was independent of drug susceptibility status. These results strongly suggest 
that the synergy between F1082 and rifampicin was specific for the combination of drugs and that the 
enhanced drug interactions inhibited M. tuberculosis growth in both RIFS and RIFR strains.  
The synergy observed between F1082 and RIF has a possible explanation: RIF is an efficient inducer 
of cytochrome P450 (CYP) (Bolt, 2004). The CYP is a superfamily of haem-containing enzymes 
involved in a wide array of NADPH/NADH-dependent reactions, in addition they play pivotal roles in 
biosynthesis of compounds such as sterols, steroids and fatty acids, as well as detoxification of 
xenobiotics and chemicals (Kelly et al., 2003). Rifampicin is a potent inducer of a variety of CYP in 
human hepatocytes, as well as in peripheral blood lymphocytes (Haas et al., 2005; Rae et al., 2001). 
The complete genome of M. tuberculosis reveals at least 20 CYP, but precise functions for these 
genes and enzymes remain to be elucidated (McLean et al., 2006). Like their mammalian 
counterparts, the mycobacterial CYP were induced by rifampicin but not by isoniazid treatment 
(Ramachandran and Gurumurthy, 2002). Therefore, the haem-containing enzyme of CYP may 
interact with F1082 and produce a more active metabolite of F1082. It is also possible that the 
expression levels of the currently unknown primary target/s of F1082 is/are tightly regulated at 
transcriptional level. Since rifampicin is an inhibitor of DNA transcription could be synergising with 
F1082. However these speculations could be clarified once the target/s of F1082 has /have been 
identified. 
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(a)  
 
(b)  
 
Figure 2.9 Growth profile of RIFR M. tuberculosis treated with rifampicin (RIF) in combination with 
(a) F1082 and with (b) ethambutol EMB  
 The experiment was carried out in BACTEC 460 as described in Materials and Methods (section 
2.2.1.2).  GI readings were obtained daily until the 1:100 inoculum control vial reached a ∆GI value 
>30 at day 7. The MIC of RIF and F1082 in the RIFR strain were > 100 µg/ml and 8 µg/ml, 
respectively..  
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2.3.5 Cytotoxicity 
 
In order to determine the specificity of F1082 activity, it was considered necessary to obtain the 
general cytotoxicity on human cell line (THP1). THP-1 cells were chosen because they differentiate 
into phagocytes (Tsuchiya et al., 1982), which are predominant cells in the chronic inflammatory 
response. For this, the antiproliferative activity of F1082 was evaluated on human monocytic THP1 
cells using the microculture tetrazolium (MTT) assay. This method is based on the ability of viable 
cells to convert the tetrazolium salt (MTT) to colored formazan (Ali-Vehmas et al., 1991; Yajko et 
al., 1995). The IC50 for F1082 was estimated to be 1 µg/ml (Figure 2.10). This is the concentration 
that kills 50% of the THP-1 cells. 
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Figure 2.10 Cytotoxic effect of F1082 on the THP-1 cell line. 
The selective index (SI) of F1082 was calculated as a quotient of the IC50 value of the THP-1 over the 
IC50 of M. tuberculosis and was found to be 0.25 (Table 2.7). For TB drug development an SI of ≥ 10 
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is considered significant by the TB-Alliance. This indicates that F1082 is more damaging to THP1 
cells than M. tuberculosis. Clearly this is not a good indicator, as a compound should be at least 10 
fold more active against M. tuberculosis than against a mammalian cell line.  
The complex chemical structure of F1082 is depicted and possible degradation components that may 
be attributed to the observed cytotoxicity (Figure 2.11). The observed cytotoxicity could be attributed 
to a number of reasons. Firstly the lactone is hydrolytically labile under both acidic and basic 
conditions (Figure 2.11). Any opening of the lactone would result in hemiacetal formation and rapid 
release of the phenolic component. This would result in an aldehyde becoming available. Aldehydes 
are powerful cross-linking groups for proteins, reacting with free amino groups (lysines, thiols etc.). 
This could result in a loss of protein function resulting in toxicity. Secondly, the NH groups may be 
metabolically labile and may result in either toxic metabolites. Lastly the bromide may generate stable 
radicals. In published data, furanones  (chlorohydroxyfuranones) induce genetic alterations in 
numerous biological systems in vitro, causing chromosomal aberrations in rodents (Harrington-Brock 
et al., 1995) and DNA damage (Brunborg et al., 1991). Therefore suggesting that F1082 may also be 
cytotoxic to human cell line. 
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Figure 2.11 Depicts the structure of F1082 and possible degradation components 
In order for F1082 to be used or developed into an anti-TB candidate drug, the cytotoxic effect has to 
be reduced but the antibiotic activity maintained. Derivatives are being synthesised by removal of the 
bromine group in the 2(5H) furanone, since this may contribute to cytotoxicity. Re-structuring of 
precursor molecules could perhaps provide us with a furanone based or similar compound with less 
cytotoxicity.  
Table 2.7 In vitro antituberculosis activity, cytotoxicity and selective index (SI) values for F1082 
Compound M. tuberculosis IC50 
(µg/ml) 
THP1 IC50 (µg/ml) SIa 
F1082 4 1 0.25 
 
aSI, cytotoxicity THPI IC50/M. tuberculosis IC50 
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In conclusion, F1082 has shown some potential as a compound that can be developed into an anti TB 
candidate drug. Although it has a higher MIC (8 µg/ml) than compared to current anti-TB drugs, it 
also must be taken into account that in combination with current anti-TB drugs (RIF) there is 
synergism of potency. F1082 was shown to synergize with rifampicin. Another important 
characteristic about F1082 is that it is active against MDR strains of M. tuberculosis, suggesting a 
different mechanism of action with the current anti-TB drugs. This suggests that F1082 has a greater 
chance of being used with the current anti-TB drugs in combating MDR and perhaps XDR-TB strains 
of M. tuberculosis. Unfortunately, F1082 shows high toxicity against a human cell-line. The cytotoxic 
characteristic of the compound might be overcome by synthesis of derivatives that are less cytotoxic. 
The use of F1082 as a candidate can provide new anti-mycobacterial targets and its scaffold can be 
used to try to synthesise improved compounds with higher potency activity and less cytotoxicity. In 
the next chapter we investigate the manner by which F1082 inhibits the growth of M. tuberculosis 
using gene expression profiling. 
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Appendix A 
 
I. First Generation Compounds based on F1082 
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First Generation Compounds based on F1082 
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First Generation Compounds based on F1082 
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First Generation Compounds based on F1082 
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First Generation Compounds based on F1082 
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First Generation Controls First  
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First Generation Controls First  
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II. Activity and cytotoxicity results of F1082 derivative 
 
Compound 
Code 
Percentage Inhibition 
M. tuberculosis H37Rv 
In vitro Cytotoxicity 
(CHO line) 
45 uM 22.5 uM 11.25 uM 5.625 uM IC50 Value 
JP-001 0 %    52.9 uM 
JP-002 0 %    88.4 uM 
JP-003 0 %    84.1 uM 
JP-004 68.9%    91.4 uM 
JP-005 0 %    38.8 uM 
JP-008 0 %    45.4 uM 
JP-009 61.2 %    > 100 uM 
JP-010 2.2 %    54.0 uM 
JP-011 5.5 %    76.0 uM 
JP-022 0 %    > 100 uM 
JP-023 9.9 %    > 100 uM 
JP-025 32.6 %    > 100 uM 
JP-043 9.9 %    64.5 uM 
JP-044 33.1 %    87.1 uM 
JP-046 25.9 %    88.9 uM 
JP-047 5.6 %    22.2 uM 
JP-048 17.3 %    86.5 uM 
JP-050 0 %    89.6 uM 
JP-051 92.4 %    30.85 uM 
JP-053 53.1 %    > 100 uM 
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Compound 
Code 
Percentage 
Inhibition 
M. 
tuberculosis 
H37Rv 
In vitro 
Cytotoxicity
(CHO line) 
Compound 
Code 
Percentage 
Inhibition 
M. 
tuberculosis 
H37Rv
In vitro Cytotoxicity 
(CHO line) 
JP-065 46.8 %    > 100 uM 
JP-067 36.9 %    > 100 uM 
JP-085 0 %    51.5 uM 
JP-091 3.3 %    79.5 uM 
JP-097 0 %    > 100 uM 
JP-098 0 %    83.6 uM 
JP-103 1.6 %    85.5 uM 
JP-115 26.7 %    63.6 uM 
JP-127 31.6 %    > 100 uM 
JP-133 48.4 %    54.7 uM 
JP-134 36.5 %    51.9 uM 
JP-193 68.9 %    45.5 uM 
JP-194 98.5 % 99 % 98 % 82 % 13.5 uM 
JP-195 93.8 %    > 100 uM 
JP-196 30.9 %    > 100 uM 
JP-197 64.1 %    29.8 uM 
JP-198 43.6 %    82.5 uM 
JP-200 58.5 %    42.3 uM 
JP-201 47.4 %    25.4 uM 
JP-203 98.4 % 98 % 91 % 70 % 23.5 uM 
JP-204 83.1 %    45.1 uM 
JP-205 97.7 % 71 % 55 % 39 % 22.1 uM 
*JP-206 95.7% 99 % 99 % 97 % 68.6 uM 
JP-207 96.5 % 89 % 50 % 45 % 10.7 uM 
JP-208 98.1% 82 % 49 % 32 % 42.1 uM 
JP-209 38.7 %    11.6 uM 
*JP-210 78.4 %    > 100 uM 
JP-211 99.6 % 99 % 93 % 52 % 9.53 ± 0.10 ug/mL 
JP-212 0 %    14.5 uM 
JP-213 0 %    48.3 uM 
JP-214 0 %    18.9 uM 
JP-215 0 %    > 100 uM 
*JP-216 98.1 % 98.1 % 98.1 %  82.8 uM 
JP-217 0 %    47.9 uM 
JP-218 0 %    40.3 uM 
JP-219 4.3 %    > 100 uM 
JP-220 0.7 %    44.8 uM 
JP-221 0 %    36.1 uM 
JP-222 8.5 %    32.1 uM 
*JP-223 99.7 % 99.7 % 99.7 % 99.0 % 83.4 uM 
JP-224 29.7 %    36.9 uM 
JP-C001 35.8 %    > 100 uM 
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Compound 
Code 
Percentage 
Inhibition 
M. 
tuberculosis 
H37Rv 
In vitro 
Cytotoxicity
(CHO line) 
Compound 
Code 
Percentage 
Inhibition 
M. 
tuberculosis 
H37Rv
In vitro Cytotoxicity 
(CHO line) 
JP-C003 1.0 %    > 100 uM 
JP-C004 3.4 %    > 100 uM 
JP-C005 0.2 %    92.9 uM 
JP-C006 1.5 %    > 100 uM 
JP-C007 0 %    > 100 uM 
JP-C008 0 %    > 100 uM 
JP-C009 12.9 %    > 100 uM 
JP-C010 12.2 %    60.2 uM 
JP-C011 0 %    > 100 uM 
JP-C013 24.2 %    > 100 uM 
JP-C015 43.9 %    14.6 uM 
JP-C016 35.3 %    > 100 uM 
JP-C017 10.8 %    > 100 uM 
JP-C018 17.7 %    > 100 uM 
JP-C019 60.9 %    > 100 uM 
JP-C020 16.7 %    > 100 uM 
JP-C021 11.7 %    > 100 uM 
JP-C022 0 %    > 100 uM 
JP-C023 0 %    > 100 uM 
JP-C024 0 %    > 100 uM 
F-1082 99.7 % 100 % 99 % 82 % 1.82 ug/mL 
DMSO 0 % 0 % 0 %   
Emetine     0.12 ± 0.07 ug/mL or 0.042 
ug/mL 
 
All compounds were tested for activity against M. tuberculosis H37Rv and for cytotoxicity against 
CHO cell line. Compounds that showed more than 90% activity at 45 µM and had greater cytotoxicity 
data (IC50 >50 µM) warranted MIC determination and * indicates compounds that were considered to 
be promising. 
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CHAPTER THREE 
 
M. tuberculosis microarray gene profiling by 
F1082 
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3.1 Introduction 
 
The sequencing of the complete genome of M. tuberculosis (Cole et al., 1998b) has provided an 
invaluable resource for TB research and has facilitated functional genomics studies such as 
transcriptomics and proteomics that enable investigation of the biology of M. tuberculosis at a whole 
genome level (Betts, 2002). The use of DNA microarray is one such approach and has many potential  
applications within the drug discovery process, from target identification and validation through hit 
generation and lead optimization (Barry et al., 2000).  
Target selection may be critical for the development of new drugs, but understanding the dynamics of 
the metabolic response to interruption of target function may also be important. An organism responds 
to changes in its environment by altering the level of expression of critical genes that transduce such 
signals into metabolic changes favouring continued growth and survival (Boshoff et al., 2004). 
Analysis of the transcriptional response by microarray can provide clues to such adaptive responses 
(Agarwal et al., 2003; Betts et al., 2003 and Wilson et al., 1999). Co-ordinately regulated sets of 
genes (regulons) are often controlled by single transcriptional regulators that function as a genetic 
master switches, committing the bacterium to a major alteration in metabolism (Boshoff et al., 2004). 
Induced genes could be predicted to either compensate for inhibition of the target pathway or respond 
to the toxic effect of the drug and lead to the proposal that RNA response profiles could serve as a 
fingerprint of a given drug’s mode of action (Wilson et al., 1999). In this study, we applied genome 
wide expression profiling in order to search for the mode of action of F1082. 
For the design and full run of the study conducted, a pilot study was performed with regard to F1082 
as to establish concentrations to be used. At initial we planned to start the experiment at with F1082 at 
subinhibitory concentration (4, 8 and 64 µg/ml). The rational was based on the fact that we identify 
gene xpression levels at low concentration i.e. half MIC, and 8 times the MIC. In our preliminary 
results we only saw 5 genes that were differentially regulated at this concentration. These include 
Rv3161, Rv3160, Rv3159, Rv1813c and Rv3839. Based on the fact that these genes are regulated in 
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the same way as by 8 µg/ml and also due to the expensive nature of microarray we decided to do two 
concentrations (8 and 64 µgml). The following methodologies describe how this study was performed 
and carried out to reach to our conclusions. 
3.2 Materials and Methods 
 
3.2.1 Bacterial strains and growth conditions 
 
M. tuberculosis H37Rv  (frozen stock, 2 x 108 CFU/ml) 1:10 dilution was initially inoculated into five 
25 cm2 tissue culture flasks containing 10 ml of Middlebrook 7H9 media supplemented with (OADC) 
and were cultured at 37 °C for 5 days. Each culture was transferred into 75 cm2 tissue culture flasks 
containing 50 ml of 7H9 media (1:6), incubated at 37°C and shaken continuously on an orbital shaker 
until the OD600 reached 0.3, which corresponded to 1.3-1.99 x106 CFUs (Chapter 2, Figure 2.5).  
Each culture of M. tuberculosis H37Rv from the same flask was split into 2 volumes (20 ml) in two 
75 cm2 tissue flasks. Each 20 ml received F1082 at 8 µg/ml and an equal amount of the DMSO 
solvent in which F1082 was dissolved. Similarly, flasks were set up for F1082 at 64 µg/ml and INH at 
5 µg/ml, however, INH was dissolved in water. The final percentage DMSO used for all 
concentrations was less than 1% (0.64%) and these served as reference controls for each time point 
per concentration see (Table 3.2). The concentrations used for F1082 were chosen based on the MIC 
of 8 µg/ml and a pilot study that showed that this was the lowest concentration that gave reasonable 
chnges in gene expression. The highest concentration (64 µg/ml) was used to assess the overall effect 
of the drug. Isoniazid was used as a control drug at 5 µg/ml and 5 hours of incubation (Fu and 
Shinnick, 2007).  Cultures were incubated for 4 or 24 hours for F1082, also based on a pilot study, 
and the fact that M. tuberculosis generation time ranges from 24 to 36 hours (Fontán et al., 2008).   
Bacterial cultures (20 ml) were harvested by centrifugation at (5000 rpm for 5 minutes) in a bench-top 
centrifuge (Eppendorf 5810 R, Hamburg, Germany) at room temperature (25°C). After removing the 
supernatant, pellets were immediately frozen on dry ice and stored at -80°C until RNA extraction. 
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3.2.2 RNA isolation 
 
The frozen bacterial pellets were resuspended in 2 ml TRIZOL (Invitrogen) and mixed well by 
pipetting. The mix was transferred as 1 ml aliquots into 2 ml tubes containing 0.5 ml of Zirconia 
beads (0.1mm in diameter). The cells were lysed using a bead beater (MP Biosciences) set at 6.5 W 
for 30 seconds and thereafter cooled on ice for another 30 seconds. Each cycle was repeated three 
times. The samples were centrifuged at 14000 rpm for 15 minutes at 4°C in a bench-top centrifuge 
and the aqueous phase was removed from the beads. A volume of 300 µl of chloroform were added to 
each sample, the sample was gently mixed by inverting for 10-15 seconds and thereafter centrifuged 
at 14000 rpm at 4°C for 15 minutes in a bench-top centrifuge. The clear top-layer (approximately 600 
µl) was transferred into new tubes (1.5 ml) with rubber O-ring caps. Nucleic acids were precipitated 
by addition of 0.6 % v/v (approximately 360 µl) of absolute ethanol (ice cold, -20°C). The RNA was 
isolated using the MACHEREY-NAGEL kit (GmbH & Co.KG, Germany) as instructed. 
Briefly, for each sample, one NucleoSpin RNAII column was placed in a 2 ml centrifuge tube. All 
centrifugation steps were carried out in a bench top centrifuge. The lysate (precipitated nucleic acids) 
was pipetted up and down 2-3 times, loaded onto the column and then centrifuged for 30 seconds at 
11 000 rpm. The column was placed in a new collecting tube. To desalt the silica membrane, 350 µl 
of membrane desalting buffer (MBD) was added and the column was centrifuged for 1 minute at 
11 000 rpm to dry the membrane. 
DNA digest was performed by preparation of DNase reaction mixture in a sterile micro-centrifuge 
tube: DNase reaction mixture was prepared by mixing 10 µl of reconstituted (r) DNase in 90 µl of 
reaction buffer for rDNase in a sterile 1.5 ml centrifuge tube for each isolation. The tube was mixed 
by flicking and 95 µl of DNase mixture was applied directly on the centre of the silica membrane of 
the column and incubated at room temperature for 15 minutes. The silica was washed and dried in 
three steps: (1) two hundred microliters of RA2 buffer was added to the NucleoSpin RNAII column, 
centrifuged for 30 seconds at 11 000 rpm and the column was placed in a new collecting tube (RA2 
buffer inactivates the rDNase). (2) Six hundred microliters of RA2 buffer was added to the 
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NucleoSpin II column, centrifuged for 30 seconds at 11 000rpm, discarded the flow-through and 
placed back into the collecting tube. (3) two hundred and fifty microliters of RA3 buffer was added to 
the column, centrifuged for two minutes at 11 000 rpm to dry the membrane completely. The column 
was added into a nuclease-free 1.5 microcentrifuge tube. Pure RNA was eluted in 60 µl water (RNase-
free), by column centrifugation at 11 000rpm for 1 minute. 
The purity of RNA was estimated by the ratio of the readings at 260 and 280 nm (A260/A280) using 
Nanodrop. Agarose gel electrophoresis was used to assess the integrity of and relative proprtion of 
mRNA with ribosomal RNA using Nanodrop. The agarose gel electrophoresis revealed prominent 
23S and 16S ribosomal bands, indicating that the RNA was not degraded. Extracted mRNA in water 
was stored at -80°C until use. All RNA samples were sent and furher checked through quality and 
quantity test before microarray byCenter for Applied Genomics. 
3.2.3 Microarray Processing 
 
Microarray processing was perfomed by the Center for Applied Genomics, Public Health Research 
Institute, UMDNJ-New Jersey Medical School (Newark, NJ, USA) on receival of 3 ng/ml of samples 
and experimental design. In principle, microarray analysis was perfomed as follows with minor 
changes and is indicated in Institutes public website (refer 
<http://www.cag.icph.org/downloads_page.htm>). M. tuberculosis oligoarrays were printed at the 
Center for Applied Genomics, Public Health Research Institute, UMDNJ-New Jersey Medical School 
(Newark, NJ, USA). These microarrays consisted of 4295 70-mer oligonucleotides representing 3924 
open reading frames (ORFs) from M. tuberculosis strain H37Rv and 371 unique ORFs from M. 
tuberculosis strain CDC 1551 that are not present in H37Rv.  The arrays were prepared by spotting 
oligonucleotides (Tuberculosis Genome set version 1.0, Operon Biotechnologies) onto poly-L-lysine 
coated glass microscope slides using an Omnigrid 100 Arrayer and SMP3 pins. 
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3.2.3.1 cDNA synthesis and labelling 
 
Total RNA (3 µg each) was reverse transcribed into cDNA using Superscript II in the presence of 
Cyanine-3 (Cy-3) or Cyanine-5 (Cy-5) dUTP by a modification of a published procedure (Voskuil et. 
al, 2003).  The RNA was incubated with a reaction mix containing a final concentration of 0.17µg/µl 
random hexamers, 0.96x first strand buffer, 9.6 mM DTT, 0.44 mM dATP, dCTP and dGTP, 0.02 
mM dTTP, 0.06mM Cy-3 or Cy-5 dUTP and 9.4 units Superscript II for ten minutes at 25°C followed 
by ninety minutes at 42°C.  The labelled cDNA probes were then purified and concentrated to 5 µl 
using a Microcon YM10 filter and TE buffer pH 8.0.  
3.2.3.2 Hybridization 
 
Prior to hybridization, slides were blocked by submersion in a solution of 3% BSA and 0.1% SDS for 
1 hour in a glass chamber placed in a 42°C water bath. After blocking, the slides were washed with 
water for 2 minutes, followed by washing in 100% isopropanol for 2 minutes, and dried by 
centrifugation at 500 x g for 3 minutes.  The purified cDNA probes were mixed with 10 µl 
hybridization solution containing a final concentration of 0.5 µg/µl tRNA, 2.0X SSC, 0.25% 
Formamide and 0.1% SDS and applied to the array.  The probes were covered by a flat 22 x 22 mm 
coverslip and hybridized in sealed hybridization chambers for sixteen hours in a 50°C water bath.  
After hybridization, the coverslips were removed from the slides by submerging into a solution of 2X 
SSC/0.1% SDS. The slides were washed with vigorous agitation for 1 minute in a solution of 1X 
SSC/0.05% SDS, following by 2 minutes in a solution of 0.06X SSC, and dried by centrifugation at 
500 x g for 1 minute. The complete protocol can be found in (APPENDIX 3A). For each pair of RNA 
samples, dye flips were performed as follows: (1) the test RNA was labelled with Cy3 and the control 
RNA with Cy5, or (2) the test RNA was labelled with Cy5 and the control RNA with Cy3, and the 
results were compared.   
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3.2.4 Microarray Analysis 
 
The slides were scanned using an Axon 4000A scanner at 532 nm (for Cy3) and 635 nm (for Cy5) 
with a 10 micron resolution. Images were processed using GenePix Pro 5.1 software (Molecular 
Devices Corporation, Union City, CA). Data were filtered by removing all spots that were below the 
background noise or flagged as ‘bad’.  Spots were considered to be above the background noise if the 
median intensity of at least one of the channels was greater than twice the median local background 
for the spot.   The chips were normalized by the print-tip Lowess method (Dudoit and Speed, 2000).  
The ratio of the average median intensity of Cy5 over the average median intensity of Cy3 was 
determined for each spot and the fold relative change values were calculated.   
The experimental design was perfomed as as follows: The concentration and the time points were 
chosen based on our own pilot studies and by overviewing of the published data on microarray 
studies. To ensure that the primary effects of the compound were captured we used the MIC (8 µg/ml) 
and 8 times the MIC (64 µg/ml) as our high dose for global effect (Table 3.1). RNA isolated from 
solvent treated cultures at each time point was pooled and used as the reference to which each sample 
from a corresponding time point was compared by co-hybridization. In order to test reproducibility 
within slides and dye-bias, each sample was split twice, labelled in separate reactions with Cy3 and 
Cy5 and hybridised to a single array. In simple terms, RNA samples from F1082 treated and RNA 
from DMSO counterparts were split into two. RNA from the F1082 treated sample labelled with Cy3 
was co-hybridised with RNA from DMSO treated sample labelled with Cy5 and then dyes were 
flipped with F1082 treated sample labelled with Cy5 and DMSO treated sample labelled with Cy3 
(Figure 3.1). Three biological replicates from separate experiments were used for this study. Figure 
3.1 shows the organisation and labelling of our samples for this study. 
Triplicate cultures were treated with either 1 x or 8 x MIC of F1082, and RNA was isolated from 
these as well as from the solvent-treated control samples after 4 or 24 hours of incubation. RNA 
isolated from multiple solvent-treated cultures at each time point was pooled and used as the reference 
to which each sample from a corresponding time point was compared by cohybridization. Each 
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triplicate sample was hybridized twice, with the flours (dyes) reversed for the second batch of 
hybridizations. The whole genome was printed twice on each slide, hence giving a total of twelve 
measurements per gene for each treatment. Genes were considered differentially expressed if there 
was a fold change of at least 1.5 fold up or down.  A one-class Significance Analysis of Microarrays 
(SAM) analysis (Tusher et al., 2001) was performed with the MEV 4.3 software (Saeed et al., 2003) 
to find genes with changes that occurred consistently in all replicates.  A median FDR (false discovery 
rate) of zero, and a mean change of at least 1.5 fold were considered the cut-off values for 
significance. Genes with value changes in response to compound treatment (n-fold) of more or less 
than 1.5 times those in the solvent-treated control were retained as compound-induced or compound-
suppressed changes, respectively 
 
Table 3.1 Experimental design for microarray analysis 
 
Time of treatment 
Samples per concentration 
F1082 (8 µg/m)l F1082 (64 µg/ml) INH (5 µg/ml) 
 
4 hrs 
DMSO control DMSO control DMSO control 
5 hrs     Test sample Test sample Test sample 
 
24 hrs 
DMSO control DMSO control 
Test sample Test sample 
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Figure 3.1 RNA sample organisation and labelling for microarray analysis and dye flip for each 
experiment. INH experiment was performed in the same way and can be represented by one time 
point and one concentration of F1082 as depicted in the above figure.  
 
3.2.5 Microarray validation by relative quantification of mRNA by real-time PCR 
 
1. cDNA conversion:  
Each cDNA pool was prepared following the protocol for SuperScriptTM III First-Strand synthesis 
SuperMix for qRT-PCR (InvitrogenTM). Briefly a reaction mixture (20 µl) included 1 µg RNA, 2X RT 
Reaction Mix, RT Enzyme Mix and DEPC-treated water. Each reaction mix was gently mixed and 
incubated at 25°C for 10 minutes for primer to anneal then at 50°C for 30 minutes for cDNA 
synthesis. The reaction was terminated by heating to 85°C for 5 minutes then chilled on ice. Addition 
of 1 µl (2U) of E. coli RNase H and incubation at 37°C was performed immediately to remove RNA 
template from the cDNA. The cDNA was diluted to 10% in DEPC-treated water and stored at -20°C 
until use. 
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2. Candidate gene selection and primer design: 
A set (n = 11) of genome-directed primers designed to prime all ORFs of interest in the M. 
tuberculosis genome was used for reverse transcription (Table 3.2). These genes were chosen based 
on the fact that they were highly upregulated and random selection of genes that were differentialy 
regulated to validate the microarray data. Forward and reverse primers for real-time PCR 
amplification were designed with Primer Express Software (Primer 3 version 0.4.0). Real-time PCR 
was performed on eleven genes, namely (Rv3159c, Rv3160c, Rv0676c, Rv2358, Rv2190c, Rv0652, 
Rv2246, Rv3804c, Rv1094, Rv0724, and Rv1592c) (Table 3.1).  
Table 3.2 List of RT-PCR and PCR oligonucleotide primers used to amplify genes selected for 
microarray validation. 
Name Primer sequence  
(5’ to 3’) 
Length of 
the primer 
Tm [°C] G+C (%) Product 
length 
Rv3159c f 
Rv3159c r 
gaaaccgaggctttggaaac 
gaggttattgtcgccgttgt 
20 
20 
60.97 
60 
50 
50 
 
173 
Rv3160c f 
Rv3160c r 
ccggccatctacaaacactt 
atggaaaccagcacataggg 
20 
20 
59.99 
59.81 
50 
50 
 
191 
Rv3161c f 
Rv3161c r 
gacacgttgacctgccaata 
gatccacaccaatccattcc 
20 
20 
59.57 
59.99 
50 
50 
 
153 
Rv0676c f  
Rv0676c r 
gacacgttgacctgccaata 
gatccacaccaatccattcc 
20 
20 
59.99 
59.79 
50 
45 
 
207 
Rv2358 f 
Rv2358 r 
agccagaaactgaccgagaa 
gtcgaaatccgcaatatggt 
19 
20 
61.67 
59.83 
63.16 
50 
 
237 
Rv2190c f 
Rv2190c r 
gtttctttgcgagcttcacc 
cgagcttttcgttgagatcc 
20 
20 
60 
59 
50 
50 
 
162 
Rv0652 f 
Rv0652 r 
caaggaaatgaccctgttgg 
gatcacgtcgaactcggact 
20 
20 
60.34 
60.27 
50 
55 
 
160 
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Name Primer sequence  
(5’ to 3’) 
Length of 
the primer 
Tm [°C] G+C (%) Product 
length 
Rv2246 f 
Rv2246 r 
gaccgtgcagaagtacatgc 
gttgttggtggacatcacga 
20 
20 
59.32 
60.43 
55 
50 
 
244 
Rv3804c f 
Rv3804c r 
agcttgttgacagggttcgt 
cactttggaattggaccttga 
20 
21 
59.77 
59.96 
50 
42.86 
 
210 
Rv1094 f 
Rv1094 r 
ccgagaagtacacgcaggtc 
gtaacgaggttggcgaagaa 
20 
20 
60.85 
60.25 
60 
50 
 
175 
Rv0724 f 
Rv0724 r 
ggaggcggacttgttctaca 
cgaccccggataactgacta 
20 
20 
60.25 
59.95 
55 
55 
 
232 
Rv1592c f 
Rv1592c r 
gagtacgcaccggacctaga 
taccgttgtcatctccgtca 
20 
20 
60.28 
60.11 
60 
50 
 
225 
16S rRNA f 
16S rRNA r 
ggactgagatacggcccagact 
cgcgacaaaccacctacga 
20 
22 
60 
65 
60 
60 
 
271 
 
3. RT-qPCR design and analysis 
Relative quantitative PCR was performed in MxPro4000 Multiplex quantitative PCR System 
(Stratagene, Santa Clara, CA) using SYBR® GreenERTM qPCR SuperMix Universal (InvitrogenTM) 
following the manufacturer’s instructions. All PCR reactions were carried out in duplicate with the 
following PCR conditions: 10 minutes at 95° followed by 40 cycles of 30 seconds at 95°C for 
denaturation, and 30 s annealing at 55°C, and 30 seconds extension at 72°C. Each cDNA preparation 
included a primer for 16S rRNA and ROX (contained in SYBR green mix as an internal reference 
dye) internal controls. Levels of the target RNAs were normalized for 16S rRNA in the same sample 
and evaluated as [Target mRNA]/[16S rRNA] by the instrument.  
The fluorescence emission was detected for each PCR cycle and the threshold cycle (CT) values were 
determined. The CT value was defined as the actual amplification cycle when the fluorescence signal 
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increased above the background threshold. Average CT values from duplicate PCR reactions were 
normalized to average CT values for 16S rRNA from the same cDNA preparations. The ratio of 
expression of each gene in F1082 treated vs. vehicle (DMSO only) treated sample was calculated as  
2-(∆∆CT) of that treatment where CT is the threshold cycle and ∆∆CT is the difference CT [(test gene) − 
CT (house keeping gene)], for treated sample minus vehicle sample. Assays were carried out in 
triplicate from three different experiments. 
For statistitical significancy; all values were presents as mean ± standard deviation or mean standard 
error of means of three independent samples with multiple samples. Comparisons between 
experimental conditions were analysed by the Student’s t-test. Differences were considered 
statistically significant when P ≤ 0.05.  
3.3 Results and Discussion 
3.3.1 M. tuberculosis gene signature profile from exposure to isoniazid (INH). 
 
INH was initially used as model compound to validate the microarray technology as the genes 
associated with this compound mechanism of action is already known (Boshoff et al., 2004). The 
result shown in Table 3.3 is mainly based on the presence or absence of the characteristic gene-
expression signature of FAS-II inhibition, rather than based on individually differentially regulated 
genes observed in the experiments. The most highly induced genes in response to INH were members 
of the kas operon (Rv2243-Rv2247). Isoniazid has been previously been shown to upregulate this 
operon, which contains five FAS-II components including kasA and kasB (Slayden et al., 2000; 
Vilchèze et al., 2000; Betts et al., 2003b; Fu and Shinnick, 2007). Amongst the induced seven genes, 
four genes belong to a functional class category of lipid metabolism, one to cell wall and cell 
processes and the other two remaining fall into conserved hypothertical. The fact that most genes 
induced belong to lipid metabolism and cell wall processes indicate that INH affects the pathway of 
the cell wall biosynthesis. Different laboratories have used different conditions depending on their 
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primary need but all came to produce the gene signature profile of INH. Our microarray data under 
the conditions we used confirmed these findings and showed that the kas operon is induced even by 5 
µg/ml INH treatment (Table 3.3). At this stage we gained confidence that our micro array data is 
reliable by reproducing what is in literature. From this onwards we decided to persue our main 
objectives with F1082 and INH was no further used in microarray studies. Therefore test experiments 
with F1082 under conditions outlined in materials and methods (Figure 3.1) were performed. 
Table 3.3 M. tuberculosis genes regulated by INH treatment at 5 µg/ml 
Gene ID Gene name Fold change  
 
Description Functional 
category(ies) 
Rv0411c glnH 2.2 Probable glutamine binding protein Cell wall and cell 
processes 
Rv3413c Rv3413 3.1 Hypothetical protein Conserved 
hypotheticals 
Rv1592c sucC 3.1 Probable succinyl-CoA synthase Conserved 
hypotheticals 
Rv2246 kasB 2.8 β-ketoacyl synthase Lipid metabolism 
Rv2245 kasA 2.8 β-ketoacyl synthase Lipid metabolism 
Rv2244 acpM 2.9 Acyl carrier protein Lipid metabolism 
Rv2247 accD6 2.1 Acetyl-CoA carboxylase Lipid metabolism 
Rv1886c fbpB -3.1 Secreted antigen 85-B Lipid metabolism 
Rv1094 desA -1.7  Possible acyl-[ACP] desaturase Lipid metabolism 
 
3.3.2 M. tuberculosis gene signature profile from exposure to F1082  
 
In order to determine the mode of action of new or novel compounds, it is necessary to identify the 
genes that are regulated by the compound prior to a generalized response. Hence we used the lowest 
concentration (8 µg/m, F1082) at the earliest time point (4 hours) to determine the specific gene 
signature profile of F1082. Twenty four (24) hour time point, was also used since M. tuberculosis 
replicates within 24-36 hours (Fu and Shannick, 2007). It is not only the gene signature profile that is 
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important in order to understand the mechanism of action, but also the general response that is of 
importance. For this reason we included a concentration that was 8 times MIC (64 µg/ml) over 4 and 
24 hours of treatment. 
The total number of genes significantly regulated at each concentration and time point and the 
overlapping of these gene sets is displayed (Figure 3.2). Numbers within the sectors indicate the total 
number of genes regulated uniquely or in common by either 1 x or 8 x MIC treatment of F1082 at 
either 4 or 24 hours (P < 0.05). A cut-off of a minimum of 1.5 fold change was used and SAM 
statistical software was used to establish statistical significance. The Venn diagrams (Figure 3.2) 
indicate that many genes are uniquely regulated by one concentration and that there are time scale 
dependencies. There were 26 genes by 8 µg/ml for both time points, 179 genes by 64 µg/ml at 4 hours 
and 193 genes by 64 µg/ml that were uniquelly differentially regulated. Genes that were commonly 
regulated by 8 µg/ml and 64 µg/ml at 4 hours were only 10. There is a greater overlap of genes 
regulated by F1082 at 8 and 64 µg/ml (24 genes).  Genes common to all concentrations and time 
points are only 77 and can be used as global gene expression Most of the genes regulated by 8 µg/ml 
are a subset of those regulated by 64 µg/ml at both time points (Table 3.4). This could suggest that 
these genes are a primary response to F1082 treatment, before a more general response ensued.  
 
Figure 3.2 Representation of the significant differentially expressed genes, unique to, and common in 
Mtb H37Rv after 4 and 24 hours exposure at 8 and 64 µg/ml F1082  
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The twenty four genes regulated by F1082 and presumed to form part of the gene signature profile for 
F1082 fell into several categories (Table 3.4). One group encodes proteins that are annotated to be 
directly involved in either iron acquisition (mbtB, mbtC, mbtD, mbtE, mbtH, and mbtI), also called the 
mbt cluster, composed of 10 genes, and iron storage genes (bfrB). All the genes involved in iron 
acquisition were regulated by the lower concentration (8 µg/ml) only, at both time points (4 and 24 
hours) but only the late time point (24 hours) at the highest concentration (64 µg/ml). This could 
suggest that we see F1082 primary effect at a delayed time point as F1082 has inhibitory activity not 
necessarily killing the bacteria. When M. tuberculosis is faced with low iron conditions, it up-
regulates the mbt cluster for siderophore biosynthesis and down regulates the iron storage genes (bfrA 
and bfrB) (Quadri et al., 1998). From our data we noted that the mbt cluster was up-regulated by more 
than two fold whereas the iron storage genes (bfrB) were down-regulated by more than one 1.5 fold. 
This could mean that M. tuberculosis “senses” low iron conditions under F1082 treatment.  
The second group of genes encoded (annotated) proteins are involved in detoxification. Molecules 
with aromatic characteristics in general have been reported to be potent inducers of monooxygenases, 
dioxygenases, certain methylases, efflux systems, and the associated carboxylic acid degradation gene 
(Boshoff et al., 2004). Since F1082 is an aromatic compound, this result is consistent in that there was 
high induction of genes involved in drug detoxification and efflux mechanisms (Rv3160c- Rv3161c, 
upregulated by more than 20 fold). We considered that induction of these genes could be a non-
specific effect of F1082. The other group of genes involved included conserved hypothetical proteins 
and members of the PE/PPE family proteins with no known specific function. The last group involve 
up-regulation of the sigma (σ) factors (SigB and SigE). In M. tuberculosis, the response to cell 
envelope damage is regulated by σE and the response to oxidative stress and heat shock is regulated by 
σH, and σB is a component of both regulons (Manganelli et al., 2002). We speculated that F1082 could 
be interfering with iron acquisition either by being an iron chelator or directly affecting genes 
regulating iron acquisition; alternatively, it could be that F1082 exerts its effect by generation of 
oxidative stress. 
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The genes that are marked yellow are commonly regulated as in M. tuberculosis and are involved in 
acquisition and storage of iron and may be part of gene signature profile of F1082. 
 
Table 3.4 A list of 24 M. tuberculosis genes whose regulation is affected by 8 µg/ml and 64 µg/ml of F1082. These 
genes were classified into different functional categories according to TubercuList 
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Mining the transcriptome data in the context of functional categories yielded particularly interesting 
results when applied to genes whose expression was repressed in M. tuberculosis following F1082 
treatment (Figure 3.3). The expression of more than an anticipated number of genes belonging to the 
Intermediary metabolism and respiration, Information pathways and Lipid metabolism categories 
were repressed after 24 hours post inoculation. These results indicate that in response to F1082 
treatment, a significant reduction of the expression of genes belonging to many key biosynthetic 
pathways is observed. These results indicate that F1082 treatment causes a later/ secondary effect in 
the expression of specific such as transcriptional regulators that mediate the pathogen’s response to 
cell membrane damage, coupled with a silencing in expensive energetic processes such as lipid-
metabolism, and DNA, RNA and protein synthesis. One such transcriptional factor is σB, which has 
been shown to protect M. tuberculosis against membrane damaging stress (Fontán et al., 2009) and 
whose expression was induced in response to F1082 (64 µg/ml) after 24 hours of post inoculation. 
 
Figure 3.3 Distribution of the common 77 M. tuberculosis genes, where expression changes are 
between 4 and 24 hours at 64 µg/ml to F1082 exposure, into functional categories. 
Genes differentially regulated common to 8 and 64 µg/ml were distributed in functional categories 
according to TubercuList (http://genolist.pasteur.fr/TubercuList/). 
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3.3.2.1 M. tuberculosis genes whose expression was affected by high concentration of 
F1082 (64 µg/ml) 
 
When we investigated the global gene expression change induced by F1082 at a high concentration 
(64 µg/ml), we observed that almost all the genes that were differentially regulated at 8 µg/ml were a 
subset of genes altered by a high concentration (64 µg/ml). This clearly showed that as the 
concentration of F1082 increases, more genes were affected in terms of expression but the genes that 
were affected by low concentration consistently were also affected at high concentration (Figure 3.2). 
This suggests that the gene signature profile of the compound or mode of action is still the same. For 
the microarray data analysis, two paradigms were used to analyze the data, one having been to look at 
the genes that were differentially regulated between the control and the treated and the other one was 
to look at genes that are coordinately regulated. When we used the initial paradigm, genes that were 
down regulated at high concentration were all involved in information pathways. These genes are all 
involved in ribosomal protein synthesis (Table 3.5) and this suggests that F1082 inhibits the growth of 
M. tuberculosis somehow by interference with transcription and translation therefore cell replication 
is interrupted. 
Stellenbosch University  http://scholar.sun.ac.za
 99 
 
Table 3.5 M. tuberculosis genes from Information pathways suppressed by F1082 (64 µg/ml).  
 
3.3.3 Validation by RT-qPCR 
 
We validated by quantitative RT-PCR, the DNA array data for selected M. tuberculosis genes that 
were found to be differentially expressed by F1082. The RNA used was the same as was used in 
microarray analysis. RT-qPCR confirmed that these were induced, to a level 2 to 10 times above 
control and genes that were down-regulated were similarly suppressed (Figure 3.4). The expression 
values of the genes from microarray  in Table 3.6 were compared with expression values from 
quantitative RT-qPCR (B). The expression of each gene in every condition has been normalised to the 
expression of the reference gene 16S rRNA. Induction is expressed as ± standard deviation (error 
bars) of the ratios from three biological replicates. The induction levels as measured by RT-qPCR 
were generally higher than those observed using DNA microarray, probably due to greater sensitivity 
and dynamic range achievable using quantitative PCR technique rather than two-color 
microarrays.This was most apparent with genes Rv3159 to Rv3161, for which induction levels 
measured using RT-qPCR were up to 30 times higher than those observed using microarray. 
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Figure 3.4 Validation of M. tuberculosis genes expression by quantitative RT-PC. Fold induction is 
expressed as means ± standard deviations (error bars) of the ratios from three biological replicates. 
 
Summary 
 
We used microarray to examine the effect of F1082 on M. tuberculosis growth. This has provided a 
gene signature expression profile of INH and F1082 from which the pathways involved in their 
activities can be drawn. As have been mentioned from our results that we were able to reproduce the 
gene signature profile of IHN, the FAS II operon induction. In conclusion, although F1082 has 
affected quite a number of genes including upregulation of the efflux pump for detoxification of 
Table 3.6 M. tuberculosis genes selected from microarray data for qPCR validation 
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antibiotics, it appears that the iron acquisition pathway has been greatly affected by the low 
concentration (8µg/ml) and high concentration (64 µg/ml). The induction of efflux detoxication genes 
such Rv3159-3161did not attrct much of our attention as these genes are upregulated by most 
aromatic compounds. Our interest was more into genes that are coordinately regulated, the mbt cluster 
of the genes and other genes that are involved in iron macquisition and storage.This prompted us to 
look at the role of iron in M. tuberculosis and iron acquisition and regulation as controlled by the 
IdeR. It has been postulated that the up-regulation of the siderophore biosynthetic genes in activated 
macrophages is not only by low intracellular iron condition but also by inactivation of IdeR 
(Schnappinger et al., 2003). In the next chapter we investigate the putative role of F1082 in 
upregulation of the iron acquisition genes and possible mechanism of action of this compound. 
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Appendix 3A 
Probe Preparation/Hybridization Using TB RNA and Random Primers 
 
Synthesis and Labeling of cDNA 
 
Bring 1.5µg of RNA to a volume of 11µl (in a PCR tube) with nucleotide-free water and add 2.2µl 
(2mg/ml) random primers (pulse centrifugation to collect contents). 
Heat for 2 minutes at 98oC, snap cool on ice. 
(Keep on ice) and add 11.1µl of the following reaction mix: 
 5.0µl 5X First-Strand buffer   
2.5µl 100 mM DTT      
2.3µl low dTdNTP mix (5mM A,G,C and 0.2 mM T stock)  
1.5ul Cy3 or Cy5 
 Then add 1.2ul Superscript, vortex to mix and spin to collect contents 
Incubate 10 min at 25oC followed by 90 min at 42oC in PCR machine.   
**Can freeze or leave at 4oC overnight if necessary 
Prime a microcon10 column (YM10 from Millipore) with 400µl TE and centrifuge for 10 min at 
10,000 x g.  Empty flow-through in collection tube and return primed column.  Add both reactions 
(cy3 and cy5) to column and centrifuge at 10,000 x g until ~25µl remaining (~20-30 min).  Wash with 
200µl TE and spin until almost dry (<5µl). 
Recover cDNA by inverting microcon into new collection 1.5 ml tube and centrifuge at half max 
speed 1 min. 
Bring sample to 5µl with TE. 
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Prehybridization 
 
1.  Prepare Pre-hybridization Solution (Fresh Each Time) 
**this volume is based on a glass dish with a base measurement of 11x8cm.  This dish allows for a 
pre-hybridization of 1-4 slides.  Adjust volume accordingly based on size of dish and/or number of 
slides. 
 106.0ml dH2O 
 3.0g BSA  
 1.2ml 10%SDS 
Add Prehybridization solution to a glass slide-staining dish and place post-processed slides array side 
up into solution.  Make sure there are no bubbles on the surfaces of the slides. 
Place the staining jar containing the Prehybridization solution and slides into a water bath and 
hybridize for 1 hour at 42oC. 
Take the prehybridized slides out of the Prehybridization solution and place into a slide holder 
submerged in a slide-washing tray containing nuclease-free water.   Wash slides for 2 minutes with 
constant shaking up and down. 
Transfer slide rack to a slide washing tray containing isopropanol and wash for 2 minutes with 
constant shaking up and down. 
Take the slides in the isopropanol bath to the centrifuge to keep the slides wet until you can dry them 
rapidly.  Centrifuge at 600 rpm in a 50 ml conical flask for 3 minutes to dry.  
**Complete this step within one hour of hybridization 
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Hybridization 
 
Add the following to the 5µl labeled cDNAsample. 
0.5µl 10 mg/ml tRNA 
1.0µl 20X SSC 
2.5ul Formamide 
1.0µl 1% SDS  
Heat to 98 oC for 2 minutes. Spin in centrifuge for 1 min at 12,000 Xg.  Let cool for 5 min. 
Pipette cooled 10µl hybridization solution on microarray.  Apply 22 x 22 coverslip to cover array (if 
bubbles appear under the cover slip, they will slowly migrate to the edges provided that the volume is 
accurate).  
Optional:  Apply thin wall of rubber cement around the 4 corners of the coverslip to avoid movement.  
This step is recommended if water bath is not perfectly level. 
Hybridize in standard hybridization chambers with ~40 µl water under each slide (20 ul under both 
ends of each slide) overnight in 50oC water bath 
**Bubbles (especially large ones) can be troublesome for arrays since they can cause areas of non-
hybridization.  To avoid bubbles, do not use the blowout feature of the pipette when adding the probe 
to the slide.  Also, clean your coverslips with alcohol and lint-free wipes before placing over probe. 
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IV. Post Hybridization washes (next day) 
Remove cover slip while array is submerged in first wash solution (2XSSC + 0.1% SDS), transfer to 
submerged microscope slide staining racks and rinse for 1 min in 1X SSC+0.05% SDS with 
agitation/shaking.  
Rinse in 0.06X SSC with shaking. Transfer to another submerged staining rack and wash 2 min in 
fresh 0.06X SSC with gentle shaking. 
Centrifuge 3 min at 1000 rpm in a 50 ml conical flask (array edge up) to dry.  Scan immediately. 
V. Reagents 
  
Name Stock Concentration Source Catalog # 
Random Hexamers 2.0ug/ul IDT Custom oligos 
5X First-Strand Buffer From Kit Invitrogen Superscript Kit:  
18064-014 
0.1M DTT From Kit Invitrogen Superscript Kit:  
18064-014 
Superscript II RT From Kit Invitrogen Superscript Kit:  
18064-014 
Low dTdNTP mix 
5mM A,G,C and 0.2mM T 
100mM (each) Invitrogen 10297-018 
Cyanine 3-dUTP 25nmol/25ul Perkinelmer NEL578 
Cyanine 5-dUTP 25nmol/25ul Perkinelmer NEL579 
Milipore YM10 Microcon 
centrifugal columns 
 Fisher 42406 
TE  TE pH8.0 Ambion 9849 
BSA BSA Fraction V, heat 
shock 50g  
Roche 100360 
SDS 10% Ambion 9822 
Isopropanol 99+% Sigma I-9516 
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Name Stock Concentration Source Catalog # 
tRNA  Invitrogen 15401011 
20X SSC  Ambion 9763 
Formamide 
 
 Sigma F-9037 
Corning coverslips (22x22)  Fisher 12-524B 
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Appendix 3B 
A list of all M. tuberculosis genes expressed under F1082 treatment  
1. M. tuberculosis gene regulated by 8 µg/ml for both time points (4 & 24 hours) of post inoculation. Significance Analysis of microarray was used for each 
concentration and time point each performed in triplicate. Av: average; FC: fold change; STDEV: Standard deviation. 
 ID Gene 
name 
Function Category Av/FC STDEV 
1 Rv2020c esxS ESAT-6 LIKE PROTEIN Cell wall and cell processes 2.093953 0.179233 
2 Rv3402c Rv3402c CONSERVED HYPOTHETICAL PROTEIN Cell wall and cell processes 2.012823 0.521572 
3 Rv0431 Rv0431 PUTATIVE TUBERCULIN RELATED PROTEIN Cell wall and cell processes -0.86101 0.927315 
4 Rv3524 Rv3524 PUTATIVE CONSERVED MEMBRANE PROTEIN Cell wall and cell processes -1.48663 1.212765 
5 Rv3839 Rv3839 CONSERVED HYPOTHETICAL PROTEIN Conserved hypotheticals 2.518153 0.924702 
6 Rv1057 Rv1057 CONSERVED HYPOTHETICAL PROTEIN Conserved hypotheticals 1.425914 1.858394 
7 Rv1813c Rv1813c CONSERVED HYPOTHETICAL PROTEIN Conserved hypotheticals -1.95528 2.792233 
8 Rv2710 SigB RNA POLYMERASE SIGMA FACTOR B Information pathways 2.715585 1.952806 
9 Rv1221 SigE ALTERNATE RNA POLYMERASE SIGMA FACTOR E Information pathways 1.496848 1.227774 
10 Rv3161c Rv3161c POSSIBLE DEOXYGENASE Intermediary metabolism and 
respiration 
27.54526 24.38284 
11 Rv2122 IrgL PROBABLE PHOSPHO-RIBOSYL-AMP 
PYROPHOSPHATASE 
Intermediary metabolism and 
respiration 
2.428293 0.920567 
12 Rv3841 BfrB POSSIBLE BACTERIOFERRITIN Intermediary metabolism and 
respiration 
-1.57729 1.304538 
13 Rv2382c MbtC POLYPEPTIDE SYNTHASE  Lipid metabolism 3.20911 1.288678 
14 Rv2380c MbtE POLYPEPTIDE SYNTHASE (MYCOBACTIN) Lipid metabolism 2.981983 1.070068 
15 Rv2381c MbtD POLYKETIDE SYNTHASE  Lipid metabolism 2.433865 0.597357 
16 Rv2377c MbtH PUTATIVE CONSERVED PROTEIN Lipid metabolism 2.169838 0.464288 
17 Rv2383c MbtB PHENYLOXAZOLINE SYNTHASE Lipid metabolism 1.71465 0.135848 
18 Rv2386c MbtI PUTATIVE ISOCHORISMATE SYNTHASE Lipid metabolism 1.3324 1.045023 
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 ID Gene 
name 
Function Category Av/FC STDEV 
19 Rv3252 alkB PROBABLE ALKANE-1-MONOOXYGENASE Lipid metabolism -0.06073 1.235364 
20 Rv3159c Rv3159c PPE FAMILY PROTEIN PE/PPE  10.93322 5.072333 
21 Rv0280 PPE PE-PPE FAMILY PROTEIN PE/PPE  -2.01427 0.461642 
22 Rv1387 Rv1387 PPE20-PPE FAMILY PROTEIN PE/PPE  -2.16936 0.515985 
23 Rv1386 Rv1386 PE FAMILY PROTEIN PE/PPE  -3.62666 1.281864 
24 Rv3160c Rv3160c POSSIBLE "TET R" FAMILY TRANSCRIPTIONAL 
REGULATORY PROTEIN 
Regulatory protein 30.76966 30.33673 
25 Rv3269 Rv3269 CONSERVED HYPOTHETICAL PROTEIN Virulence, detoxification, adaptation 1.778381 1.22058 
 
 
2. M. tuberculosis gene regulated by F1082 (64 µg/ml at 4 hours) of post inoculation 
 ID Gene 
name 
Function Category AV/FC STDEV 
1 Rv0227c Rv0227c UNKNOWN Cell wall and cell 
processes 
-2.14486 0.253084 
2 Rv0418 lpqL UNKNOWN; HYDROLYZES PEPTIDES AND/OR PROTEINS Cell wall and cell 
processes 
-1.84473 0.231635 
3 Rv0559c Rv0559c POSSIBLE CONSERVED SECRETED PROTEIN Cell wall and cell 
processes 
1.740238 0.222031 
4 Rv0676c mmpL5 UNKNOWN. THOUGHT TO BE INVOLVED IN FATTY ACID TRANSPORT Cell wall and cell 
processes 
3.247001 2.090757 
5 Rv0677c mmpS5 UNKNOWN. Cell wall and cell 
processes 
5.34875 2.30678 
6 Rv0821c phoY2 INVOLVED IN TRANSCRIPTIONAL REGULATION OF ACTIVE TRANSPORT 
OF INORGANIC PHOSPHATE ACROSS THE MEMBRANE 
Cell wall and cell 
processes 
1.663298 0.107193 
7 Rv0847 lpqS PROBABLE LIPOPROTEIN LPQS Cell wall and cell 
processes 
1.905438 0.297441 
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 ID Gene 
name 
Function Category AV/FC STDEV 
8 Rv0867c rpfA MAY BE PROMOTE THE RESUSCITATION AND GROWTH OF DORMANT, 
NONGROWING CELL. 
Cell wall and cell 
processes 
-2.11903 0.174592 
9 Rv1037c exsI UNKNOWN Cell wall and cell 
processes 
-1.70708 0.147981 
10 Rv1072 Rv1072 UNKNOWN Cell wall and cell 
processes 
2.447351 0.470731 
11 Rv1411c lprG UNKNOWN Cell wall and cell 
processes 
1.782393 0.267503 
12 Rv1614 lgt PROLIPOPROTEIN MODIFICATION Cell wall and cell 
processes 
-2.04061 0.281786 
13 Rv1857 modA PROBABLE MOLYBDATE-BINDING LIPOPROTEIN MODA Cell wall and cell 
processes 
-1.87352 0.091365 
14 Rv2053c Rv2053c PROBABLE TRANSMEMBRANE PROTEIN Cell wall and cell 
processes 
2.083238 0.259944 
15 Rv2091c Rv2091c UNKNOWN Cell wall and cell 
processes 
2.17082 0.548018 
16 Rv2115c Rv2115c UNKNOWN. Involved in protection against reactive nitrogen intermediates Cell wall and cell 
processes 
2.334079 0.423334 
17 Rv2272 Rv2272 UNKNOWN Cell wall and cell 
processes 
-1.75163 0.18104 
18 Rv2450c rpfE PROBABLE RESUSCITATION-PROMOTING FACTOR RPFE Cell wall and cell 
processes 
-3.60328 1.011716 
19 Rv2743c Rv2743c UNKNOWN Cell wall and cell 
processes 
2.526051 0.640498 
20 Rv3006 lppZ UNKNOWN Cell wall and cell 
processes 
1.761933 0.221079 
21 Rv3036c TB22.2 PROBABLE CONSERVED SECRETED PROTEIN TB22.2 Cell wall and cell 
processes 
1.856761 0.132504 
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 ID Gene 
name 
Function Category AV/FC STDEV 
22 Rv3197 Rv3197 PROBABLE CONSERVED ATP-BINDING PROTEIN ABC TRANSPORTER Cell wall and cell 
processes 
2.279493 0.237291 
23 Rv3524 Rv3524 UNKNOWN Cell wall and cell 
processes 
-2.13909 0.614227 
24 Rv0057 Rv0057 UNKNOWN Conserved hypotheticals -2.02752 0.204432 
25 Rv0164 TB18.5 UNKNOWN Conserved hypotheticals -1.96143 0.121362 
26 Rv0250c Rv0250c UNKNOWN. POSSIBLY DOWN-REGULATED BY HSPR Conserved hypotheticals 1.943959 0.225218 
27 Rv0293c Rv0293c UNKNOWN Conserved hypotheticals 2.163719 0.266863 
28 Rv0313 Rv0313 UNKNOWN Conserved hypotheticals 1.84183 0.27179 
29 Rv0466 Rv0466 UNKNOWN Conserved hypotheticals -2.01962 0.399045 
30 Rv0516c Rv0516c UNKNOWN Conserved hypotheticals 2.539985 0.897858 
31 Rv0635 Rv0635 FUNCTION UNKNOWN Conserved hypotheticals -1.94149 0.239289 
32 Rv0678 Rv0678 UNKNOWN Conserved hypotheticals 2.44694 1.064667 
33 Rv0724 Rv0724A UNKNOWN Conserved hypotheticals 2.171285 0.425157 
34 Rv0898c Rv0898c UNKNOWN Conserved hypotheticals 2.432205 1.444775 
35 Rv0937c Rv0937c UNKNOWN Conserved hypotheticals 1.549623 0.036306 
36 Rv1057 Rv1057 UNKNOWN Conserved hypotheticals 3.914258 0.93924 
37 Rv1059 Rv1059 UNKNOWN Conserved hypotheticals 1.784418 0.219353 
38 Rv1130 Rv1130 UNKNOWN Conserved hypotheticals 2.905394 0.535371 
39 Rv1331 Rv1331 UNKNOWN Conserved hypotheticals 1.900691 0.262327 
40 Rv1592c Rv1592c UNKNOWN Conserved hypotheticals -2.83567 0.773827 
41 Rv1709 Rv1709 UNKNOWN Conserved hypotheticals -1.75427 0.115468 
42 Rv2050 Rv2050 UNKNOWN Conserved hypotheticals 2.165823 0.384023 
43 Rv2052c Rv2052c UNKNOWN Conserved hypotheticals 4.461768 2.767002 
44 Rv2405 Rv2405 UNKNOWN Conserved hypotheticals 1.988194 0.344172 
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45 Rv2627c Rv2627c UNKNOWN Conserved hypotheticals -1.65633 0.157207 
46 Rv2641 cadI UNKNOWN Conserved hypotheticals 2.108186 0.146417 
47 Rv2694c Rv2694c UNKNOWN Conserved hypotheticals 3.400801 1.098051 
48 Rv2744c 35kd ag CONSERVED 35 KDA ALANINE RICH PROTEIN Conserved hypotheticals 3.895726 1.191273 
49 Rv2747 Rv2747 GCN5-RELATED N-ACETYLTRANSFERASE Conserved hypotheticals 1.74522 0.25303 
50 Rv3412 Rv3412 UNKNOWN Conserved hypotheticals 1.744778 0.211103 
51 Rv3747 Rv3747 UNKNOWN Conserved hypotheticals -2.73691 0.915266 
52 Rv3748 Rv3748 UNKNOWN Conserved hypotheticals -2.1328 0.586852 
53 Rv3822 Rv3822 UNKNOWN Conserved hypotheticals 1.600105 0.014313 
54 Rv0430 Rv0430 UNKNOWN Conserved hypotheticals -1.99441 0.509638 
55 Rv0009 ppiA PPIASES ACCELERATE THE FOLDING OF PROTEINS  Information pathways -2.41061 0.221555 
56 Rv0053 rspF BINDS TOGETHER WITH S18 TO 16S RIBOSOMAL RNA. Information pathways -2.46591 0.29265 
57 Rv0055 rpsR1 TRANSFER RNA BINDING. IT APPEARS TO BE SITUATED AT THE 
DECODING SITE OF MESSENGER RNA. 
Information pathways -1.97819 0.485315 
58 Rv0056 rsplI BINDS TO THE 23S RRNA. Information pathways -2.04093 0.346984 
59 Rv0652 rplL PROBABLE 50S RIBOSOMAL PROTEIN L7/L12 RPLL (SA1) Information pathways -2.33791 0.195555 
60 Rv0667 rpoB DNA-DIRECTED RNA POLYMERASE (BETA CHAIN) RPOB Information pathways -1.96706 0.325744 
61 Rv0683 rpsG PROTEIN S7 BINDS SPECIFICALLY TO PART OF THE 3' END OF 16S 
RIBOSOMAL RNA 
Information pathways -1.70907 0.102503 
62 Rv0700 rpsJ 30S RIBOSOMAL PROTEIN S10 RPSJ (TRANSCRIPTION ANTITERMINATION 
FACTOR NUSE 
Information pathways -2.22706 0.331334 
63 Rv0701 rplC PROBABLE 50S RIBOSOMAL PROTEIN L3 RPLC Information pathways -2.8227 0.338625 
64 Rv0702 rplD PROBABLE 50S RIBOSOMAL PROTEIN L4 RPLD Information pathways -1.99993 0.210684 
65 Rv0703 rplW PROBABLE 50S RIBOSOMAL PROTEIN L23 RPLW Information pathways -2.44792 0.251863 
66 Rv0704 rplB PROBABLE 50S ribosomal protein L2 RPLB Information pathways -2.15861 0.248816 
67 Rv0705 rpsS PROTEIN S19 FORMS A COMPLEX WITH S13 THAT BINDS STRONGLY TO 
THE 16S RIBOSOMAL RNA 
Information pathways -2.57109 0.527435 
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68 Rv0706 rplV PROBABLE 50S RIBOSOMAL PROTEIN L22 RPLV Information pathways -1.95896 0.415036 
69 Rv0707 rpsC PROBABLE 30S RIBOSOMAL PROTEIN S3 RPSC Information pathways -2.58143 0.344279 
70 Rv0708 rplP PROBABLE 50S RIBOSOMAL PROTEIN L16 RPLP Information pathways -1.81911 0.136984 
71 Rv0709 rpmC PROBABLE 50S RIBOSOMAL PROTEIN L29 RPMC Information pathways -2.19868 0.319817 
72 Rv0714 rplN PROBABLE 50S RIBOSOMAL PROTEIN L14 RPLN Information pathways -1.96694 0.448699 
73 Rv0715 rplX PROBABLE 50S RIBOSOMAL PROTEIN L24 RPLX Information pathways -2.11051 0.294595 
74 Rv0718 rpsH PROBABLE 30S RIBOSOMAL PROTEIN S8 RPSH Information pathways -2.1371 0.498698 
75 Rv0721 rpsE PROBABLE 30S RIBOSOMAL PROTEIN S5 RPSE Information pathways -1.88354 0.247095 
76 Rv0722 rpmD PROBABLE 50S RIBOSOMAL PROTEIN L30 RPMD Information pathways -1.59247 0.067732 
77 Rv0723 rplO PROBABLE 50S RIBOSOMAL PROTEIN L15 RPLO Information pathways -1.9892 0.227835 
78 Rv1221 sigE ALTERNATIVE RNA POLYMERASE SIGMA FACTOR SIGE Information pathways 1.80489 0.36104 
79 Rv1298 rpmE INVOLVED IN TRANSLATION Information pathways -1.60805 0.069438 
80 Rv1630 rspA PROBABLE RIBOSOMAL PROTEIN S1 RPSA Information pathways -1.80495 0.266426 
81 Rv2069 sigC INVOLVED IN PROMOTER RECOGNITION, TRANSCRIPTION INITIATION. Information pathways -1.73223 0.172544 
82 Rv2412 rpsT PROBABLE 30S RIBOSOMAL PROTEIN S20 RPST Information pathways -2.70561 1.000659 
83 Rv2710 sigB RNA POLYMERASE SIGMA FACTOR SIGB Information pathways 2.877154 0.655779 
84 Rv2841c nusA PROBABLE N UTILIZATION SUBSTANCE PROTEIN A NUSA Information pathways 1.918749 0.223708 
85 Rv2890c rspB PROBABLE 30S RIBOSOMAL PROTEIN S2 RPSB Information pathways -1.85639 0.272286 
86 Rv3442c rpsI PROBABLE 30S RIBOSOMAL PROTEIN S9 RPSI Information pathways -2.10591 0.779982 
87 Rv3443c rplM PROBABLE 50S RIBOSOMAL PROTEIN L13 RPLM Information pathways -2.13444 0.349073 
88 Rv3457c rpoA PROBABLE DNA-DIRECTED RNA POLYMERASE (ALPHA CHAIN) RPOA Information pathways -2.00649 0.307426 
89 Rv3458c rpsD PROBABLE 30S RIBOSOMAL PROTEIN S4 RPSD Information pathways -1.67463 0.119311 
90 Rv3460c rpsM PROBABLE 30S RIBOSOMAL PROTEIN S13 RPSM Information pathways -2.15981 0.339098 
91 Rv3462c infA PROBABLE TRANSLATION INITIATION FACTOR IF-1 INFA Information pathways -1.84949 0.272725 
92 Rv3598c lysS LYSYL-TRNA SYNTHETASE 1 LYSS Information pathways -1.76318 0.173022 
93 Rv3646c topA DNA TOPOISOMERASE I TOPA Information pathways -1.77926 0.137459 
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94 Rv3923c rnpA RIBONUCLEASE P PROTEIN COMPONENT RNPA Information pathways -1.84334 0.114949 
95 Rv0717 rpsN1 PROBABLE 30S RIBOSOMAL PROTEIN S14 RPSN1 Information pathways -1.72332 0.165787 
96 Rv1945 Rv1945 UNKNOWN Insertion seqs and 
phages 
2.164855 0.545776 
97 Rv0077c Rv0077c UNKNOWN; PROBABLY INVOLVED IN CELLULAR METABOLISM Intermediary 
metabolism and 
respiration 
7.40796 4.82858 
98 Rv0155 pntAa FUNCTIONS AS A PROTON PUMP ACROSS THE MEMBRANE Intermediary 
metabolism and 
respiration 
-2.22465 0.20165 
99 Rv0315 Rv0315 INVOLVED IN EXOPOLYSACCHARIDE BIOSYNTHESIS/DEGRADATION Intermediary 
metabolism and 
respiration 
-4.00494 1.191568 
100 Rv0317c glpQ2 POSSIBLE GLYCEROPHOSPHORYL DIESTER PHOSPHODIESTERASE GLPQ2 Intermediary 
metabolism and 
respiration 
-1.60156 0.074614 
101 Rv0462 lpdC NVOLVED IN ENERGY METABOLISM Intermediary 
metabolism and 
respiration 
-1.77957 0.172944 
102 Rv0467 icl INVOLVED IN GLYOXYLATE BYPASS (AT THE FIRST STEP), AN 
ALTERNATIVE TO THE TRICARBOXYLIC ACID CYCLE 
Intermediary 
metabolism and 
respiration 
1.249717 1.207101 
103 Rv0510 hemC INVOLVED IN PORPHYRIN BIOSYNTHESIS BY THE C5 PATHWAY Intermediary 
metabolism and 
respiration 
-1.94294 0.347216 
104 Rv0560c Rv0560c POSSIBLE BENZOQUINONE METHYLTRANSFERASE (METHYLASE) Intermediary 
metabolism and 
respiration 
8.608646 5.363083 
105 Rv0636 Rv0636 UNKNOWN Intermediary 
metabolism and 
respiration 
-1.68351 0.117666 
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106 Rv0848 cysK2 POSSIBLE CYSTEINE SYNTHASE A CYSK2  Intermediary 
metabolism and 
respiration 
2.280215 0.667022 
107 Rv0897c Rv0897c UNKNOWN; PROBABLY INVOLVED IN CELLULAR METABOLISM. Intermediary 
metabolism and 
respiration 
1.743603 0.174047 
108 Rv1131 gltA1 INVOLVED IN TRICARBOXYLIC ACID CYCLE (KREBS CYCLE) 
[CATALYTIC ACTIVITY 
Intermediary 
metabolism and 
respiration 
4.05827 0.831812 
109 Rv1304 atpB PROBABLE ATP SYNTHASE A CHAIN ATPB (PROTEIN 6) Intermediary 
metabolism and 
respiration 
-1.88764 0.26711 
110 Rv1307 atpH PROBABLE ATP SYNTHASE DELTA CHAIN ATPH Intermediary 
metabolism and 
respiration 
-1.87421 0.396862 
111 Rv1471 trxB PROBABLE THIOREDOXIN TRXB1 Intermediary 
metabolism and 
respiration 
2.123795 0.233627 
112 Rv1475c can INVOLVED IN TRICARBOXYLIC ACID CYCLE [CATALYTIC ACTIVITY Intermediary 
metabolism and 
respiration 
-1.74941 0.228654 
113 Rv1497 lipL PROBABLE ESTERASE LIPL Intermediary 
metabolism and 
respiration 
2.44596 0.516323 
114 Rv1611 trpC PROBABLE INDOLE-3-GLYCERON PHOSPHATE SYNTHASE trpC Intermediary 
metabolism and 
respiration 
-1.72631 0.108178 
115 Rv1612 trpB PROBABLE TRYPTOPHAN SYNTHASE, BETA SUBUNIT trpB Intermediary 
metabolism and 
respiration 
-2.18738 0.435589 
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116 Rv1613 trpA PROBABLE TRYPTOPHAN SYNTHASE, ALPHA SUBUNIT trpA Intermediary 
metabolism and 
respiration 
-1.83088 0.172585 
117 Rv1855c Rv1855c POSSIBLE OXIDOREDUCTASE Intermediary 
metabolism and 
respiration 
1.558758 0.037439 
118 Rv2043c pncA CONSERVED AMIDES SUCH AS NICOTINAMIDE TO  CORRESPONDING 
ACID 
Intermediary 
metabolism and 
respiration 
1.903435 0.324548 
119 Rv2211c gcvT PROBABLE ANIMOMETHYLTRANSFERASE GcvT Intermediary 
metabolism and 
respiration 
-2.07647 0.380197 
120 Rv2220 glnA1 GLUTAMINE SYNTHETASE GLNA1 (GLUTAMINE SYNTHASE) (GS-I) Intermediary 
metabolism and 
respiration 
-2.04807 0.502865 
121 Rv2460c clpP2 PROBABLE ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 2 
CLPP2 
Intermediary 
metabolism and 
respiration 
2.623966 0.669298 
122 Rv2952 Rv2952 THOUGHT TO CAUSE METHYLATION Intermediary 
metabolism and 
respiration 
-2.05237 0.256055 
123 Rv2958c Rv2958c POSSIBLE GLYCOSYL TRANSFERASE Intermediary 
metabolism and 
respiration 
-1.93967 0.379021 
124 Rv2959c Rv2959c THOUGHT TO CAUSE METHYLATION Intermediary 
metabolism and 
respiration 
-2.7926 0.851517 
125 Rv2987c leuD PROBABLE 3-ISOPROPYLMALATE DEHYDRATASE (SMALL SUBUNIT) Intermediary 
metabolism and 
respiration 
-2.17163 0.405632 
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126 Rv2988c leuC PROBABLE 3-ISOPROPYLMALATE DEHYDRATASE (LARGE SUBUNIT) 
LEUC 
Intermediary 
metabolism and 
respiration 
-1.87118 0.192825 
127 Rv3002c ilvN PROBABLE ACETOLACTATE SYNTHASE (SMALL SUBUNIT) ILVN  Intermediary 
metabolism and 
respiration 
-2.13677 0.509705 
128 Rv3161c Rv3161c POSSIBLE DIOXYGENASE Intermediary 
metabolism and 
respiration 
25.49128 26.30773 
129 Rv3837c Rv3837c PROBABLE PHOSPHOGLYCERATE MUTASE Intermediary 
metabolism and 
respiration 
1.891065 0.373739 
130 Rv0129c fbpC SECRETED ANTIGEN 85-C FBPC (85C) (ANTIGEN 85 COMPLEX C) (AG58C) 
(MYCOLYL TRANSFERASE 85C) 
Lipid metabolism 1.7287 0.179517 
131 Rv0243 fadA2 FUNCTION UNKNOWN, BUT INVOLVED IN LIPID DEGRADATION Lipid metabolism 1.847155 0.142639 
132 Rv0270 fadD2 FUNCTION UNKNOWN, BUT INVOLVED IN LIPID DEGRADATION Lipid metabolism 1.619445 0.081922 
133 Rv0468 fadB2 BUTYRATE/BUTANOL-PRODUCING PATHWAY [CATALYTIC ACTIVITY Lipid metabolism 1.753015 0.305655 
134 Rv0642c mmaA4 METHOXY MYCOLIC ACID SYNTHASE 4 MMAA4 (METHYL MYCOLIC 
ACID SYNTHASE 
Lipid metabolism -1.7029 0.127587 
135 Rv0643c mmaA3 METHOXY MYCOLIC ACID SYNTHASE 3 MMAA3 (METHYL MYCOLIC 
ACID SYNTHASE 
Lipid metabolism -1.98273 0.345851 
136 Rv0947c Rv0947c FUNCTION UNKNOWN; THOUGHT TO BE INVOLVED IN MYCOLIC ACID 
BIOSYNTHESIS 
Lipid metabolism -2.09224 0.607665 
137 Rv1094 desA2 POSSIBLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA2 Lipid metabolism -1.7626 0.149297 
138 Rv1665 pks11 POSSIBLE CHALCONE SYNTHASE PKS11 Lipid metabolism -1.86442 0.317725 
139 Rv1886c fbpB SECRETED ANTIGEN 85-B FBPB (85B) (ANTIGEN 85 COMPLEX B) 
(MYCOLYL  
Lipid metabolism -3.13589 1.304213 
140 Rv2243 fadD2 CATALYZES MALONYL-COA-ACP TRANSACYLASE (MCAT) ACTIVITY 
USING HOLO-ACPM AS SUBSTRATE FOR TRANSACYLATION 
Lipid metabolism -2.06329 0.567616 
141 Rv2246 kasB 3-OXOACYL-[ACYL-CARRIER PROTEIN] SYNTHASE 2 Lipid metabolism -1.62817 0.138421 
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142 Rv2500c fadE19 POSSIBLE ACYL-CoA DEHYDROGENASE FADE19 (MMGC) Lipid metabolism 1.979723 0.227066 
143 Rv2947c pks15 POLYKETIDE SYNTHASE POSSIBLY INVOLVED IN LIPID SYNTHESIS Lipid metabolism -1.76768 0.256155 
144 Rv2950c fadD29 FUNCTION UNKNOWN, BUT INVOLVED IN LIPID DEGRADATION Lipid metabolism -1.83998 0.330412 
145 Rv3804c fbpA SECRETED ANTIGEN 85-A FBPA Lipid metabolism -2.09282 0.238717 
146 Rv3825c pks2 PROBABLE POLYKETIDE SYNTHASE PKS2 Lipid metabolism 1.785388 0.112709 
147 Rv1386 PE15 UNKNOWN PE/PPE -1.88178 0.225971 
148 Rv1806 PE20 PE FAMILY PROTEIN PE/PPE 2.140563 0.746306 
149 Rv2431c PE25 UNKNOWN PE/PPE -2.03352 0.293417 
150 Rv3159c PPe53 UNKNOWN PE/PPE 8.920608 8.033187 
151 Rv0872c PE 
PGRS15 
UNKNOWN PE/PPE) 2.752313 1.076616 
152 Rv0078 Rv0078 POSSIBLY INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 1.9027 0.269015 
153 Rv1129c Rv1129c INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 1.938548 0.36358 
154 Rv2358 Rv2358 INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 2.258721 0.615515 
155 Rv2359 furB PROBABLE FERRIC UPTAKE REGULATION PROTEIN FURB Regulatory proteins 1.943689 0.256762 
156 Rv2745c Rv2745c POSSIBLY INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 4.144364 1.557585 
157 Rv3160c Rv3160c POSSIBLY INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 16.87395 11.10883 
158 Rv0251c hsp RIBOSOMAL SUBUNIT. POSSIBLY A MOLECULAR CHAPERONE Virulence, 
detoxification, 
adaptation 
2.355203 0.800261 
159 Rv0440 groEl2 PREVENTS MISFOLDING AND PROMOTES THE REFOLDING AND PROPER 
ASSEMBLY OF POLYPEPTIDES UNDER STRESS. 
Virulence, 
detoxification, 
adaptation 
-2.19329 0.473026 
160 Rv0563 htpX PROBABLE PROTEASE TRANSMEMBRANE PROTEIN HEAT SHOCK 
PROTEIN HTPX 
Virulence, 
detoxification, 
adaptation 
3.804163 0.948096 
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161 Rv1932 tpx HAS ANTIOXIDANT ACTIVITY. COULD REMOVE PEROXIDES OR H(2)O(2) Virulence, 
detoxification, 
adaptation 
-1.69969 0.137077 
162 Rv2190c Rv2190c UNKNOWN Virulence, 
detoxification, 
adaptation 
-3.60516 0.41591 
163 Rv2428 ahpC ALKYL HYDROPEROXIDE REDUCTASE C PROTEIN AHPC Virulence, 
detoxification, 
adaptation 
-3.47518 1.485351 
164 Rv3269 Rv3269 CONSERVED HYPOTHETICAL PROTEIN Virulence, 
detoxification, 
adaptation 
2.144943 0.621441 
165 Rv3417c groEL1 60 KDA CHAPERONIN 1 GROEL1 Virulence, 
detoxification, 
adaptation 
-1.76904 0.174847 
166 Rv3648c cspA PROBABLE COLD SHOCK PROTEIN A CSPA Virulence, 
detoxification, 
adaptation 
-1.89202 0.267815 
167 Rv3922c Rv3922c POSSIBLE HEMOLYSIN Virulence, 
detoxification, 
adaptation 
-1.98405 0.280321 
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3. M. tuberculosis gene regulated by 64 µg/ml at 24 hours of post inoculation 
 ID Gene 
name 
Function Category Av/FC STDEV 
1 Rv0116c Rv0116c UNKNOWN Cell wall and cell 
processes 
0.308579 0.557829 
2 Rv0188 Rv0188 UNKNOWN Cell wall and cell 
processes 
3.454465 1.33538 
3 Rv0284 Rv0284 UNKNOWN Cell wall and cell 
processes 
1.89602 0.617859 
4 Rv0287 esxG UNKNOWN Cell wall and cell 
processes 
2.785722 1.270164 
5 Rv0288 esxH LOW MOLECULAR WEIGHT PROTEIN ANTIGEN 7 ESXH (10 kDa ANTIGEN) Cell wall and cell 
processes 
2.257887 1.034699 
6 Rv0292 Rv0292 UNKNOWN Cell wall and cell 
processes 
2.667309 1.046146 
7 Rv0676c mmpL5 UNKNOWN. THOUGHT TO BE INVOLVED IN FATTY ACID TRANSPORT Cell wall and cell 
processes 
3.019831 1.105876 
8 Rv1072 Rv1072 UNKNOWN Cell wall and cell 
processes 
3.010396 1.327689 
9 Rv1073 Rv1073 UNKNOWN Cell wall and cell 
processes 
1.878788 0.639475 
10 Rv1303 Rv1303 UNKNOWN Cell wall and cell 
processes 
-1.47838 1.306097 
11 Rv1463 Rv1463 PROBABLE CONSERVED ATP-BINDING PROTEIN ABC TRANSPORTER Cell wall and cell 
processes 
2.163168 0.942712 
12 Rv1884c rpfC PROBABLE RESUSCITATION-PROMOTING FACTOR RPFC Cell wall and cell 
processes 
-3.86179 2.717854 
13 Rv1997 ctpF PROBABLE METAL CATION TRANSPORTER P-TYPE ATPASE A CTPF Cell wall and cell 
processes 
-1.29187 1.282785 
14 Rv2053c Rv2053c PROBABLE TRANSMEMBRANE PROTEIN Cell wall and cell 
processes 
2.890922 1.607423 
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15 Rv2091c Rv2091c UNKNOWN Cell wall and cell 
processes 
1.690154 0.606482 
16 Rv2115c Rv2115c UNKNOWN Cell wall and cell 
processes 
2.007678 0.846804 
17 Rv2450c rpfE PROBABLE RESUSCITATION-PROMOTING FACTOR RPFE Cell wall and cell 
processes 
-1.68642 1.497623 
18 Rv2688c Rv2688c PROBABLE ANTIBIOTIC-TRANSPORT ATP-BINDING PROTEIN ABC 
TRANSPORTER 
Cell wall and cell 
processes 
2.076917 0.659206 
19 Rv2743c Rv2743c UNKNOWN Cell wall and cell 
processes 
1.887702 0.485809 
20 Rv2846c efpA POSSIBLE INTEGRAL MEMBRANE EFFLUX PROTEIN EFPA Cell wall and cell 
processes 
-3.44348 2.282469 
21 Rv3019c esxR UNKNOWN Cell wall and cell 
processes 
2.35757 1.111639 
22 Rv3020c esxS UNKNOWN Cell wall and cell 
processes 
3.405513 1.3425 
23 Rv3036c TB22.2 PROBABLE CONSERVED SECRETED PROTEIN TB22.2 Cell wall and cell 
processes 
1.700149 0.553723 
24 Rv3197 Rv3197 PROBABLE CONSERVED ATP-BINDING PROTEIN ABC TRANSPORTER Cell wall and cell 
processes 
1.740114 0.598303 
25 Rv3270 ctpC PROBABLE METAL CATION-TRANSPORTING P-TYPE ATPASE C CTPC Cell wall and cell 
processes 
1.951628 0.670036 
26 Rv3402c Rv3402c THOUGHT TO BE INVOLVED IN CELL PROCESS Cell wall and cell 
processes 
1.839049 0.585625 
27 Rv3766 Rv3766 UNKNOWN Conserve hypothetical 1.65081 0.556115 
28 Rv3767c Rv3767 UNKNOWN Conserve hypothetical 1.548992 0.497318 
29 Rv3706c 3706c UNKNOWN Conserve hypothetical 4.270889 2.043633 
30 Rv3839 Rv3889 UNKNOWN Conserve hypothetical 1.827095 0.773945 
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31 Rv3879c Rv3879c UNKNOWN Conserve hypothetical 1.816651 0.827142 
32 Rv0079 Rv0079 UNKNOWN Conserve hypothetical -1.45402 1.363151 
33 Rv0080 Rv0080 UNKNOWN Conserve hypothetical -1.6969 1.582253 
34 Rv0108c Rv0108c UNKNOWN Conserve hypothetical -1.94938 1.130768 
35 Rv0164 TB18.5 UNKNOWN Conserve hypothetical -1.78315 1.568015 
36 Rv0289 Rv0289 UNKNOWN Conserve hypothetical 1.916764 0.884446 
37 Rv0678 Rv0678 UNKNOWN Conserve hypothetical 2.192649 0.958524 
38 Rv0692 Rv0692 UNKNOWN Conserve hypothetical -2.18124 1.97288 
39 Rv0724 Rv0724A UNKNOWN Conserve hypothetical 1.730289 0.757193 
40 Rv0950c Rv0950c UNKNOWN Conserve hypothetical -1.33937 1.234598 
41 Rv1057 Rv1057 UNKNOWN Conserve hypothetical 2.792005 1.673761 
42 Rv1078 pra UNKNOWN Conserve hypothetical -1.43453 1.329032 
43 Rv1331 Rv1331 UNKNOWN Conserve hypothetical 1.58741 0.698234 
44 Rv1462 Rv1462 UNKNOWN Conserve hypothetical 1.69537 0.628539 
45 Rv1466 Rv1466 UNKNOWN Conserve hypothetical 3.598182 1.500445 
46 Rv1535 Rv1535 UNKNOWN Conserve hypothetical 2.069276 0.794238 
47 Rv1592c Rv1592c UNKNOWN Conserve hypothetical -3.02859 1.986183 
48 Rv1636 TB15.3 UNKNOWN Conserve hypothetical -1.40747 1.247084 
49 Rv1670 Rv1670 UNKNOWN Conserve hypothetical 1.72018 0.567502 
50 Rv1738 Rv1738 UNKNOWN Conserve hypothetical -4.41426 3.934279 
51 Rv1813c Rv1813c UNKNOWN Conserve hypothetical -3.84729 3.291971 
52 Rv1870c Rv1870c UNKNOWN Conserve hypothetical -1.5493 0.832972 
53 Rv2004c Rv2004c UNKNOWN Conserve hypothetical -2.328 2.368567 
54 Rv2005c Rv2005c UNKNOWN Conserve hypothetical -1.85736 2.10947 
55 Rv2028c Rv2028c UNKNOWN Conserve hypothetical -2.2641 2.165947 
56 Rv2030c Rv2030c UNKNOWN Conserve hypothetical -7.64199 5.685122 
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 ID Gene 
name 
Function Category Av/FC STDEV 
57 Rv2032 acg MAY HAVE A ROLE FOR BACTERIA WITHIN THE HOST ENVIRONMENT Conserve hypothetical -3.14219 2.761482 
58 Rv2050 Rv2050 UNKNOWN Conserve hypothetical 2.175217 0.838504 
59 Rv2052c Rv2052c UNKNOWN Conserve hypothetical 4.365885 2.56016 
60 Rv2271 Rv2271 UNKNOWN Conserve hypothetical -1.35344 1.349987 
61 Rv2325c Rv2325c UNKNOWN Conserve hypothetical 1.516453 0.521006 
62 Rv2405 Rv2405 UNKNOWN Conserve hypothetical 1.98052 0.895512 
63 Rv2623 TB31.7 UNKNOWN Conserve hypothetical -4.61677 6.032121 
64 Rv2624c Rv2624c UNKNOWN Conserve hypothetical -1.99781 1.815636 
65 Rv2626c Rv2626c UNKNOWN Conserve hypothetical -3.9021 3.769517 
66 Rv2627c Rv2627c UNKNOWN Conserve hypothetical -4.12147 5.859899 
67 Rv2628 Rv2628 UNKNOWN Conserve hypothetical -2.59259 2.681199 
68 Rv2630 Rv2630 UNKNOWN Conserve hypothetical -1.98005 1.775833 
69 Rv2676c Rv2676c UNKNOWN Conserve hypothetical 1.504228 0.48085 
70 Rv2694c Rv2694c UNKNOWN Conserve hypothetical 3.0403 1.015513 
71 Rv2744c 35kd ag CONSERVED 35 KDA ALANINE RICH PROTEIN Conserve hypothetical 3.925886 1.504433 
72 Rv2840c Rv2840c UNKNOWN Conserve hypothetical 1.632055 0.517419 
73 Rv3126c Rv3126c UNKNOWN Conserve hypothetical -1.19456 1.088076 
74 Rv3127 Rv3127 UNKNOWN Conserve hypothetical -3.48938 2.682606 
75 Rv3131 Rv3131 UNKNOWN Conserve hypothetical -3.33124 2.355824 
76 Rv3484 cpsA UNKNOWN Conserve hypothetical -1.24897 1.153071 
77 Rv3642c Rv3642c UNKNOWN Conserve hypothetical 1.575123 0.509848 
78 Rv3747 Rv3747 UNKNOWN Conserve hypothetical -1.54665 1.633619 
79 Rv0430 Rv0430 UNKNOWN Conserve hypothetical -1.4261 1.288258 
80 Rv0009 ppiA PPIASES ACCELERATE THE FOLDING OF PROTEINS  Information pathways -1.30988 1.221769 
81 Rv0570 nrdZ PROBABLE RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE  Information pathways -2.59018 2.405685 
82 Rv0652 rplL PROBABLE 50S RIBOSOMAL PROTEIN L7/L12 RPLL (SA1) Information pathways -2.233 1.319094 
Stellenbosch University  http://scholar.sun.ac.za
 123 
 
 ID Gene 
name 
Function Category Av/FC STDEV 
83 Rv0667 rpoB DNA-DIRECTED RNA POLYMERASE (BETA CHAIN) RPOB Information pathways -0.53004 1.125775 
84 Rv0700 rpsJ 30S RIBOSOMAL PROTEIN S10 RPSJ (TRANSCRIPTION ANTITERMINATION 
FACTOR NUSE 
Information pathways -0.03154 0.793014 
85 Rv0701 rplC PROBABLE 50S RIBOSOMAL PROTEIN L3 RPLC Information pathways -1.40706 1.297251 
86 Rv0703 rplW PROBABLE 50S RIBOSOMAL PROTEIN L23 RPLW Information pathways -1.2395 1.140483 
87 Rv0704 rplB PROBABLE 50S ribosomal protein L2 RPLB Information pathways -1.33021 1.160337 
88 Rv0706 rplV PROBABLE 50S RIBOSOMAL PROTEIN L22 RPLV Information pathways -0.01838 0.697287 
89 Rv0714 rplN PROBABLE 50S RIBOSOMAL PROTEIN L14 RPLN Information pathways -1.92754 1.714155 
90 Rv0715 rplX PROBABLE 50S RIBOSOMAL PROTEIN L24 RPLX Information pathways -1.41734 1.348857 
91 Rv0716 rplE PROBABLE 50S RIBOSOMAL PROTEIN L5 RPLE Information pathways -1.51144 1.361296 
92 Rv0718 rpsH PROBABLE 30S RIBOSOMAL PROTEIN S8 RPSH Information pathways -1.67088 1.475071 
93 Rv1221 sigE ALTERNATIVE RNA POLYMERASE SIGMA FACTOR SIGE Information pathways 2.183545 0.889734 
94 Rv2412 rpsT PROBABLE 30S RIBOSOMAL PROTEIN S20 RPST Information pathways -0.50767 1.102222 
95 Rv2710 sigB RNA POLYMERASE SIGMA FACTOR SIGB Information pathways 2.296367 2.672677 
96 Rv2890c rspB PROBABLE 30S RIBOSOMAL PROTEIN S2 RPSB Information pathways -1.53677 1.479332 
97 Rv3052c nrdI PROBABLY INVOLVED IN RIBONUCLEOTIDE REDUCTASE FUNCTION Information pathways 1.712417 0.558376 
98 Rv3442c rpsI PROBABLE 30S RIBOSOMAL PROTEIN S9 RPSI Information pathways -0.00528 0.685922 
99 Rv0336 Rv0336 THOUGHT TO BE REGULATED BY Rv2720|LEXA Insertion seqs and 
phages 
-1.30287 1.145501 
100 Rv0077c Rv0077c UNKNOWN; PROBABLY INVOLVED IN CELLULAR METABOLISM Intermediary 
metabolism and 
respiration 
2.069728 1.10689 
101 Rv0291 mycP3 THOUGHT TO HAVE PROTEOLYTIC ACTIVITY Intermediary 
metabolism and 
respiration 
1.608456 0.580266 
102 Rv0315 Rv0315 INVOLVED IN EXOPOLYSACCHARIDE BIOSYNTHESIS/DEGRADATION Intermediary 
metabolism and 
respiration 
-1.5705 1.897698 
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name 
Function Category Av/FC STDEV 
103 Rv0560c Rv0560c POSSIBLE BENZOQUINONE METHYLTRANSFERASE (METHYLASE) Intermediary 
metabolism and 
respiration 
8.167123 5.609433 
104 Rv0848 cysK2 POSSIBLE CYSTEINE SYNTHASE A CYSK2  Intermediary 
metabolism and 
respiration 
1.630602 0.52215 
105 Rv1177 fdxC FERREDOXINS ARE IRON-SULFUR PROTEINS THAT TRANSFER ELECTRONS IN 
A WIDE VARIETY OF METABOLIC REACTIONS 
Intermediary 
metabolism and 
respiration 
-1.27341 1.1338 
106 Rv1304 atpB PROBABLE ATP SYNTHASE A CHAIN ATPB (PROTEIN 6) Intermediary 
metabolism and 
respiration 
-3.09786 2.655309 
107 Rv1305 atpE PROBABLE ATP SYNTHASE C CHAIN ATPE (LIPID-BINDING PROTEIN) Intermediary 
metabolism and 
respiration 
-1.3961 1.406573 
108 Rv1306 atpF PROBABLE ATP SYNTHASE B CHAIN ATPF Intermediary 
metabolism and 
respiration 
-2.77336 2.55119 
109 Rv1307 atpH PROBABLE ATP SYNTHASE DELTA CHAIN ATPH Intermediary 
metabolism and 
respiration 
-1.20709 1.100842 
110 Rv1308 atpA PROBABLE ATP SYNTHASE ALPHA CHAIN ATPA Intermediary 
metabolism and 
respiration 
-1.66703 1.546506 
111 Rv1310 atpD PROBABLE ATP SYNTHASE BETA CHAIN ATPD Intermediary 
metabolism and 
respiration 
-1.19907 1.075943 
112 Rv1464 csd PROBABLE CYSTEINE DESULFURASE CSD Intermediary 
metabolism and 
respiration 
3.767939 1.473816 
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name 
Function Category Av/FC STDEV 
113 Rv1465 Rv1465 POSSIBLE NITROGEN FIXATION RELATED PROTEIN Intermediary 
metabolism and 
respiration 
2.055772 0.809375 
114 Rv1612 trpB PROBABLE TRYPTOPHAN SYNTHASE, BETA SUBUNIT TRPB Intermediary 
metabolism and 
respiration 
-1.21941 1.073177 
115 Rv1736c narX PROBABLE NITRATE REDUCTASE NARX Intermediary 
metabolism and 
respiration 
-1.68648 1.959071 
     -2.47411 3.080402 
     -5.50719 5.790081 
     -3.44152 5.068395 
119 Rv2122c hisE THOUGHT TO BE INVOLVED IN HISTIDINE BIOSYNTHESIS Intermediary 
metabolism and 
respiration 
1.924921 0.648981 
120 Rv2124c metH PROBABLE 5-METHYLTETRAHYDROFOLATE--HOMOCYSTEIN 
METHYLTRANSFERASE METH 
Intermediary 
metabolism and 
respiration 
1.564868 0.579201 
116 Rv1812c Rv1812c PROBABLE DEHYDROGENASE Intermediary 
metabolism and 
respiration 
3.059531 1.239747 
117 Rv2007c fdxA INVOLVED IN ELECTRON TRANSFER Intermediary 
metabolism and 
respiration 
2.224867 0.985802 
118 Rv2029c pfkB INVOLVED IN GLYCOLYSIS: CONVERTS SUGAR-1-P TO SUGAR-1,6-P Intermediary 
metabolism and 
respiration 
1.576235 0.546357 
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name 
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124 Rv2959c Rv2959c THOUGHT TO CAUSE METHYLATION Intermediary 
metabolism and 
respiration 
-1.43967 1.287455 
125 Rv3161c Rv3161c POSSIBLE DIOXYGENASE Intermediary 
metabolism and 
respiration 
13.58208 9.364385 
126 Rv3206c moeB1 POSSIBLY INVOLVED IN MOLYBDOPTERIN METABOLISM Intermediary 
metabolism and 
respiration 
1.495546 0.466619 
127 Rv3596c clpC1 PROBABLE ATP-DEPENDENT PROTEASE ATP-BINDING SUBUNIT CLPC1 Intermediary 
metabolism and 
respiration 
1.563453 0.501396 
128 Rv3841 bfrB INVOLVED IN IRON STORAGE Intermediary 
metabolism and 
respiration 
-2.52993 1.586847 
129 Rv0642c mmaA4 METHOXY MYCOLIC ACID SYNTHASE 4 MMAA4 (METHYL MYCOLIC ACID 
SYNTHASE 
Lipid metabolism -1.43369 1.373953 
130 Rv0824c desA1 PROBABLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA1 Lipid metabolism -4.01504 2.708589 
131 Rv1094 desA2 POSSIBLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA2 Lipid metabolism -2.61738 1.569879 
132 Rv1886c fbpB SECRETED ANTIGEN 85-B FBPB (85B) (ANTIGEN 85 COMPLEX B) (MYCOLYL  Lipid metabolism -3.40309 3.158262 
133 Rv2243 fadD2 CATALYZES MALONYL-COA-ACP TRANSACYLASE Lipid metabolism -1.53594 1.664022 
134 Rv2244 acpM INVOLVED IN FATTY ACID BIOSYNTHESIS (MYCOLIC ACIDS SYNTHESIS Lipid metabolism 0.003447 0.818778 
135 Rv2245 kasA INVOLVED IN FATTY ACID BIOSYNTHESIS (MYCOLIC ACIDS SYNTHESIS Lipid metabolism -1.98833 1.405819 
136 Rv2246 kasB 3-OXOACYL-[ACYL-CARRIER PROTEIN] SYNTHASE 2 Lipid metabolism -2.46937 1.769753 
137 Rv2377c mbtH PUTATIVE CONSERVED PROTEIN MBTH Lipid metabolism 2.005751 0.723677 
138 Rv2380c mbtE PEPTIDE SYNTHETASE MBTE (PEPTIDE SYNTHASE) Lipid metabolism 3.158833 1.172777 
139 Rv2381c mbtD POLYKETIDE SYNTHETASE MBTD  Lipid metabolism 2.304321 0.932392 
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name 
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140 Rv2382c mbtC INVOLVED IN THE BIOGENESIS OF THE HYDROXYPHENYLOXAZOLINE-
CONTAINING SIDEROPHORE MYCOBACTINS 
Lipid metabolism 3.408963 1.166422 
141 Rv2383c mbtB PHENYLOXAZOLINE SYNTHASE MBTB Lipid metabolism 1.878343 0.593032 
142 Rv2386c mbtI PUTATIVE ISOCHORISMATE SYNTHASE MBTI Lipid metabolism 1.705159 0.570991 
143 Rv2500c fadE19 POSSIBLE ACYL-CoA DEHYDROGENASE FADE19 (MMGC) Lipid metabolism 1.982758 0.842339 
144 Rv2524c fas PROBABLE FATTY ACID SYNTHASE FAS Lipid metabolism -1.33446 1.264049 
145 Rv2932 ppsB PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSB Lipid metabolism 2.015846 0.838399 
146 Rv2933 ppsC PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSC Lipid metabolism 1.628158 0.594133 
147 Rv2935 ppsE PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSE Lipid metabolism -2.41067 2.457257 
148 Rv2950c fadD29 FUNCTION UNKNOWN, BUT INVOLVED IN LIPID DEGRADATION Lipid metabolism -1.60769 1.846339 
149 Rv3130c tgs1 INVOLVED IN SYNTHESIS OF TRIACYLGLYCEROL Lipid metabolism -4.4683 4.254869 
150 Rv3774 echA21 OXIDISES FATTY ACIDS Lipid metabolism -0.00031 0.590971 
151 Rv3804c fbpA INVOLV ED IN CELL WALL MYCOLATION Lipid metabolism 0.014214 0.78962 
152 Rv3824c papA1 INVOLVED IN LIPID METABOLISM Lipid metabolism 3.154036 1.2955 
153 Rv0280 PPE3 UNKNOWN PE/PPE -1.72056 1.885468 
154 Rv0285 PE5 UNKNOWN PE/PPE 2.169799 0.9537 
155 Rv1195 PE13 UNKNOWN PE/PPE -1.86037 1.278426 
156 Rv1196 PPe18 UNKNOWN PE/PPE -1.38937 1.361668 
157 Rv1386 PE15 UNKNOWN PE/PPE -7.48898 11.92575 
158 Rv1387 PPE20 UNKNOWN PE/PPE -3.55211 4.378693 
159 Rv1806 PE20 PE FAMILY PROTEIN PE/PPE 3.346305 1.81478 
160 Rv3135 PPE50 UNKNOWN PE/PPE -1.36637 1.324047 
161 Rv3159c PPE53 UNKNOWN PE/PPE 5.372833 2.8863 
162 Rv3478 PPE60 UNKNOWN PE/PPE -1.2902 1.206951 
163 Rv0872c PE 
PGRS15 
UNKNOWN PE/PPE) 2.161618 0.823924 
164 Rv0823c Rv0823c THOUGHT TO BE INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins -1.90771 1.735217 
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165 Rv1460 Rv1460 INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 4.95915 2.174647 
166 Rv1534 Rv1534 POSSIBLY INVOLVED IN A TRANSCRIPTIONAL MECHANISM Regulatory proteins 2.395037 0.940763 
167 Rv2358 Rv2358 INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 2.127472 0.885409 
168 Rv2359 furB PROBABLE FERRIC UPTAKE REGULATION PROTEIN FURB Regulatory proteins 1.714664 0.678632 
169 Rv2745c Rv2745c POSSIBLY INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 2.838931 0.965348 
170 Rv3132c devS TWO COMPONENT SENSOR HISTIDINE KINASE DEVS Regulatory proteins -2.42076 2.124356 
171 Rv3133c devR TWO COMPONENT TRANSCRIPTIONAL REGULATORY PROTEIN DEVR Regulatory proteins -2.00683 2.01749 
172 Rv3160c Rv3160c POSSIBLY INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins 27.50748 20.20303 
173 Rv3219 whiB1 INVOLVED IN TRANSCRIPTIONAL MECHANISM Regulatory proteins -1.56847 0.850976 
174 Rv0251c hsp RIBOSOMAL SUBUNIT. POSSIBLY A MOLECULAR CHAPERONE Virulence, 
detoxification, 
adaptation 
3.31728 1.945331 
175 Rv0440 groEl2 PREVENTS MISFOLDING AND PROMOTES THE REFOLDING AND PROPER 
ASSEMBLY OF POLYPEPTIDESUNDER STRESS 
Virulence, 
detoxification, 
adaptation 
0.002757 0.764281 
176 Rv0563 htpX PROBABLE PROTEASE TRANSMEMBRANE PROTEIN HEAT SHOCK PROTEIN 
HTPX 
Virulence, 
detoxification, 
adaptation 
2.285772 0.982294 
177 Rv2031c hspX HEAT SHOCK PROTEIN HSPX (ALPHA-CRYSTALLIN HOMOLOG) Virulence, 
detoxification, 
adaptation 
-5.55299 6.917586 
178 Rv2190c Rv2190c UNKNOWN Virulence, 
detoxification, 
adaptation 
-3.30833 2.758203 
179 Rv2428 ahpC ALKYL HYDROPEROXIDE REDUCTASE C PROTEIN AHPC Virulence, 
detoxification, 
adaptation 
-2.81099 3.015622 
180 Rv3269 Rv3269 CONSERVED HYPOTHETICAL PROTEIN Virulence, 
detoxification, 
adaptation 
3.308076 1.560983 
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181 Rv3418c groES 10 KDA CHAPERONIN GROES (PROTEIN CPN10) (PROTEIN GROES)  Virulence, 
detoxification, 
adaptation 
-0.00782 0.747637 
182 Rv3648c cspA PROBABLE COLD SHOCK PROTEIN A CSPA Virulence, 
detoxification, 
adaptation 
-0.0016 0.683954 
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CHAPTER FOUR 
 
Understanding the mechanism of action of 
F1082 
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4.1 Introduction 
 
The gene signature profile from the micro array data (Chapter 3) provides some clues for us to 
understand the mechanism of action of F1082. From the data it appeared that M. tuberculosis “senses” 
a low iron concentration enviromention when treated with F1082. An organism responds to 
environmental changes by altering the level of expression of genes that effect metabolic changes to 
favour its survival and continuing growth (Boshoff et al., 2004). When M. tuberculosis is faced with 
low iron conditions, it up-regulates the genes involved in siderophore biosynthesis and down-
regulates the genes that are involved in iron storage (Quadri et al., 1998), which could also be as a 
result of inactivation of IdeR (Schnappinger et al., 2003). A schematic representation of iron 
regulation is shown in (Figure 4.2)  
4.1.1 Iron–responsive changes in gene expression 
 
Iron limitation in bacteria induces a response aimed at increasing iron acquisition. To achieve this, the 
siderophore production is upregulated (Raghu et al., 1993) and iron is transported through the irtAB 
system (Rodriguez and Smith, 2006). Mycobacteria produce two classes of siderophores, mycobactins 
and exochelin (Ratledge and Ewing, 1996). The details of siderophore structure (Figure 4.1) and 
biosynthesis are known  (De Voss et al., 1999). Pathogenic mycobacteria produce mycobactins only, 
whereas saprophytic mycobacteria such as M. smegmatis and Mycobacterium neoarum produce both 
mycobactins and exochelin (Ratledge and Ewing, 1996). Mycobactins are salicylate-containing 
siderophores, and exochelins are peptidic molecules. Mycobactins are found in two forms that differ 
in the length of the alkyl substitution and hence in polarity and solubility. The less polar form remains 
cell associated (mycobactins), whereas the more polar one (carboxymycobactin) is secreted into the 
culture medium. Mycobacterial siderophores, like most other siderophores, are synthesized by non-
ribosomal peptide synthetases (Gobin et al., 1995).  
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Annotation of the complete genome sequence of M. tuberculosis identified a cluster of 10 genes, (the 
mbt locus) that, based on homology with other systems, encode the appropriate enzymes for the 
synthesis of mycobactin and the carboxymycobactin core(De Voss et al., 2000). Three peptide 
synthetases (MbtB, MbtE and MbtF), two polypeptide synthases (MbtD and MbtC), an isochorismate 
synthase (Mbtl) that converts chorismate to salicylate, a salicyloyl-AMP ligase (MbtA), and a 
hydroxylase (MbtG) are encoded by the mbt genes (Quadri et al., 1998). A common core structure 
isshared by the two siderophores but they differ in the length of alkyl substitution. A long alkyl chain 
(e.g., 10-21 carbons) is found in mycobactins, whereas a shorter one (2-9 carbons) is found in 
exomycobactins (Ratledge and Dover, 2000). Independent disruption of the siderophore producing 
enzymes is therefore necessary in order to understand their contribution in iron uptake (Rodriguez et 
al., 2008).   
 
 
Figure 4.1. The structure of mycobactin and exomycobactin and the mbt gene cluster. The yellow 
highlighted mbt genes were upregulated in the microarray gene profile after F1082 treatment. 
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4.1.2 The IdeR protein in M. tuberculosis 
 
IdeR is found in pathogenic and non-pathogenic mycobactria and is a closely related homologue of 
DtxR (Doukhan et al., 1995). In M. tuberculosis, when intracellular iron levels increase, IdeR 
combines with Fe2+ and binds to specific sequences (iron boxes) in the promoter region of iron-
regulated genes modulating their transcription (Figure 4.2) (Rodriguez and Smith, 2003). Under these 
conditions, IdeR-Fe2+ down-regulates iron uptake by repressing siderophore production and increases 
iron storage by activating transcription of bfrA and bfrB encoding bacterioferritin and ferritin 
(Weinberg, 1984). In an indirect manner, IdeR also positively modulates protection against oxidative 
stress (Dussurget et al., 1998). In low-iron conditions, the IdeR-Fe2+ complexes are not formed, and 
IdeR-repressed genes are transcribed while iron storage genes are not expressed (Rodriguez et al., 
2002).  
Upregulation of 
defenses against 
oxidative stress
Mbt genes
Repression of siderophore synthetic genes
Increase of intracellular iron levels
Activation of 
iron storage
I J A B C D E F G H
bfrB and bfrA
 
Figure 4.2 Iron-dependent regulatory function of IdeR (Adapted from Rodriguez and Smith, 2003).   
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4.1.3 IdeR and the oxidative stress response in Mycobacteria 
 
Oxidative stress occurs when abnormally high levels of reactive oxygen species (ROS) are generated, 
causing DNA, protein and lipid damage. Iron levels and oxidative stress are closely linked in aerobic 
organisms (Rodriguez and Smith, 2003). On one hand, iron deficiency can lead to oxidative stress by 
decreasing the activity of iron containing enzymes such as superoxide dismutase and catalase 
involved in protection against ROS and reactive nitrogen species (RNS). Conversely, increasing 
intracellular free iron available to participate in a Fenton reaction results in enhanced generation of 
oxygen radicals and oxidative stress (Imlay et al., 1988). Therefore it is not surprising that many 
organisms couple regulation of iron metabolism with regulation of proteins against oxidative stress. 
Three hypotheses can be tested (1) F1082 could be more active against M. tuberculosis under low iron 
conditions; alternatively (2) F1082 could be directly interfering with the iron dependent regulators 
such that it up-regulates genes for iron acquisition under high iron conditions and (3) F1082 could be 
aiding or exacerbating the generation of intracellular oxidative stress. In this chapter the three above-
mentioned scenarios will be investigated. The aim of this chapter is to understand the mechanism by 
which F1082 inhibits M. tuberculosis growth in an iron-dependent manner. 
4.3 Materials and Methods 
4.3.1 Bacteria, media and growth conditions 
M. tuberculosis and M. smegmatis strains were cultured in Middlebrook 7H9 broth or on 7H10 agar 
(Difco), supplemented with 0.2% glycerol, 0.05% Tween 80 and 10% albumin-dextrose-NaCl 
complex (ADN) (Appendix 4A).The  M. tuberculosis irtAB mutant, M. smegmatis sodA mutant, and 
M. smegmatis transformed strains were provided by Dr Marcela M. Rodriquez from the TB Center, 
The Public Health Research Institute at the International Center for Public Health. The H37Rv 
reference strain and H37Rv mshA mutant were obtained from Prof. WR Bill Jacobs’s lab, Albert 
Einstein College, USA. The strains used in this study have been described (Table 4.1). Antibiotics 
were included when required at the following concentrations: kanamycin (Kan) at 20 µg/ml, 
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streptomycin (Str) at 20 µg/ml, and hygromycin (Hyg) at 150 µg/ml. For M. tuberculosis or M. 
smegmatis grown in low iron medium, we used a defined medium as described by Rodriquez and 
Smith (2006). Briefly, a defined medium (MM) containing 0.5% w/v asparagine, 0.5% w/v KH2PO4, 
2% glycerol, 0.05% Tween 80 and 10% ADC was used. The pH was adjusted to 6.8. To reduce any 
trace metal contamination, the medium was treated with Chelex-100 (Bio-Rad Laboratories) 
according to the manufacturer’s instructions. Before use the medium was supplemented with 0.5 mg/l 
ZnCl2, 0.1 mg/l MnSO4, 40 mg/l MgSO4 and the desired concentration of FeCl3 was also added. 
Table 4.1 Bacterial strains and plasmids used in this work 
Strain Description Mutant Functional use 
H37R v M. tuberculosis laboratory 
strain, wild type 
 Baseline 
susceptibility testing 
ST73 irtAB-M. tuberculosis mutant 
(HygR) 
Hyg. resistant cassette inserted in 
Rv1348 (Rodriguez and Smith, 
2006) 
Iron transport 
deficient mutant 
incapable of 
transporting iron into 
cell 
SM60 M. smegmatis-pSM128* 
(SmR) 
MC2 155 with integrated pSM128 
(Dussurget et al., 1999) 
IdeR- independent 
regulation, serves as 
baseline testing 
SM160 M. smegmatis-pSM128-bfrB-
LacZ (SmR) 
MC2 155 with integrated pSM128-
bfrB-LacZ (SmR), (Rodriguez et al., 
1999) 
IdeR-iron dependent 
regulation 
SM193 M. smegmatis-pSM128-
mbtB-LacZ (SmR) 
MC2 155 with integrated pSM128-
mbtB-LacZ (SmR), (Rodriguez et 
al., 1999) 
IdeR-iron dependent 
regulation 
MC2155 M. smegmatis wild type MC2 
155 
 Base-line screen 
SM90 M. smegmatis superoxide 
dismutase mutant (KmR) 
MC2 155 with integrated pSM299 
kanamycin resistant plasmid in 
sodA gene (Dussurget et al., 1998) 
Susceptible to 
oxidative stress 
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Strain Description Mutant Functional use 
CDC 1551 M. tuberculosis-CDC 1551 
wild type 
 Baseline testing to 
oxidative generating 
compounds 
ΔmshA M. tuberculosis-CDC 1551 
mycothiol mutant (HmR) 
Deletion of mshA gene by 
specialised transduction with 
phAE222 (Vilchèze et al., 2008) 
Susceptible to 
oxidative stress 
*pSM 128 and its derivatives contain the mycobacteriophage L5 int system that promotes integration 
at the chromosomal L5 at site. KmR, kanamycin resistant; SmR, streptomycin resistant; HygR, 
hygromycin resistant. 
4.3.2 Alamar blue assay 
 
Mycobacterium tuberculosis H37Rv from frozen stocks was inoculated onto 7H10 agar plates. An 
aliquot was taken from the 7H10 plate and liquid cultures were grown in minimal medium (MM) with 
no iron added. Pre-incubation in MM with no iron was done in order to exhaust the stored iron. 
H37Rv was grown in MM from an OD540 of 0.1 to 0.8 (three generations) and then diluted in MM to 
an OD540 of 0.1(1 x 107 cells). After two days the culture was diluted again to an OD540 of 0.02 (2 x 
106 cells/ml) in MM alone or MM with iron (FeCl3, 50 µm/ml) containing the different concentrations 
of F1082. To assay for activity of F1082 in MM with or without iron, we used the Alamar Blue assay 
in a 96 well plate. Different concentrations of F1082 (ranging from16 to 0.125 µg/ml) were tested in 
duplicate with each experiment performed at least twice. Bacterial suspension (100 µl) was added to 
test wells and to controls. The control wells included no drug (bacterial culture only), drug only 
(medium and highest drug concentration used), and medium only (serves as the blank). The plates 
were incubated for five days at 37°C and 20 µl of Alamar Blue solution (Trek Diagnostics, Westlake) 
was added to each well on the fifth day and incubated for another 24 hours. Results were read by 
visual detection or using fluorescence in a plate flourometer (Fluoroskan Ascent FL, Thermo, 
Finland) at an excitation wave-length of 490 nm and an emission wavelength of 540 nm, and the 
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relative fluorescence units (rfu) were recorded.  Visual MIC was determined as the lowest 
concentration of the compound that inhibited growth (purple colour), whereas growth was recorded if 
the wells turned pink after 24 hour of addition of the alamar blue. Percentage growth was calculated 
relative to the untreated control based on the rfu. There was always a correlation between fluorometric 
and visual observations, i.e. pink wells represented high rfu values. 
4.3.3 β-galactosidase assay 
 
Cultures of M. smegmatis harbouring the different gene promoters with LacZ fusion (SM 60-pSM128, 
SM 160-bfrB promoter-LacZ and SM193-mbtB promoter-LacZ) were grown in appropriate media: in 
MM only (no iron-LI) or MM supplemented with 100 µM FeCl3 (high iron-HI). The bacterial cultures 
were collected at OD600 of 0.5-0.7, washed twice in phosphate buffered saline (PBS), centrifuged at 
14 000 rpm in a bench top centrifuge at room temperature (25°C) for five minutes and resuspended in 
Z buffer (Appendix 4A; Miller J.F., 1972). Suspensions were mixed with Zirconia beads (0.5 mm in 
diameter) and bacteria were lysed by three pulses of bead-beating for 30 s in a Mini Bead-beater 
(Biospec Products). The extracts were centrifuged at 14 000 rpm for 5 minutes and the supernatant 
was collected. 
4.3.3.1The LacZ transcriptional fusions used 
 
The LacZ transcriptional fusions in M. smegmatis were kindly provided by Dr Marcela Rodriquez 
from UMDNJ as described and published (Table 4.1). The transformed M. smegmatis strains were 
made by: amplification of a 180 base pair DNA fragment containing the putative IdeR binding site 
and promoter regions of mbtB and bfrB by PCR from M. tuberculosis H37Rv chromosome using 
primers Ppe.1 and Ppe. 2. These PCR fragments were cloned in the Scal site of pSM128 plasmid 
(Figure 4.3) and integrated into M. smegmatis chromosome to generate M. smegmatis strains SM160 
and SM193. SM160 contained the plasmids pSM128-bfrB promoter-LacZ and SM193 contained 
pSM128-mbtB promoter-LacZ. SM60 contained plasmid pSM128-LacZ and was used for background 
expression activity as this strain was not controlled by the iron dependent regulator (IdeR). 
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4.3.3.2 Protein concentrations  
 
Protein concentrations of the extracts were estimated by using the Bio-Rad protein assay (Bio-Rad), 
with bovine serum albumin (Fraction V) as a standard. Briefly, an initial stock (20 ml) of 5 mg/ml 
BSA was prepared in sterile distilled water. Aliquots of 100 ml BSA concentrations ranging from (5 
to 0.1 mg/ml) were prepared from the stock (Appendix 4A-III, Table 4.2). Aliquots of 25 µl of BSA 
concentrations, water (serves as a blank) and samples tested to be tested were transferred into sterile 
15 ml glass tubes. Aliquots of 125 µl of Reagent A and 1 ml of Reagent B (Bio-Rad) were added to 
each of the tubes and were incubated at room temperature (25°C) for 15 minutes. The optical density 
at 600 nm (OD600) was recorded for each of the sample and a BSA standard curve was plotted using 
the OD600 values of the BSA concentration (Appendix 4A-III, Figure 4.4). Estimation of protein 
concentration for each sample was calculated from the curve. 
 
4.3.3.3 β-galactosidase activity measurement 
 
β-galactosidase activity assay (Appendix 4A): 50 µl of the supernatant of each sample was transferred 
into a 1,5 ml Eppendorf tube. An aliquot of 600 µl of Z-buffer with β-mercaptoethanol (complete) 
was added to each tube and incubated at 30°C for 5 minutes to equilibrate. Subsequently, 200 µl of o-
nitrophenyl-b-D-galactopyraniside (ONPG), a substrate for β-galactosidase was added and time was 
recorded as reaction start time. The reaction was stopped when the reaction mixture started turning 
yellow by addition of 1 molar sodium carbonate (1M NaCO3) and the time was recorded again as time 
of reaction termination. The difference between the reaction start time and the reaction termination 
time was recorded as the reaction for each sample. The OD420nm was measured for each sample 
relative to the blank. β-galactosidase activity was calculated as follows. 
β-galactosidase activity  = 1000 * A420nm/ Reaction time * Protein concentration (OD600)  
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β-galactosidase activity of the extracts was determined by using Miller’s method (Miller J.F., 1972) 
and is expressed as nanomoles of nitrophenol/min/mg protein.  
4.4 Results and Discussion 
 
4.4.1 Activity testing of F1082 under low or high iron conditions. 
The results presented in Chapter 3 (Table 3.4) suggest that M. tuberculosis “senses” low iron 
conditions under F1082 treatment by up-regulating the genes involved in iron acquisition and down-
regulating the genes involved in iron storage. We therefore hypothesized that the activity of F1082 
could be affected by varying the iron concentration. Therefore we tested M. tuberculosis H37Rv 
susceptibility to F1082 under low (MM only) and high iron (MM + 50 µM FeCl3) conditions (Table 
4.3). The Alamar Blue assay described in materials and methods (section 4.3.2) where M. tuberculosis 
was grown under various concentrations of F1082 was used (Table 4.3). These results show that 
F1082 is most active under high iron concentration, with an MIC of 2 µg/ml, compared to low iron 
concentration, with an MIC of 4 µg/ml. These results refute our first hypothesis that F1082 could be 
an iron chelator. If F1082 was an iron chelator, we expect that it would chelate the available iron, 
amplifying its effect under low iron concentration and with minimal activity under high iron 
concentration. 
Table 4.3 MIC determination of F1082 treatment of M. tuberculosis under iron limitation. 
H37Rv F1082 (µg/ml) 
Low iron (MM only) 4 
High iron (MM + 50 µM/ml FeCl3) 2 
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4.4.2 F1082 activity in an M. tuberculosis iron transport deficient mutant (irtAB 
mutant) 
If F1082 is not an iron chelator, then it may affect iron transport in M. tuberculosis. We tested the 
activity of F1082 in an M. tuberculosis irtAB mutant described (Table 4.1). This strain is incapable of 
transporting iron into the cell because the irtAB gene is disrupted which normally is involved in the 
active translocation of Fe(III)-siderophore complexes through the plasma membrane (Braun and 
Killmann, 1999). Whether most F1082 activity is inside the cell or outside the cell also remained to be 
tested. The irtAB mutant was tested in MM with various concentrations of FeCl3 (50 to 5 µM). When 
the M. tuberculosis irtAB mutant was tested against INH, it was susceptible, with an MIC of 0.05 
µg/ml. We observed that the M. tuberculosis irtAB mutant offered resistance to F1082, and noted an 
increase in MIC to 8 fold higher than the wild type H37Rv (Figure 4.5). This could suggest that most 
F1082 activity requires it to be transported via iron mediated active transport through the irtAB 
system or depends on the abundance of intracellular iron. The low  inhibitory activity observed at high 
F1082 concentrations against irtAB mutant could be as a result of residual intracellular iron within the 
mycobacterium or toxic effect at high concentrations.  
 
Figure 4.5 Percentage growth of M. tuberculosis (irtAB) mutant with F1082 in MM containing FeCl3 
concentrations (50-5 µM). Controls DMSO and INH (0.05 µg/ml) were used. Errors bars represent 
mean standard deviation of three indepent experiment with each done in duplicate. 
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4.4.3 Evaluation of the interference of function of the iron dependent regulator 
(IdeR) by F1082. 
 
4.4.3.1 F1082 activity testing against M. smegmatis under low or high iron conditions 
 
The second hypothesis was tested, viz., whether F1082 could be interfering with the iron dependent 
regulator (IdeR). Since we had transformed strains of M. smegmatis for measuring IdeR activity, it 
was necessary that M. smegmatis would be sensitive to F1082. The results show a similar pattern, in 
that F1082 is most active in mycobacteria that have been grown in high iron medium than in low iron 
(Figure 4.6). 
 
Figure 4.6 Percentage growth of M. smegmatis in low iron (MM only-LI) or high iron (MM + 100 
µM-HI) at various concentrations of F1082. Errors bars represent mean standard deviation of three 
indepent experiment with each done in duplicate. 
The percentage growth was calculated relative to the DMSO control with no compound and values 
were obtained using the cell titer flourometric assay. Three biological replicates with each performed 
in duplicate generated this data. These results show a similar pattern as is the case for M. tuberculosis, 
at slightly higher concentrations of F1082.  
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4.4.3.2 β-galactosidase activity in a transformed M. smegmatis strain. 
It has been shown in the literature that bfrB and mbtB gene expression is iron-dependent and regulated 
by IdeR (Rodriguez et al., 2002). To test whether F1082 directly interferes with IdeR, we performed a 
β-galactosidase assay. The activity is driven by the promoter of M. tuberculosis genes whose 
expression is regulated by IdeR under iron availability. We used M. smegmatis strains that contained 
the bfrB-lac-Z and mbtB-lac-Z reporter genes of M. tuberculosis (Table 4.1). The activity of F1082 on 
IdeR interference was tested at a subinhibitory concentration of F1082 (10 µg/ml). For the calculation 
of the β-galactosidase activity we used the formula where protein concentration was determined using 
the BSA standard curve (Figure 4.4). 
The β-galactosidase activity of SM60 (pSM128 plasmid only) did not change under any condition 
tested (low or high iron)  (Table 4.4). This was as expected, since the plasmid did not contain any 
fragment regulated by IdeR and F1082 did not affect its activity. This strain was used as a base-line to 
measure the activities of the strains habouring IdeR regulated genes. We observed that SM160 
(pSM128-bfrB-LacZ) had a low β-galactosidase activity (low expression of bfrB) under low iron and 
19 times more activity under high iron conditions which was similar when F1082 was added (Table 
4.4). Conversely, SM193 (pSM128-mbtB-LacZ) had a high β-galactosidase activity (high expression 
of mbtB gene) which was7 fold more under low iron conditions compared to high iron 
conditions.When F1082 was added, there was increased β-galactosidase activity: 8 fold more under 
low iron conditions, compared to high iron conditions. These results show that F1082 does not 
directly interfere with IdeR activity, since there was no change whether F1082 was added or not in the 
β-galactosidase assay (Table 4.4). 
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Table 4.4 Expression of mbtB and bfrB in M. smegmatis wild type and ideR mutant background 
Strain IdeR β-galactosidase specific activitya 
M. smegmatis  Low ironb High ironb 
No compound F1082(10µg/ml) No compound F1082(10µg/ml)
SM60 (pSM128) + 0.49 ± 0.3 0.72 ± 0.07 0.54 ± 0.4 0.58 ± 0.2 
SM160 (bfrB-LacZ) + 7.20 ± 5 9.56 ± 7 135.40 ± 5 197.45 ± 4 
SM193 (mbtB-LacZ) + 133.0 ± 0.5 151.0 ± 8 19.1 ± 8 19.0 ± 6 
aNanomoles of nitrophenol/min/mg protein. The values obtained with strains carrying pSM128 have 
not been subtracted from the values obtained with other transformed strains. Values are the mean ± 
standard deviation of three independent experiments with each done in duplicate.  
bLow iron, MM medium chelex treated, high iron, MM chelex treated and supplemented with 100 
µM/ml FeCl3. 
The work done so far nullifies our first two hypotheses. The results suggest that F1082 is not an iron 
chelator, since it was more active in high iron than in low iron media. Secondly we have shown that 
F1082 requires intracellular iron for most activity, since the irtAB mutant offered tolerance to the 
compound. Finaly, the results of three independent experiments show that F1082 does not interfere 
directly with IdeR activity in iron regulation. The role of iron in F1082 activity is still unknown, 
although it appears to be key to its (F1082) activity.  
4.4.3.3 Testing whether F1082 activity involves generation of oxidative stress.  
A working hypothesis for F1082 is that it could be generating or exacerbating oxidative stress via 
modulation of iron availability. Since bacterial pathogens encounter different environments during the 
process of pathogenesis, adaptive responses and modulation of virulence gene expression are required 
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for their survival (Miller et al., 1989). Response to oxidative stress is a crucial factor for the survival 
of aerobic pathogens. 
Therefore, we used M. smegmatis strains defective in protection against oxidative stress and tested 
their susceptibility to F1082. Table 4.4.17 shows the susceptibility of a M. smegmatis (sodA) mutant 
to F1082 or hydrogen peroxide (H2O2) when compared to the wild type. The results show that 
hydrogen peroxide effectively kills the mutant, since the MIC is one third (0.5 mM) that of the wild 
type. With F1082, it appears that the mutant survives as well as the wild type, since they have the 
same MICs (Table 4.5).  
 
Table 4.5 MICs of F1082 and H2O2 for M. smegmatis WT and SOD mutant as determined by Alamar 
Blue. 
 
Agent 
MICs 
Wild type SM90 (sodA) 
F1082 40 (µg/ml) ± 0.06 40 (µg/ml) ± 0.04 
H2O2 1.5 (mM) ± 0.05 0.5 (mM) ± 0.08 
Values are the mean ± standard deviation of two independent experiments with each done in 
duplicate. 
A combination of the two compounds (F1082 and hydrogen peroxide) activity on the growth of M. 
smegmatis wild type was tested. A combination of the two compounds does not show enhanced 
activity (Figure 4.7 B) against wild type M. smegmatis. However we see enhanced activity of the 
same combination on a (sodA) mutant (Figure 4.8). It is possible that F1082 generates more oxidative 
stress in combination with hydrogen peroxide, which is not tolerated by the (sodA) mutant. This could 
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be interpreted thus: F1082 exacerbates the generation of oxidative stress in the presence of hydrogen 
peroxide. 
In Figure 4.7 (A) it can be seen that the most growth inhibitory concentration for hydrogen peroxide 
appeared to be 1.6 mM whereas it was 40 µg/ml for F1082. Other (lower) concentrations gave less 
than 10% growth inhibition. For the combined effect of the two compounds we used the 
concentrations that gave minimal inhibition alone i.e. hydrogen peroxide at 0.8 mM (35% inhibition) 
and F1082 at 20 µg/ml (30% inhibition) (Figure 4.7 A). In combination, these two concentrations did 
not show much growth inhibition against M. smegmatis as shown in Figure 4.7 B. This can be 
interpreted to mean that M. smegmatis WT appears to cope well with the oxidative stress generated by 
the two compounds in combination. 
A       
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B 
 
 
Figure 4.7 M. smegmatis WT grown in the presence of varying concentrations(A) of hydrogen 
peroxide (H) range from 0.2 to 1.6 mM alone and F1082 (F) range from 5 to 40 µg/ml alone; (B) 
combination effect of the (F and H) compounds. Where H: hydrogen peroxide and F: F1082. Errors 
bars represent mean standard deviation of three indepent experiment with each done in duplicate. 
However when we considered the same drug combination in an M. smegmatis superoxide dismutase 
mutant (SOD), we observed a significant growth inhibitory effect of the two compounds in 
combination, showing more than 90% growth inhibition (Figure 4.8). Since a sodA mutant is more 
susceptible to oxidative stress generating molecules/compounds, it may be concluded that F1082 
generates oxidative stress or exacerbates the generation of oxidative stress in combination with other 
oxidative stress generating molecules in M. smegmatis. 
Stellenbosch University  http://scholar.sun.ac.za
 147 
 
 
 
Figure 4.8 Combination effect of F1082 with H2O2 in M. smegmatis (SOD) mutant. Errors bars 
represent mean standard deviation of three indepent experiment with each done in duplicate.  
Since it has now been shown that the M. smegmatis (sodA) mutant is more susceptible to F1082 in 
combination with hydrogen peroxide, it would be of interest to show the same or a similar effect in M. 
tuberculosis strains that are more susceptible to oxidative stress. Although M. tuberculosis strains 
with sodA deletion were not available, we used M. tuberculosis strains that are more susceptible to 
oxidative stress owing to mutations in the mycothiol genes (mshA) (Vilchèze et al., 2008). The mshA 
mutant lacks the ability to synthesize the enzyme involved in the first step of mycothiol biosynthesis 
(Vilchèze et al., 2008). Mycothiol has wide range of functions that include detoxification of 
electrophilic compounds, conjugation with antibiotics, and maintenance of the redox potential within 
the cell (Jothivasan and Hamilton, 2008) (Newton et al., 2008); (Rawat et al., 2007) and therefore 
susceptible to oxidative stress. M. tuberculosis H37Rv WT and H37Rv mshA mutant were grown in 
the BACTEC 460 system [described in Materials and Methods, Chapter 2 (section 2.1)] with various 
concentrations of F1082. The results show that the mshA mutant was more susceptible to F1082 at 2 
µg/ml giving an 80% inhibition of growth compared to 20% growth inhibition in the wild type (Figure 
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4.9). We therefore suggest that the F0182 mode of action is via the generation of oxidative stress in 
mycobacteria. 
 
Figure 4.9 Dose response curve of M. tuberculosis CDC 1551 and mshA mutant strains to F1082 
exposure. 
Summary  
 
In this Chapter we have explored a number of hypotheses which emerged from the results from M. 
tuberculosis microarray gene profiling. In our earlier results we have shown that F1082 is more active 
under high iron condition (Table 4.3). This latest work dismissed the hypothesis that F1082 could be 
an iron chelator as it would have been more effective in low iron conditions. This prompted us to 
investigate whether F1082 exerts its activity via intracellular or extracellular activity. An irtAB mutant 
(incapable of transporting iron into the cell) was resistant to F1082. This could imply that F1082 
requires transportation through irtAB transport or that F1082 requires sufficient intracellular iron to 
exert its effect.  The first hypothesis can be dismissed since F1082 was most effective against H37Rv 
grown under high iron conditions where the strain has efficient irtAB transport. The least activity 
shown under low iron conditions could be as a result of residual trace amounts of intracellular iron in 
the mycobacterium or probably by other less efficient/redundant iron transport systems which may 
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exist in the mycobacteria but are less efficient than the irtAB transport systems (Rodriguez and Smith, 
2006).  The results support the second hypothesis, viz. that F1082 exerts activity preferably under 
high intracellular iron conditions.  
In M. tuberculosis the availability of iron is regulated by IdeR and the expression of mbt  genes is 
subject to IdeR inactivation (Schnappinger et al., 2003) or depleted amount of intracellular iron 
(Rodriguez et al., 2002). Our results show that F1082 does not interfere with IdeR (Table 4.4). 
Therefore it seems that under F1082 treatment, M. tuberculosis reacts as if under low iron conditions.  
It has been published that excessive iron in mycobacteria allows generation of oxidative stress via the 
Fenton reaction and we have shown that F1082 requires sufficient intracellular iron to exert its effects. 
It could be possible that available intracellular iron is used somehow by F1082, resulting in M. 
tuberculosis sensing low iron conditions.  
We have also shown that in M. smegmatis, F1082 in combination with hydrogen peroxide generates 
oxidative stress. This stress is less tolerated in a sodA mutant compared to wild type (Figure 4.9). It 
could then be hypothesised that in the presence of other molecules generating oxidative stress, F1082 
exacerbates the generation of oxidative stress. The effect of F1082 on a M. tuberculosis mutant 
deficient in protection against oxidative stress was tested. This was a M. tuberculosis mshA mutant 
deficient in mycothiol production and was tested initially with INH and was found to be sensitive to 
INH at 0.06 µg/ml, consistent with published data (Vilchèze et al., 2008).  The mycothiol (MSH) 
functions as general-use detoxification agent against antibiotics, alkylating agents, electrophiles and 
other endogenous and exogenous reactive intermediates(Rawat et al., 2002). The M. tuberculosis 
mshA mutant was more susceptible to F1082 compared to the wild type (Figure 4.9). This suggests 
that F1082 generates oxidative stress in M. tuberculosis which inhibits growth.  The co- involvement 
of oxidative stress in growth which varies between M. smegmatis and M. tuberculosis could be 
possibly thus: M. smegmatis has evolved as an environmental saprophyte and may have developed 
alternative systems to cope with oxidative and nitrosative stressors. In contrast, M. tuberculosis faces 
a far different environment in the human host.  
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A definitive mechanism of action of F1082 remains to be explored through target identification; 
however, this work has shown the involvement of oxidative stress in F1082 activity. In addition it 
suggests that iron regulatory and acquisition pathways remain important for anti-TB drug 
development. 
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Appendix 4A 
I. Β-galactosidase activity determination 
 
This method describes the classic colorimetric assay for ß-galactosidase widely used in early studies 
of lac gene expression.  It provides a simple, reliable and economical quantitative estimate of LacZ 
expression by measuring enzyme activity directly.  The assay was essential to the exploitation of the 
lac operon as a model system for the study of gene regulation. 
β-Galactosidase is able to hydrolyze β-D-galactosides. This enzyme facilitates growth on carbon 
sources such as lactose by cleaving it into a molecule of glucose and a molecule of galactose, which 
the cells can catabolize and used for growth. In the assay described below, the artificial chromogenic 
substrate ortho-nitrophenyl-β-D-galactopyranoside (ONPG) is used in place of lactose. When the β-
galactosidase cleaves ONPG, ortho-nitrophenol is released. ONPG is colorless, while the product 
compound has a yellow color, and absorbs light (λmax = 420 nm).  Therefore, enzyme activity can be 
measured by the rate of appearance of yellow color using a spectrophotometer. 
β-Galactosidase assay 
 Strains of M. smegmatis grown in 15 ml LI or HI (100 µM FeCl3) to OD600 0.8 
 Centrifuge the cells at 5000 rpm for 5 min at 4°C 
 Resuspend the pellets (pellets of 15 ml bacterial cultures) in phosphate buffer saline (PBS) 
(30 ml), centrifuge and store the pellets at -80°C until use or proceed with the following steps 
 Resuspent the pellets in 800 µl of Z-buffer 
 Bead beat the cells with 200 µl of beads for 30 sec, two times 
 Centrifuge at maximum speed in micro centrifuge for 5 min 
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 Collect the supernatant (extract). Keep 50-100 µl for protein concentration determination 
(OD600) 
Reaction 
 Keep 200 or 50 µl of extract in a tube at 30°C for (equilibration of the extract) for 5 min 
 Add 600 µl of buffer Z with β-mecaptoethanol (30 µl of β-mecaptoethanol /15 ml Z 
buffer) 
 Add 200 µl of o-nitrophenyl-b-D-galactopyraniside (ONPG) – substrate for β-
galactosidase) ( 4 mg/ml stock in buffer Z with β-ME {30 µl of β-ME/15 ml Z buffer}). 
Record the time (time of starting the reaction) 
 Stop the reaction, when the reaction mix starts turning visually yellow, by adding 400 µl 
of 1M Na2CO3 . Again record the time (time of reaction termination), this time duration 
will be the reaction time 
 Read OD420nm 
Miller units: 1000 * (OD420/ (T * V *OD600[protein concentration]) 
Solutions for β-galactosidase assays 
 
Z buffer, per 50 mL: 
 O.80g Na2HPO4.7H2O (0.06M) 
 0.28g NaH2PO4.H2O (0.04M) 
 0.5 mL 1M KCl (0.01M) 
 0.05 mL 1M MgSO4 (0.001M) 
 0.135 mL β -mercaptoethanol (BME) (0.05M) 
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 bring to approximately 40 mL with H2O, dissolve all the salts 
 adjust the pH to 7.0 
 use a graduated cylinder to bring the buffer to 50 mL 
 store at 4° C for no more than a few days. 
ONPG (4 mg/ml) (Sufficient for 100 assays -- make fresh daily) 
80 mg o-nitrophenyl-ß-D-galactoside (o-nitrophenyl-ß-D-galactopyranoside) 
20 ml dH2O 
1 M Na2CO3 (Sufficient for 100 assays -- store in refrigerator) 
5.3 g Na2CO3 
50 ml dH2O 
β-mercaptoethanol (βME) is added to the reaction buffer to stabilize the β-galactosidase enzyme. The 
important part of BME is a reactive thiol (SH group). Thiols react with oxygen in the air and oxidize 
(inactivate) over time. Therefore, one must not make more Z buffer than will be used in a few days. 
Store the unused portion at 4° C. 
 
O-nitrophenyl-b-D-galactopyraniside (ONPG) should be dissolved fresh each day. Dissolve the 
ONPG to a final concentration of 4mg/mL in 0.1M phosphate buffer pH 7.0. 
 
Phosphate buffer, per 100 mL: 
 1.61g Na2HPO4.7H2O (0.06M) 
 0.55g NaH2PO4.H2O (0.04M) 
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 adjust the pH to 7.0 
 phosphate buffer is stable at room temperature and does not need to be made fresh each time. 
What is sufficient yellow colour? To get the most accurate measure of activity, the absorbance at 420 
nm (A420) should range from 0.6 to 0.9. Readings as low as 0.1 and as high as 1.2 are acceptable. 
Tubes that have become as yellow as a tube of (unused) LB broth will probably be sufficiently 
yellow. 
 
If the reading is too low, the assay can be tried again with more cells or longer incubation time. When 
the promoter is not expressed to any meaningful extent, it will probably take hours to develop enough 
yellow colour. If a control starts to turn yellow (after several or more hours) it means that the substrate 
is beginning to auto-hydrolyze. The assay can be left overnight. The auto-hydrolysis is then accounted 
for by subtracting the A420 and A500 of the negative control from that of the tests before doing any 
further calculations. 
 
If the reading is too high, try the assay again with fewer cells. Aim to stop the reaction after 15 
minutes. For example, if in at first attempt, 0.5 mL of cells + 0.5 mL of Z buffer were added, and it 
was too yellow after 5 minutes, try adding 0.1 mL cells + 0.9 mL of Z buffer. Watch the tube 
carefully. Some cultures may have to be diluted even further. 
 
Adding the 1 M Na2CO3 stops the reaction by raising the pH of the solution to 11. At this pH the 
enzyme is not active. 
 
The reading at 420 nm is a combination of absorbance by o-nitrophenol and light scattering by cell 
debris. The absorbance at 550 corrects for light scattering. There is no absorbance from o-nitrophenol 
at this wavelength. The light scattering at 420 nm is proportional to that at 550 nm: 
light scattering at 420 nm = 1.75 x OD550 
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Use the following equation to calculate units of enzyme activity: 
Miller Units = 1000 x [(OD420 - 1.75 x OD550)] / (T x V x OD600) 
 OD420 and OD550 are read from the reaction mixture. 
 OD600 reflects cell density in the washed cell suspension. 
 T = time of the reaction in minutes. 
 V = volume of culture used in the assay in mLs. 
The units give the change in A420/min/mL of cells/OD600 
(Conversion of the raw data is necessary) 
The sample activity of enzyme present in a sample is a rate, or velocity, value:  how much yellow 
colour develops after incubation for a specific time.  λ A420 min-1. These total activity values alone are 
not very informative because two assay tubes may have different cell concentrations. Rather, it is 
important to know the enzyme activity level relative to the cell biomass.  This quantity can be called a 
specific activity. 
To get a specific activity from sample activity one must take into account the volume of cell culture 
put in the sample and the biomass concentration of the culture.  Firstly standardize sample activity 
values on the basis of 1.0 ml of culture.  So, the units of the standardized sample activity would be λ 
A420 min-1 ml-1.  Lastly, use OD600 readings of the culture as a standard measure of cell biomass. 
Therefore specific activity values are in 
λ A420 min-1 ml-1 OD600-1.   
For this experiment data is collected in five points: 
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 Sample volume in ml 
 λ A420 (a measure of ONP produced) 
 OD550 to correct for light scattering 
 incubation time in minutes 
 OD600 of the culture  (as measure of biomass) 
Typical values: 
a fully induced lac+ operon (+IPTG) = 1500 units 
an uninduced lac+ operon (no IPTG) = 1.5-3 units 
 
 
II. Growth assay-Alamar Blue Assay 
Inoculate M. tuberculosis strains from frozen stocks to 7H10  supplemented with 0.2% glycerol, 
0.05% Tween 80 and 10% albumin-dextrose-NaCl-complex (ADN) agar plates and incubate at 37°C 
for 5-8 days. Take swab and inoculate in a MM medium with no iron to an OD540 0.1 (1 x 107 cfu/ml). 
 Add 200 µl of sterile deionised water to all outer-perimeter wells of the 96 well plate 
(minimize evaporation of medium in test wells during incubation. 
 Wells in rows B to G in columns 3 to 11 receive 100 µl of the medium (Fe + or Fe -) 
 Add 100 µl of 2 x drug solution to well in rows B to G I columns 2 and 3 
 By using multichannel pipette transfer 100 µl from column 3 to 4 and mix the contents well 
 Identical serial 1:2 dilution are continued through column 10, and 100 µl of excess medium is 
discarded from wells in column 10 
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 Inoculate 100 µl of M. tuberculosis (1 x 105 cfu/ml) inoculums in wells in row B to G in 
columns 2 to 11 (yielding a final volume of 200 µl per well), thus the wells in column 11 
serve as a drug-free (inoculum only) controls. 
 The plates are sealed with Parafilm and incubated at 37°C for 5 days. 
 Add 50 µl of a freshly prepared 1:1 mixture of 10 x Alamar Blue reagent and 10% Tween 80 
to wells in B11 
 Re-incubate the plates at 37°C for 24 hours. 
 If well in B11 turned pink, the reagent mixture is added to all the wells in the microplate (if 
the wells remained blue, the reagent mixture is added to another control well and the results 
will be read on the following day) 
 The microplates are sealed with Parafilm and incubated at 37°C for another 24 hours, and the 
colours of all the wells are recorded. 
 A blue colour in the well is interpreted as no growth, and a pink colour is scored as growth. 
 The MIC is defined as the lowest concentration which prevented a colour change from blue to 
pink 
 
III Protein concentration and pSM plasmid 
 
Figure 4.3 The structure of the pSM128 plasmid 
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Table 4.2 Standard BSA solution preparation 
[BSA] µg/ml Volume (µl) of 5mg/ml BSA 
Stock 
Volume (µl) of MilliQ water 
0.5 10 90 
1.0 20 80 
1.5 30 70 
2.0 40 60 
2.5 50 50 
3.0 60 40 
3.5 70 30 
4.0 80 20 
4.5 90 10 
5.0 100 0 
 
Figure 4.4 BSA standard curve for protein determination of extracts from M. smegmatis for β-
galactosidase activity determination. 
 
Stellenbosch University  http://scholar.sun.ac.za
 159 
 
CHAPTER FIVE 
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The advent of MDR/XDR TB has highlighted the need for the discovery of novel compounds with 
activity against M. tuberculosis (Raviglione, 2007). These new compounds would ideally not only kill 
M. tuberculosis, but would also shorten regimen times, be compatible with antiretroviral drugs, active 
against non-replicating persisters (NRP), and act through different mechanisms of action from those 
employed by the existing front-line and second-line anti-TB drugs. In this study we evaluated the 
activity of a candidate compound (F1082) on the growth of M. tuberculosis and the mechanism by 
which it inhibits M. tuberculosis growth. F1082 is a furanone based compound; furanones are 
endowed with an array of biological activities (anti-fungal, antibacterial, anticancer activities). In the 
context of medicinal chemistry, a chemically tractable “hit” or “lead” molecule is one that lends itself 
to the synthesis of a diverse range of analogues. In this regard the mucohalic (mucobromic and 
mucochloric) acid furanones represent attractive starting points.  These compounds are highly 
functionalized molecules, which makes them useful as building blocks to make functionalized and 
diverse new pharmacologically relevant furanones. From our starting synthetic product (F1082), a 
furanone, our collaborators were able to synthesise 92 furanone based compounds. These compounds 
were screened for anti-M. tuberculosis activity to improve on the activity of the original F1082. Our 
research efforts directed towards the development of antituberculosis agents, lie in the direction of 
discovering new classes of compounds, which have a different mechanism of action from known anti-
TB drugs. The current work describes the identification of a novel 2(5H)-furanone (F1082) with anti-
TB activity and its potential to be developed into anti-TB candidate drug.   
The anti-M. tuberculosis activity of F1082 (MIC 8 µg/ml) and selective activity for mycobacteria 
provided the basis for selecting F1082 as a “hit”. It did not inhibit growth of other selected Gram-
positive and Gram-negative bacteria. These results are supported by published data in the literature 
that brominated furanones in general are known to inhibit quorum sensing by interfering with Type 1 
and Type 2 auto-inducers (Ren et al., 2001) but do not inhibit growth of the organism at quorum 
sensing concentrations. Although in some published data it has been reported that brominated 
furanones  inhibit growth of Gram –positive bacteria, such as Bacillus subtilis, at high concentrations 
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of up to 150 µg/ml (Ren et al., 2004), such high concentrations were not used in this work and 
therefore suggest that the selectivity for mycobacteria may be concentration dependent.  
In order for any compound to be developed into a drug candidate, it has to satisfy a number of criteria. 
F1082 was tested against clinical isolates and was found to inhibit the growth of pan-susceptible and 
MDR/XDR clinical isolates in the same way as the M. tuberculosis laboratory strain H37Rv, a 
criterion for desired new compounds for TB drug development. This also suggests that F1082 may 
have a different mechanism of action since it does not show cross-resistance with the current TB 
drugs. Furthermore it synergizes with the rifampicin. This forms the basis of potential for a good TB 
candidate drug since TB is treated by combination therapy. We have shown that F1082 can be 
bactericidal to M. tuberculosis growth, although this is concentration dependent. At its (lower) 
bacteriostatic concentration, it has been shown to improve the mycobacterial killing effect when used 
in combination with some of the frontline drugs (additive effect with INH and synergistic with 
rifampicin). However the cytotoxic effect of F1082 to human cell lines still needs to be overcome for 
the compound to be effectively used for TB drug development. We hope that cytotoxicity can 
eventually be overcome through generation of derivatives. The derivatives synthesized so far have 
shown reduced cytotoxicity with concomitant increase of the killing effect of the compound (Table 
2.1).  
The studies of the mechanism of action by microarray gave an indication of the mechanism/s of 
action.  These observations led to a speculation that F1082 inhibits the growth of M. tuberculosis via 
the generation of oxidative stress that is iron dependent, since this work demonstrated reduced F1082 
activity under intracellular iron deprivation in both M. tuberculosis and M. smegmatis. This has been 
confirmed by studying mutants incapable of iron uptake and shown to be resistant to F1082 when 
grown under iron rich conditions. Furthermore, mutants lacking genes that provide protection against 
oxidative stress were more susceptible to F1082. It is possible that F1082 generates or exacerbates 
oxidative stress in its mode of action. When superoxide (O2―) and hydrogen peroxide are allowed to 
interact in the presence of a Harber-Weiss catalyst such as iron, hydroxyl radicals are formed (Kehrer, 
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2000). It could be that F1082, when taken up by mycobacteria, form intermediates that conjugate or 
complex with iron leading to a condition of oxidative stress. Consequences of oxidative stress are 
nucleic acid damage, protein damage, lipid beta-oxidation and subcellular organelle damage that 
could account for the transient reduction of the bacterial load. One unifying hypothesis is that 
membrane proteins involved in iron transport, chelation, or storage act as sites for catalysis of 
hydroxyl radicals (Mietzner et al., 1984). Hydroxyl radicals formed at these sites could cause a lethal 
increase in membrane permeability (Albrich et al., 1986)  or damage to iron-rich enzyme complexes. 
In the absence of extracellular iron, these sites may not be subjected to oxidation. Since F1082 was 
shown to be bacteriostatic (concentration dependent), it is more likely that cellular protein molecules 
are targeted by the compound at bacteriostatic activity and do not cause direct or indirect DNA 
damage which is more likely a feature of bactericidal activity. Alternatively, as the fragments of the 
molecule are degraded (Chapter 2, section 2.3.5) it is possible that F1082 may have more than one 
target. However we have shown experimentally that F1082 may  generate of oxidative stress.  
It has been supported (Kohanski et al., 2007) that bacteriostatic compounds inhibit protein 
biosynthesis. However DNA damage is attributed to bactericidal compounds. F1082 may be generally 
bacteriostatic and bactericidal, depending on concentration. Interestingly, another characteristic of the 
brominated furanones is their anti-fungal and carcinogenic activity. It has been reported that non-
mutagenic carcinogen induce oxidative DNA damage (Kawanishi et al., 2002) whilst weakly 
mutagenic carcinogen like hydrazine derivatives induce metal-dependent oxidative DNA damage (Ito 
et al., 1992). Based on the results we speculate that F1082 inhibits the growth of M. tuberculosis by 
generating oxidative stress in the presence of free iron.  
This work provided a better understanding of the furanones and specifically F1082 as possible lead 
compounds for TB drug development. The study observations generated pave the way for future 
development of this compound. Resulting from this work, the four compounds (JP 206, JP210, JP216 
and JP 223) in (Table 2.1 in results chapter 2) already present a positive development. Derivatives 
with low cytotoxicity can be further studied in an animal model for efficacy, whereafter more 
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derivatives can be synthesized to optimize activity and cytotoxicity. It is to be hoped that this work 
will be a cornerstone in driving the search for novel compounds to upscale the TB drug pipe-line and 
perhaps deliver one or more compounds that can enter clinical trials.  
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